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Abstract 
Introduction 
Alzheimer’s disease (AD) is a neurodegenerative illness characterized by a 
progressive loss of neurons in specific areas, such as forebrain, neocortex 
and subcortical cholinergic projections from nucleus basalis of Meynert. 
Loss of cholinergic neurons entails low levels of acetylcholine (ACh); this 
diminished amount of neurotransmitter is responsible for the disruption 
in the neuronal transmission between the cells involved in learning and 
memory processes. This interruption in neuronal communication is the 
origin of the cognitive symptoms of AD such as memory loss, incapacity 
to learn, to reason, to make judgments and failure to communicate.  
Understanding of disruption in cholinergic system led to 
acetylcholinesterase (AChE) as the first target in the search of 
therapeutic agents to treat AD. Acetylcholinesterase inhibitors (AChEi) 
were the first class of drugs successfully used in the symptomatic 
treatment of this disease. However, despite the improvement in cognitive 
and behavioral impairments in patients treated with AChEi’s, this kind of 
drugs is not able to stop the neurodegeneration. 
Explaining the origin of cognitive symptoms is not enough to understand 
the real cause of neurodegeneration in AD. Nowadays, beta-amyloid 
peptide (Aβ) is considered the initiating substance in the process leading 
to neuronal death. Insoluble Aβ fibrils are the main constituent of the 
senile plaques, which are considered the toxic element triggering the 
cascade of cellular responses that finally produce degeneration and death 
of neurons. Some of these events are neuro-inflammation, production of 
reactive oxygen species (ROS) and tau protein hyper phosphorylation. 
An important strategy in the search for new drugs able to avoid the 
production of Aβ and subsequent senile plaques deposition, has been the 
Abstract 
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synthesis of inhibitors of the beta-site amyloid precursor protein cleavage 
enzyme (BACE1); one of the three secretases involved in processing 
amyloid precursor protein (APP). 
Along with the decrease in ACh, there is a decline in brain levels of other 
neurotransmitters such as dopamine, serotonin and norepinephrine 
compared to healthy aging brain. At the same time, it has been 
demonstrated that levels of MAO-B increase with age in healthy humans, 
as well as in degenerative processes. These increased levels of MAO-B, 
correlate with the exacerbated production of ROS, which are responsible 
for the toxic environment characteristic of neurodegeneration. MAO 
inhibitors have been explored as a complementary alternative in the 
search of new drugs to treat AD, both to reduce ROS in the case of MAO-
B, as to treat concomitant depression of AD patients, in the case of MAO-
A. 
This brief introduction highlights the complexity of the network of factors 
influencing AD. In the rest of this report the role of these enzymes and 
some other factors will be discussed in a deeper manner. Taking into 
account this complexity, we proposed to develop the next general 
objective 
Objective 
In this work, we aimed to explore the usefulness of the N-benzyl 
piperidine (NBP) and the N, N-dibenzyl-N-methylamine (DBMA) in the 
design, synthesis and evaluation of new multitarget compounds with 
affinity for relevant enzymes related to AD. To achieve this goal, several 
naturally occurring structures, (chromone, 4-quinolinone, lipoic acid (LA) 
and cinnamic acid) which could give to the resulting products a 
multitarget profile, were hybridized with NBP and DBMA into simple 
small molecules. Synthetic ease and accessibility to the biological 
experiments was always considered to develop in the most rapid and 
Abstract 
7 
 
efficient way this research. The newly obtained products were evaluated 
in biological assays (in vitro and in vivo) and in silico experiments in order 
to establish a relationship between the structure and their biological 
activity. 
Results 
Along this work we have demonstrated that NBP and DBMA fragments 
are able to give to the new hybrids affinity for the cholinesterases, as we 
expected from the very beginning according to the initial bibliographic 
review. Depending on the complementary scaffold, newly obtained 
hybrids exhibited affinity for the several enzymes related to AD.  
We have found that the combination of these two fragments with LA give 
molecules with affinity for the 1R, and consequently, with the potential 
to preserve the health of the neurons affected in AD. Through this 
property, they may help to avoid or at least delay the neurodegenerative 
process. Simultaneously, these compounds are BACE1 inhibitors and 
neurogenic agents. 
In the second and fourth chapter we successfully combined the 
fragments of interest with the chromone scaffold and the cinnamic 
structure, respectively. Once more, naturally occurring scaffolds were the 
inspiration to obtain the desired multitarget products. These new hybrids 
exhibited the wanted AChE and MAO inhibitory activity and radical 
scavenger capacity. The cinnamic based compounds were more effective 
than the chromone-based hybrids in providing antioxidant properties, at 
the same time they were able to stimulate neurogenesis. 
The compounds obtained in the third chapter, combining the kynurenic 
acid (KA) scaffold with the NBP and DBMA fragments were utterly unable 
to antagonize the NMDA receptor, which they were designed for. 
However, they exhibited a good potency as MAO and AChEi’s. 
Abstract 
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The neurogenic properties exhibited by compounds of chapter one and 
four were a nice discovery. Although these results are qualitative, it is 
clear that a neurogenic effect was observed. Even though, the role of 
neurogenesis in adults is not yet fully understood and the usefulness of 
the neurogenic agents is still a topic of discussion; it is worth to continue 
the study of this kind of compounds. Maybe their ability to influence this 
process could be a valuable tool that may help us to increase our 
understanding in this field. 
Conclusions 
The NBP and DBMA fragments have proven to behave as privileged 
structures providing eight series of new bioactive compounds.  
The hybridization strategy applied along this research effectively provided 
new compounds with a multitarget profile. All compounds were designed 
on the basis this strategy, taking together two privileged structures into a 
single small molecule. The resulting compounds from this combination, 
exhibited in most of cases the expected biological activity. 
The new molecules presented in this work intend to be a small 
contribution in the quest for the urgently needed disease modifying drug 
to treat Alzheimer’s disease. 
 
  
 
  
  
 
  
 11 
 
General Introduction 
Alzheimer’s disease (AD) is a neurodegenerative illness characterized by a 
progressive loss of neurons in specific areas, such as forebrain, neocortex 
and subcortical cholinergic projections from nucleus basalis of Meynert.1-
4 Loss of cholinergic neurons entails low levels of acetylcholine (ACh); this 
diminished amount of neurotransmitter is responsible for the disruption 
in the neuronal transmission between the cells involved in learning and 
memory processes. This interruption in neuronal communication is the 
origin of the cognitive symptoms of AD such as memory loss, incapacity 
to learn, to reason, to make judgments and failure to communicate.  
Understanding of disruption in cholinergic system led to 
acetylcholinesterase (AChE) as the first target in the search for 
therapeutic agents to treat AD. Acetylcholinesterase inhibitors (AChEi) 
were the first class of drugs successfully used in the symptomatic 
treatment of this disease. However, despite the improvement in cognitive 
and behavioral impairments in patients treated with AChEi’s, this kind of 
drugs is not able to stop the neurodegeneration. 
Explaining the origin of cognitive symptoms is not enough to understand 
the real cause of neurodegeneration in AD. Nowadays, amyloid-beta 
peptide (Aβ) is considered the initiating substance in the process leading 
to neuronal death.5 Insoluble Aβ fibrils are the main constituent of the 
senile plaques, which are considered the toxic element triggering the 
cascade of cellular responses that finally produce degeneration and death 
of neurons.6 Some of these events are neuro-inflammation,7,8 production 
of reactive oxygen species (ROS)9-11 and tau protein hyper 
phosphorylation.12 An important strategy in the search of new drugs able 
to avoid the production of Aβ and subsequent senile plaques deposition, 
has been the synthesis of inhibitors of the beta-site amyloid precursor
General Introduction 
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protein cleavage enzyme (BACE1); one of the three secretases involved in 
processing amyloid precursor protein (APP). 
Along with the decrease in ACh, there is a decline in brain levels of other 
neurotransmitters such as dopamine, serotonin and norepinephrine 
compared to healthy aging brain.13 At the same time, it has been 
demonstrated that levels of MAO-B increase with age in healthy 
humans,14,15 as well as in degenerative processes.16 These increased 
levels of MAO-B, correlate with the exacerbated production of ROS, which 
are responsible for the toxic environment characteristic of 
neurodegeneration.11 MAO inhibitors have been explored as a 
complementary alternative in the search of new drugs to treat AD, both 
to reduce ROS in the case of MAO-B, as to treat concomitant depression 
of AD patients, in the case of MAO-A.17-19 
In this work, we have focused on the design, synthesis and biological 
evaluation of new molecules able to interact simultaneously with some of 
the most important enzymes related to AD, possessing at the same time, 
antioxidant properties. To achieve this goal, we have synthesized several 
compounds resulting from the hybridization of a variety of privileged 
structures.  
We have selected as targets of these new compounds AChE and 
butyrylcholinesterase (BuChE) given that the cholinergic hypothesis is 
still a valid approach as discussed earlier, BACE1 because which is 
considered the starting point in the amyloid hypothesis, the oxidative 
stress, common to all neurodegenerative processes, MAO-A and MAO-B 
as complementary targets related to AD symptoms, and the sigma 1 
receptor (1R) as an emerging alternative that seems to be involved in 
some processes related to memory and cognition. The next section 
explains the role of BACE1 in AD because almost all compounds have 
been evaluated as inhibitors of this enzyme. On the other hand, the 
introduction of the following chapters will discuss separately the 
General Introduction 
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importance of rest of the targeted enzymes, as well as the strategy 
applied to design and synthesize each compound.  
Beta-site Amyloid Precursor Protein Cleavage Enzyme  
Nowadays, Aβ is considered the initiating substance leading to neuronal 
death in neurodegenerative processes.5 Insoluble βA fibrils are the main 
component of the senile plaques, the pathological element triggering the 
cascade of events that finally produces degeneration and death of 
neurons.6 Some of these events are neuro-inflammation,7,8 production of 
ROS9-11 and neurofibrillary tangles deposition produced by hyper-
phosphorylated tau-protein.12 The most important strategy in the search 
for new drugs able to avoid the production of βA and subsequent senile 
plaques deposition, has been the synthesis of inhibitors of the BACE1; 
one of the three secretases involved in processing APP, namely: , β and 
-secretases. BACE1 is considered the initiating enzyme of the 
amyloidogenic pathway; it cleaves APP to produce the carboxy-terminal 
fragment (C99) and the soluble β-secretase metabolite sAPPβ. 
Subsequently, C99 is cleaved by the non-precise -secretase to produce 
mainly two forms of toxic βA peptide, differing by two amino acids βA1-40 
and βA1-42, being the latter the most toxic. Given the paramount role of β 
and -secretase in the production of toxic βA, inhibition of these two 
enzymes has been considered a valid approach to seek new disease 
modifying drugs for AD; specially BACE1 for participating in the very 
beginning of the amyloid cascade.  
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Consequences and Benefits of BACE1 inhibition in AD 
Two aspects must be taken into account when discussing about BACE1 
inhibition as a strategy against AD. It has been demonstrated that the 
levels of this protein are augmented in AD patients.20 Consequently, 
inhibition of BACE1 in the right proportion might help to recover the 
normal levels of enzyme activity and reduction of Aβ synthesis. This proof 
of concept has been validated in several preclinical and clinical studies, 
where BACE1 inhibitors effectively reduced the production of Aβ species. 
However, given the complexity of AD pathogenesis, not always, the 
reduction of Aβ correlates with a rescue of cognitive abilities as 
demonstrated in studies using different molecules targeting Aβ 
production.21 It is worth to mention the cases of tarenflurbil and 
semagacestat (-secretase inhibitors) and AN1792 (anti-Aβ vaccine) which 
effectively reduced plasma and CSF levels of Aβ and clear senile plaques 
but were not able to improve the cognitive abilities of AD patients in 
phase 3 clinical trials.22-25 On the other hand, an excessive inhibition of 
BACE1 may produce strong side effects due to the diversity of substrates, 
the lack of specificity of some inhibitors and the distribution of the 
enzyme through different nervous and peripheral organs. Some of 
secondary effects of BACE1 inhibition are inferred from gene suppression 
studies which have demonstrated that complete suppression of BACE1 
may produce perinatal mortality, smaller size, hyper activity, 
hypomyelination in CNS and peripheral nervous system (PNS), increased 
susceptibility to seizures and schizophrenia-like behavior, retinal toxicity, 
among others.26-29  
BACE1 Inhibitors 
The first class of BACE1 inhibitors was developed as transition state 
analogues. These compounds, usually show a non-hydrolysable peptide-
based structure, large enough to fill the active site of the enzyme.30 Due 
to their structural features, these inhibitors present high potencies but 
General Introduction 
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poor pharmacological properties, such as low BBB penetration and 
bioavailability. Some non peptidic BACE1 inhibitors mimicking the 
transition state include derivatives of hydroxyethylene, hydroxylamine, 
carbineamine and reduced amides.27,31 The poor drug-like properties of 
this kind of compounds led to the search of new small molecule 
inhibitors with high potencies and improved drug-like properties. Non-
peptidic small molecule inhibitors include compounds based on acyl 
guanidine, 2-aminopyridine, amino imidazole, amino hydantoins, amino 
thiazoline, amino oxazoline, dihydroquinazoline, aminoquinoline, 
pyrrolidine and some natural derivatives containing the chromone, 
flavonoid and stilbenoid scaffolds.27,32-35  
 
 
Figure 1. BACE1 inhibitors in clinical trials 
In spite of the wide variety of compounds able to inhibit potently BACE1, 
only a few molecules have reached clinical phases. BACE1 inhibitor 
E260936 developed by Eisai Company is being currently evaluated in a 
phase 2 clinical study (NCT02322021) aimed to evaluate safety and 
efficacy in AD patients. Most advanced candidates are verubecestat, also 
known as MK8931 developed by Merck and AZD3293 (figure 1) from 
AstraZeneca; these drugs have demonstrated to be able to reduce Aβ 
levels in plasma and cerebrospinal fluid (CSF) by inhibition of BACE1, 
exhibiting safety and tolerability. Currently they have advanced to phase 
3 clinical trials (NCT01739348 and NCT02245737 respectively).26-28,37 
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General Approach 
During the last years, research in drug development for 
neurodegeneration has been driven for the paradigm of one target-one 
drug,38 based on the idea that targeting specifically a single enzyme, 
receptor or gen could stop or reverse a pathological process. This 
approach has failed in putting into the clinic a disease-modifying drug or 
treatment, defined as any intervention able to affect the pathogenesis of 
disease and consequently able to prevent, to stop, or at least to delay 
neuronal loss.39  
The reason of this failure lies on the complexity of the network of 
pathophysiological processes underlying the origin of neurodegeneration, 
and our lack of knowledge about the primordial event, which triggers the 
others; if it does exist. So far, we understand that genetic, epigenetic and 
environmental factors are involved in neurodegenerative processes; 
moreover, today is accepted that multifactorial processes such 
neurodegenerative diseases cannot be stopped or prevented by a drug or 
treatment based on a single mechanism of action.  
Regarding to AD, we must tell the same story; current drugs used in AD 
therapy are based on the same paradigm and are included into two 
categories, AChEi’s and antagonists of N-methyl-D-aspartic acid (NMDA) 
receptor. These drugs are aimed to treat the symptoms of the disease but 
are not able to affect the progression of neuronal loss. Research in drug 
discovery for AD, has been conducted in a similar manner, on the basis 
of the main accepted hypotheses. It has led to the synthesis of hundreds 
of new inhibitors of the enzymes involved in its onset and progression; 
(i.e. AChE, BuChE, BACE1, glycogen synthase-3β (GSK-3β), 
phosphodiesterases (PDE’s), and MAO’s). However, in spite of their 
potency and pharmacological properties, none 
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of them has been able to act as a disease modifying drug, or at least to 
show better results than those of the currently used drugs. These 
disappointing outcomes have led to researchers to envision new 
strategies in the quest for a pharmacological cure for AD.  
Multitarget Strategy 
One of these new approaches is based on the idea that a single molecule 
acting at different targets and different levels of the pathophysiology of a 
disease would exert synergic effects, which in turn could affect in a more 
effective way the progress of the disease; this kind of drug are 
denominated, among other names, multi-target directed ligands 
(MTDL).40 This new approach could be considered an evolution of two 
older concepts, multi-medication therapy (MMT) and the multi-compound 
medication (MCM). The former consists of administering separately 
several medications with different mechanisms of action (cocktail) and 
the latter comprises the combination of several drugs in an unique 
formulation (single pill).41 
One example of MCM related to AD is the administration of rivastigmine 
and memantine in a single transdermal patch. The study of Han and 
coworkers (2012),42 evaluated the effects of this combination in patients 
with mild and moderate AD. They observed that results of this treatment 
vary depending on the apolipoprotein E genotype. According to the 
authors, patients carrying ε4 allele responded in a more favorable 
manner. However, whether or not, combined treatment of these drugs is 
better than individual administration remains controversial, since this 
putative improvement is small regard to the effects of individual 
administration of AChEi’s.43 
Disadvantages of these strategies may include different and accumulative 
side effects, different ADME properties or different regimens of 
administration. Theoretically, MDTL strategy may avoid these 
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disadvantages, since one single drug would require a unique 
administration via, showing a unique pharmacological profile and acting 
on different interconnected targets in a synergic manner and with a 
reduced pattern of side effects. 
Two Ways to MTDL’s 
Two general strategies exist to design MTDL’s; construction of molecules 
with merged or overlapping pharmacophores with in-built ability to 
interact with the desired targets, and the combination of independent 
moieties through a linker with the hope to maintain the individual 
activities in the resulting “hybrid” molecule.  
 
Figure 2. Description of the strategies used to build MTDL’s 
In both cases it is possible to apply the traditional functionalization 
strategy in order to increase the affinity or modulate the selectivity profile 
of a given ligand.40,44,45  
Traditionally, the resulting hybrid molecules are defined as the 
combination of different independently acting compounds into a single 
covalently bonded compound, able to provide a greater potency than the 
sum of each individual moiety.46 However, today it is accepted that 
MTDL’s, must not necessarily own high affinity towards each one of the 
targets which they are aimed to. Generally, it is considered unlikely that 
a single small molecule binds equally to its different targets with the 
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same high affinity. Speaking about MTDL’s, low affinity does not 
necessarily means low efficacy; a multitarget-ligand might be enough to 
produce a disease modifying effect, since would be able to affect the 
network of pathophysiological factors involved in a disease.47 
Privileged Structure Concept 
One of the most important aspects in the design of new MTDL’s, is the 
selection of the structures to be hybridized. It is possible to combine 
whole molecules or fragments believed to be involved in the interactions 
with the active site of the targets to be aimed. One important idea to be 
considered is the privileged structure concept. 
There are two ways to understand this general concept. The first one 
refers to the definition of Evans et al.48 as those structures able to 
provide ligands for more than one receptor. The second one refers to the 
concept of a privileged scaffold, defined as a molecular framework 
present in several molecules with biological activity.49,50 
Along this work, we planned to use this general concept in the design of 
new MTDL’s with potential use in AD therapy. We have selected the NBP 
fragment to be hybridized with other privileged scaffolds important to AD 
in order to obtain several families with different combinations of 
biological activities. In the next section, some studies demonstrating the 
ability of NBP to participate in molecular interaction with some enzymes 
related to AD are explained. 
NBP Fragment as a Privileged Structure with potential use in 
AD. 
NBP fragment accomplishes the classical concept of privileged structure; 
it is part of numerous molecules with affinity for different targets related 
to central nervous system (CNS). Benzetimide, (muscarinic antagonist), 
and donepezil (AChEi) bear an NBP fragment in their structure.49,51 
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Figure 3. Active molecules containing the NBP fragment 
Since we have selected BACE1, the sigma-1 receptor (1R), AChE and 
BuChE as our targets of interest, we describe here some examples 
demonstrating the importance of NBP fragment in the interactions of 
some selected ligands with these proteins. 
In donepezil-hAChE complex, the benzylic ring forms a - stacking 
interaction with tryptophan 86, while the nitrogen atom of donepezil 
interacts through a water molecule with tyrosine 341 and tyrosine 337.52 
(Figure 4) 
 
Figure 4. Molecular interactions between donepezil and AChE; taken from 
reference 31. 
Regarding to 1R, it has been demonstrated that analgesic compound 
S1RA, synthesized by Zampieri and coworkers, (Ki = 0.1 nM),53 bearing 
an NBP fragment in its structure, may interacts with the putative active 
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site of the receptor through a T-stacking - interaction between the 
benzylic ring and tryptophan 121, a salt bridge between the protonated 
nitrogen of the piperidine and aspartic 126 and finally Van de Walls 
interactions between arginine 119 and p-Cl-phenyl ring according to the 
homology model of Laurini et al.54,55 (Figure 5) 
 
    
Figure 5. Molecular interactions between S1RA and 1R homology model, taken 
from reference 33  
Concerning to BACE1, Yang and coworkers (2009),56 demonstrated the 
utility of N-(1-benzyl-piperidin-4-yl)-4-mercapto-butyramide as a probe to 
be covalently bonded to a cysteine residue in the protein in order to 
study its ability to occupy the catalytic site of the enzyme (figure 6). They 
observed that the tertiary amine of the NBP fragment is able to interact 
with Asp32, while the amide nitrogen interacts with Asp228 in the open 
conformation of the catalytic site. On the basis of these observations, 
authors developed a new series of reversible BACE inhibitors with IC50 
values in the low micromolar range.  
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Figure 6. Molecular interactions between N-(1-benzyl-piperidin-4-yl)-4-
mercapto-butyramide and human BACE1; taken from Protein Data Bank, entry 
2ZJH and reference 35 
These examples make evident the potential of a privileged structure such 
as the NBP fragment to obtain new compounds with affinity for three 
crucial enzymes involved in AD. 
We propose to use this structure to be hybridized with different privileged 
scaffolds with complementary affinity for other important targets such as 
MAO-A, MAO-B, NMDA receptors, and oxidative stress. On the other 
hand, given the similarity between the NBP and the DBMA fragments, 
and taking into account that DBMA has been successfully used in the 
synthesis of some potent AChE inhibitors such as APP2238.57 We have 
aimed to use it along this work as an isosteric replacement which could 
improve the potency or modulate the selectivity for each target. All of 
above, aiming to obtain new MTDL’s with potential use in the therapy of 
AD. 
The chapters coming next are written in a full paper style, containing 
their own introduction explaining the corresponding main target, the 
description and discussion of results and the corresponding conclusions. 
In the last part of this document, a section of concluding remarks has 
been included to give an overview of the results and some perspectives 
about future studies that could be derived from this work.
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Design Synthesis and Evaluation of New 
Sigma-1 Agonists with AChE-BACE1 
Inhibitory Activity and Antioxidant 
Properties 
Introduction 
Sigma Receptor 
The history of sigma receptor is closely related to the opioid receptors 
family; before its isolation and pharmacological characterization,58-60 it 
was mistakenly classified as a subclass of opioid receptor. The opioid-like 
effects of morphine, ketocyclazocine and alazocine (SKF10047 or SKF) 
(figure 1.1), led to Martin and co-workers in 1976, to presume the 
existence of three opioid receptors, since these three structurally related 
substances exerted three different syndromes in dogs.61 Morphine 
induced the μ syndrome, characterized by miosis, bradycardia, 
hypothermia, depression of the nociceptive responses, indifference to 
environmental stimuli and euphoria. According to the authors, this 
syndrome was attributable to the interaction between morphine and its 
putative receptor (μ receptor). On the other hand, ketocyclazocine 
symptoms including dysphoria, miosis, sedation, depression of the flexor 
reflex and low effects in nociception and pulse rate were attributed to the 
interaction of ketocyclazocine with its receptor ( receptor). The third 
compound exerted different symptoms including mydriasis, tachypnea, 
tachycardia, and surprisingly, dog delirium and hallucinations. Since the 
symptoms exerted by this opiate compound were different to those 
exerted by morphine and ketocyclazocine, Martin and coworkers 
proposed the target of alazocine as a new opioid receptor, supported by
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 the fact that this protein interacts with an opiate molecule which effects 
are antagonized by naltrexone, a classical opioid antagonist used as a 
control to determine whether or not a receptor is opioid in character 
(Figure 1.2). 
 
Figure 1.1 Compounds used by Martin and coworkers to propose μ,  and  
syndromes 
Controversially, in 1983 Vaupel reported that naltrexone was not able to 
antagonize the effects of phencyclidine (PCP) and SKF.62 This study 
observed that a dose of 0.8 mg/Kg of naltrexone, required to produce 
abstinence in SKF dependent dogs, was 40 times higher than the dose 
used for morphine dependent dogs; this finding pointed out a low affinity 
of naltrexone for the sigma receptor. Indeed, according to the authors, 
withdrawal abstinence in SKF-dependent dogs was stronger than 
naltrexone triggered abstinence, ratifying the weak affinity for the sigma 
receptor. Abstinence syndrome precipitated by naltrexone included 
antagonism on the flexor reflex paradigm.  
The observations of Vaupel, added to the study of Herling and Shannon 
(1982) in which was demonstrated that  opioid-like effects of racemic 
SKF are attributable exclusively to the isomer (-)-SKF10047, since they 
are antagonized by naloxone (figure 1.2),63 led to conclude that the  
syndrome observed by Martin is produced by the interaction between 
isomer (+)-SKF10047 and the putative sigma receptor; however, 
Chapter 1 
29 
 
considering that these effects are not antagonized by naloxone or 
naltrexone, which is a requirement for a receptor to be considered opioid, 
it was decided to avoid the terms opioid or opiate when referring to sigma 
receptor proteins.64 
 
Figure 1.2 Typical opioid antagonists  
Nowadays, it is accepted that sigma receptor is a unique kind of protein, 
different to opioid receptors and phencyclidine (PCP) binding site, an 
ionophore of the NMDA receptor which shares affinity for (+)-SKF.65 There 
are two subtypes of sigma receptors, designated as 1 and 2 on the 
basis of their different pharmacological profiles.66,67 1R structure 
consists of a 223 amino acid chain with two transmembrane domains, 
different to G-protein coupled receptors (GPCR) and with no homology 
with any other mammalian protein. 2R structure still remains to be 
elucidated. 68-70 
The work of Hayashi and Su (2007) is considered one of the most 
important studies on 1R.71 They proposed that 1 is a ligand activated 
“receptor chaperone” located on the mitochondria-associated 
endoplasmic reticulum membrane (MAM), complexed with other 
chaperon known as binding immunoglobulin protein (BiP, Grp78 or 
HSPA5). Activation of 1 leads to the dissociation of 1/BiP complex and 
subsequent redistribution of 1 to form a new complex with type 3 
inositol triphosphate receptors (3IP3R). This new association stabilizes 
3IP3R prolonging their action and maintaining the influx of calcium from 
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endoplasmic reticulum (ER) to mitochondria. Cytosolic calcium levels are 
not affected by activation of 1, since it does not form any complex with 
type 1 IP3 receptors.  
ER-stress conditions, such as glucose deprivation, ER Ca+2 depletion and 
unfolded proteins accumulation, produce 1R redistribution and 
transcriptional up-regulation which suppress ER-stress induced 
activation of PERK (protein kinase RNA–like endoplasmic reticulum 
kinase) and ATF6 (activating transcription factor 6), two proteins involved 
in unfolded protein response (UPR). This upregulation has no effects on 
ER-stress induced IRE1 (inositol-requiring transmembrane 
kinase/endonuclease 1) expression and basal activity of the three UPR 
proteins. This is considered a proof of the involvement of 1R in cell 
survival. Indeed, in the same work it was established that knocking down 
of 1R enhances apoptosis induced by ER-calcium depletion and glucose 
deprivation.71,72 
1R is currently considered a new promising target in several 
neurodegenerative diseases such as amyotrophic lateral sclerosis 
(ALS)73,74, Parkinson’s disease (PD),75 Huntington’s disease,76 and 
numerous neurodegenerative diseases.77,78 
Sigma-1 Receptor in Alzheimer’s Disease 
Presence of 1R has been demonstrated in different animal and human 
brain regions: hippocampus, neocortex, substantia nigra, dentate gyrus 
of hippocampus and cerebellum;79-82 areas involved in motor function, 
emotions and memory. Besides neurons, such as Purkinje cells, 1R has 
been detected in astrocytes, oligodendrocytes and Schwann cells.83-85 
Given its presence in neural tissue, the role of 1R has been evaluated in 
several processes related to CNS diseases. Although the whole biological 
role of these receptors remains unknown, today we know they regulate 
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the function of a variety of processes trough opioid, NMDA, dopaminergic 
and cholinergic receptors.86,87  
Regarding to AD, numerous studies have demonstrated the effects of 1R 
agonists in various models of amnesia, learning and neuroprotection, 
among others. For example, enhancement of acetylcholine release from 
rat prefrontal cortex and hippocampus has been observed after 
administration of (+)SKF10047.88 These observations led to study the 
effects of other 1 agonists in learning and memory. For instance SA4503 
(figure 1.3), a selective 1 agonist, counteracts the amnesic effects of 
scopolamine, a potent cholinergic muscarinic antagonist known for 
producing memory impairment by blockade of ACh transmission.  
 
Figure 1.3 Some of the most studied 1 receptor ligands 
On the other hand, SA4503 alleviates amnesic effects of basal forebrain 
lesion induced by ibotenic acid; this brain region is rich in cholinergic 
neurons and corresponds to nucleus basalis of Meynert in humans. 
Ibotenic acid destroys selectively these neurons, damaging the central 
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cholinergic system and simulating AD conditions. Interestingly, effects of 
SA4503 in memory impairment induced by scopolamine and basal fore 
brain lesion, are reversed by haloperidol, a typical 1 antagonist, 
confirming the involvement of this receptor in the mechanism of action of 
SA4503 and the potential of 1 agonists in AD treatment.89,90  
In regard to cognition, the 1 agonist PRE-084 (figure 1.3) was evaluated 
in aged rats by Maurice (2001) using the water-maze model.91 Aged but 
not adult animals presented learning deficits which were alleviated by 
pretreatment with PRE-084. Age matched animals treated with saline, 
did not show any significant improvement of learning abilities; however, 
this work did not provide any information about using a 1 antagonist to 
counteract beneficial effects of PRE-084 in order to confirm the 
involvement of this receptor in the mechanism of action. A later study 
reported the protective effects of PRE-084 in a model of Aβ-induced 
toxicity. Learning and memory deficits exerted by Aβ25-35 administration, 
were reverted in the spontaneous alternation test (Y maze) and passive 
avoidance test. Beneficial effects of PRE-084 were reverted in a dose-
dependent manner by administration of the 1 antagonist BD1047.92  
Apart from the effects against learning and memory deficits, several 
studies have evaluated the potential neuroprotective properties of 1R 
agonists against the oxidative stress induced by Aβ administration.92-94 
ANAVEX1-41 and ANAVEX2-73, two mixed muscarinic and 1 agonists, 
have demonstrated to protect against the cell loss induced by Aβ toxicity 
in areas of hippocampus involved in memory and cognition, and sensitive 
to senile plaques deposition. In addition to cell death rescue, ANAVEX 
compounds proved to protect neurons against oxidative stress and 
apoptosis induced by toxic Aβ fragments, as demonstrated by diminution 
of levels of some oxidative stress markers, such as protein nitration, lipid 
peroxidation and caspase-3 production. Authors proposed a synergic 
mechanism of action involving muscarinic and 1R; since protective 
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effects are antagonized by scopolamine and BD1047.93,94 Another study 
reported that ANAVEX2-73 was able to reduce Aβ25-35 induced tau hyper 
phosphorylation by two ways: restoration of levels of the active form of 
Akt (protein kinase B), which regulates the activity of GSK-3β and by 
diminution of the active form GSK-3β which was increased by Aβ25-35 
administration and is considered to be upregulated in AD patients.95 
ANAVEX 2-73 has successfully completed a phase 1 clinical trial and is 
currently being evaluated in a phase 2a clinical study (NCT02244541). 
Another important finding connecting 1R and AD is the decrease of 1 
binding sites in human AD brain. The postmortem study carried out by 
Jansen and coworkers (1993) demonstrated that loss of neurons from 
hippocampus in AD diagnosed brains, correlates with the diminished 
amount of 1 binding sites in the same regions.96 Similar findings were 
observed in vivo by Mishina et al. (2008) with positron emission 
tomography (PET), using 1 agonist [11C]-SA4503; authors reported a 
reduced cortical and cerebellar distribution of 1 in early AD patients 
compared with healthy controls.97 However, in this study, the fact that 
some of the participating patients were treated with donepezil before 
experiments was not taken into account. Donepezil is known to possess 
high affinity for 1R and might affect its levels and distribution. 
1R activation exerts protection against oxidative stress by activation of 
the antioxidant response element (ARE) and subsequent transcription of 
the proteins involved in the cellular response to oxidative damage. 
According to the results of Pal et al. (2012) in 1 transfected COS-7 cells, 
these effects can be potentiated by 1 agonists and reduced by 
antagonists.98 Moreover, 1 knocked-out mice showed higher levels of 
oxidative markers and some antioxidant proteins compared to naive 
animals; this may point out a protective role of 1R against oxidative 
offense, additional to the chaperone activity discussed earlier.  
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Additional properties of 1 agonists may include protection against 
excitotoxicity. It has been demonstrated that 1 agonists are able to 
suppress the response to NMDA in rat ganglion retinal cells,99 as 
discussed earlier, 1 chaperone activity may be involved in these effects. 
However, regardless to the mechanism, reducing response to NMDA 
could prevent excitotoxicity induced apoptosis.100,101 Lobner et al. (1990) 
demonstrated that glutamate release induced by in vitro ischemic 
conditions (anoxia and glucose deprivation) was attenuated in rat brain 
slices by addition of 1 agonist N,N'-di(o-tolyl)guanidine (DTG).102 
Moreover, inhibition of glutamate release combined with NMDA receptors 
blockade exerted neuroprotective effects in rat brain slices, noteworthy, 
NMDA blockade alone was not neuroprotective by itself. A plausible 
mechanism which explains these observations remains unknown.  
Recently, it was discovered that the 1 agonist PB190 is able to block the 
microglial response to neuronal injuries. Such response consists on 
moving toward the damaged region, engulfing apoptotic neurons and 
releasing important cytokines, chemokines and ROS. Exacerbated 
microglial response is believed to be in part, responsible for 
neurodegeneration; consequently, modulation of this response could be 
paramount in slowing down neuronal loss. It was proved that 1 agonists 
administration to zebra fish larvae, blocks the microglial response to 
neural injury, without affecting microglial motility and ability to engulf 
apoptotic neurons, allowing microglial cells to move away from injured 
areas and permitting subsequent repair. Based on these outcomes, and 
in the fact that the effect of PB190 in microglial activation were abolished 
by knocking-down of 1R, authors proposed that the role of 1 in vivo is 
to switch-off microglial reaction, reinforcing the potential of 1R as a 
therapeutic target in neurodegenerative diseases.103  
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Taken together, these findings put clear the importance of 1R as a 
plausible target in the quest for finding new disease-modifying drugs for 
AD.  
 
Figure 1.4 Protective effects of 1 agonists, adapted from Ishikawa and 
Hashimoto (2010)104  
Lipoic Acid  
Lipoic acid is a naturally occurring antioxidant substance, isolated for 
the first time by Reed et al. in 1951.105,106 Only R-LA occurs in nature, 
both in animals107 and humans.108 It has been identified as a cofactor for 
several enzymes, important in energetics and mitochondrial 
metabolism.109  
Biochemical and pharmacological features of LA make it an interesting 
tool in the search for new molecular entities with the potential to become 
anti-AD drugs. Most renowned of these features is its antioxidant 
capacity. LA is rapidly absorbed from diet and easily reaches the blood 
stream and tissues where is likely converted to its reduced form, 
dihydrolipoic acid (DHLA)110 
Chapter 1 
36 
 
 
Figure 1.5 Lipoic acid and its reduce form, dihydrolipoic acid  
LA and DHLA achieve some of the most important requirements to be 
considered as good antioxidants. They are able to quench free radicals in 
aqueous and lipid phases, possess chelating properties and are able to 
regenerate other biogenic antioxidants.111  
A great number of studies have confirmed the beneficial properties of LA 
in several models of oxidative stress and neuroprotection.112-117 Indeed, 
positive effects of LA on cognitive parameters and disease progression of 
AD patients has been reported, despite postmortem confirmation of 
diagnosis remains needed in some of these studies.118-120 These effects 
could be explained by the ability of DHLA to increase the activity of 
acetylcholine transferase, and therefore, the production of acetylcholine, 
as demonstrated by Haugaard and Levin in 2000 and 2002,121,122 to 
protect against toxicity induced by Aβ, as confirmed in cultured rat 
cerebral neurons by Zhang et al. in 2001123 and Lovell et al. in 2003,124 to 
stimulate glucose uptake, according to Seaton et al.,125 who proved the 
ability of LA to promote the incorporation of 14C-deoxyglucose in rat basal 
ganglia. These results were attributed to the ability of LA to act as an 
insulinomimetic agent and to stimulate the utilization of glucose in vivo 
and therefore, the synthesis of the neurotransmitter acetyl choline which 
is dependent on acetyl-CoA, a substrate in the glycolytic pathway. Since 
it has been hypothesized that AD could be considered a type of diabetes 
confined to CNS,126,127 a compound with the ability to regulate the 
homeostasis of glucose and insulin brain levels could be relevant to treat 
not only AD but different neurodegenerative diseases.  
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Besides their antioxidant properties, BACE-1 inhibitory properties have 
been reported for hybrid compounds containing LA. One example is 
lipocrine, a hybrid between the AChE inhibitor tacrine and LA, which 
possesses the ability to inhibit simultaneously AChE, BACE-1 and self-
induced and AChE-catalyzed Aβ aggregation.128-131 Other examples 
demonstrating the value of LA as part of bioactive molecules include 
derivatives showing cytoprotective properties,132 neuro-protectants133 and 
1R agonists.114  
In this section we aim to hybridize the LA structure with the NBP and 
DBMA fragments present in the well-known AChE inhibitors donepezil 
and AP2238,134 in order to take advantage of their privileged properties 
described earlier. We propose that a combination of LA and a moiety 
containing a tertiary amine bearing a benzyl group could interact with 
the active sites of AChE, BACE-1 and/or 1R. 
 
 
Figure 1.6 Description of the proposed LA-hybrids and their potential 
interactions 
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Recently, Prezzavento and coworkers, obtained similar esters containing 
the NBP fragment which effectively binds to the 1R.114 However, here we 
intend to obtain new amide derivatives modifying the distance and 
geometry between the amide group and the tertiary amine, keeping intact 
the benzyl fragment which is crucial for interaction with the proposed 
targets as explained in the general approach section. 
Results and Discussion 
Synthesis of LA-NBP and LA-DMBA hybrids. 
In the NBP series, the required intermediates 1-benzylpiperidin-4-amine 
(n = 0) and 2-(1-benzylpiperidin-4-yl)ethanamine (n = 2) are commercially 
available whereas NBP amines with n = 1 and 3, were synthesized by two 
different methods depending on the length of the hydrocarbon chain.  
Compound 1.1 was obtained in excellent yield (92%) reacting benzyl 
bromide and piperidine-4-carbonitrile in refluxing toluene for 3 h. 
Subsequent reduction of nitrile 1.1 gave amine 1.2 (85%) by overnight 
treatment with LiAlH4 in ethyl ether at room temperature (rt) (Scheme 
1.1).  
On the other hand, compound 1.3 was synthesized by a Knoevenagel-
Doebner reaction from 1-benzylpiperidine-4-carbaldehyde and 
cyanoacetic acid in refluxing pyridine for 3 hours. The unsaturated 
intermediates were not isolated and were reduced with LiAlH4 to obtain 
1.4 as a sole product in 87% yield. 
In the DBMA series, compounds 1.5 and 1.6 were synthesized in high 
yields (95-97%) by reaction between N-methyl benzylamine and the 
corresponding nitro benzyl bromide in refluxing toluene during 3 h. Their 
reduction by catalytic hydrogenation provided amines 1.7 and 1.8 in 
almost quantitative yields (97-98%).  
Chapter 1 
39 
 
Scheme 1.1 Reagents and conditions. (a) Toluene/Triethyl amine 
(Et3N)/reflux/3h; (b) LiAlH4/Et2O/rt.; (c) Pyridine/reflux/3h/-CO2; (d) H2/Pd-
C(5%)/EtOH/rt./overnight; (e). LA/CDI/THF/mw/120°C  
 
Finally, LA-based hybrids 1.9-1.17 were obtained by a coupling reaction 
between the corresponding amine derivative and LA into a microwave 
reactor at 120 ºC for 3 min. Carbonyl diimidazol (CDI) was used as 
activating agent and THF as solvent. In general, hybrids were isolated in 
high yields (80-93%), although in the case of 1.10 an unexpected low 
25% was obtained despite several attempts to improve the reaction work-
up (Scheme 1.1). 
For comparison purposes, previously reported compound 1.18 was also 
obtained from 2-(3,4-dimethoxyphenyl)ethan-1-amine and racemic LA.133 
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Biological Evaluation 
Human Cholinesterases Inhibition and Oxygen Radical Absorbance 
Capacity (ORAC). Initially, all LA-based hybrids were evaluated as 
inhibitors of human AChE and BuChE (h-AChE and h-BuChE), following 
the Ellman method135 (Table 1.1). For the NBP series and in relation to h-
AChE inhibition, the chain length connecting the LA and NBP fragments 
was found to be a critical parameter, the best activity results being 
obtained for n=2 (i.e., -(CH2)2-). Interestingly, racemic (R,S)-1.11 and its 
enantiomers (R)-1.12 and (S)-1.13 showed IC50 values for h-AChE in the 
sub-micromolar range, without any noticeable difference between 
racemic mixture and pure enantiomers. However, in the case of h-
BuChE, both pure enantiomers (R)-1.12 and (S)-1.13 displayed better 
inhibition (around one order of magnitude) than the corresponding 
racemic mixture (R,S)-1.11. Replacement of the NBP fragment with DBA 
did not improve the inhibitory potency of the relevant compounds but 
shifted the selectivity between the two cholinesterases. Hybrids 1.15 and 
1.16, bearing a meta-substituted intermediate ring, maintained their 
sub-micromolar inhibition for h-BuChE, unlike their para-substituted 
counterpart 1.17. These results evidenced that NBP and DBA fragments 
are important for the affinity towards both cholinesterases.  
Radical scavenging properties were evaluated with the ORAC assay.136   
Trolox, the scavenging part of vitamin E, was used as internal standard 
with the arbitrary value of ORAC = 1.0. Results are expressed as trolox 
equivalents (trolox mmol / tested compd mmol) in a comparative scale. 
All tested LA-based hybrids showed radical scavenging properties close to 
vitamin E and thus, they could be considered as good antioxidant agents 
(table 1.1). 
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Table 1.1 Inhibition of h-AChE, h-BuChE, and h-BACE1 (IC50, µM), evaluation 
of the Oxygen Radical Absorbance Capacity (ORAC, trolox equivalents.), and 
Prediction of the CNS-Permeation by the PAMPA-BBB Assay.a 
 IC50 (µM) ORAC PAMPA-BBB 
Compd h-AChE h-BuChE h-BACE1 (Trolox equiv.) Pe (10-6 cm s-1) 
1.9 6.81±0.25 7.99±0.35 27%b 0.94±0.07 nd 
1.10 31%b <20%b 6.33±0.21 nd nd 
1.11 0.39±0.03 2.13±0.14 5.65±0.26 0.96±0.02 nd 
1.12 0.43±0.11 0.79±0.20 8.11±0.26 1.04±0.09 33.0±3.1e  
1.13 0.21±0.09 0.63±0.09 9.92±0.39 0.80±0.08 26.6±0.7 e  
1.14 3.75±0.91 0.93±0.3 7.91±0.77 0.63±0.01 nd 
1.15 46%b 0.53±0.21 28%b 1.00±0.08 nd 
1.16 48%b 0.33±0.12 25%b 0.79±0.09 nd 
1.17 2.43±0.12 4.87±0.23 38%b 0.73±0.11 37.6±0.3e 
Donepezil 0.01±0.002 2.5±0.07 0.17c nd nd 
AP2238 0.044d 48.9d nd nd nd 
a Results are expressed as mean ± SEM. (n =3); b Inhibition percentage at 10 μM;  
c Taken from ref137. d Taken from ref138. e CNS permeation positive. nd: Not 
determined. 
 
Evaluation at Human BACE1 and Sigma-1 Receptor. LA-based hybrids 
were evaluated as inhibitors of the human recombinant BACE1 protein 
in a fluorescence resonance energy transfer (FRET)-based assay.139,140 
Initially, compounds were tested at a single concentration (10 µM) and 
those displaying an inhibition percentage above 50% were re-evaluated in 
a concentration range comprised between 0.1 µM and 100 µM. The 
corresponding calculated IC50 values are listed in table 1.1  
Compared to the inhibition against the cholinesterases, the activity over 
h-BACE1 was more tolerant to the modifications over the aliphatic chain 
linker, but more sensitive to the substitution of NBP by DBMA. Whereas 
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compounds 1.9 and 1.15-1.17 showed low percentage of h-BACE1 
inhibition at 10 µM, hybrids 1.10-1.14 (n=1-3) were found to be good h-
BACE1 inhibitors, with IC50 values in the low micromolar range. Thus, 
compounds containing the NBP moiety were more potent than DBMA 
derivatives. In the NBP series, hybrids 1.10-1.14 showed little variations 
in their IC50 values (5.7 – 9.9 µM, table 1.1). 
Taking into account the results reported above, we selected racemic 
mixture 1.11, pure enantiomers (R)-1.12 and (S)-1.13, which showed the 
best dual h-AChE – h-BACE1 inhibition, as well as the DBA derivatives 
(R,S)-1.15 (substitution at position 3) and (R,S)-1.17 (substitution at 
position 4) to evaluate their ability to displace the agonists 
[3H]pentazocine and [3H]-DTG from the 1 and σ2 receptors of animal 
origin obtained from guinea pig brain (σ1) and rat liver (σ2), respectively.  
Table 1.2 Affinities and selectivities towards 1R and 2R of compounds 1.11-
1.13, 1.15 and 1.17. The affinity of pentazocine and DTG is reported as 
reference compounds.  
 Ki (nM)a Selectivity vs. 1Rb 
Compd 1R 2R (Ki2R/ Ki1R) 
11 8.90 ± 0.45 232 ± 27 26 
12 7.56 ± 0.98 205 ± 42 27 
13 15.1 ± 1.4 289 ± 51 19 
15 25.3 ± 1.9 1200 ± 170 48 
17 21.0 ± 2.6 1400 ± 230 67 
Pentazocine 15.0 ± 3.0 - - 
DTG - 54 ± 8 - 
aResults are expressed as Ki (nM) and are the mean ± SEM of the experiments 
repeated in triplicates. bSelectivity vs. 1R was calculated as Ki2R/ Ki1R 
Two well-known sigma binding site ligands, (+)-pentazocine and DTG, 
were also tested for comparative purposes (Table 1.2). 
As shown in table 1.2, tested compounds showed good affinities for 
sigma receptors, with Ki’s comprised between the low-micromolar and the 
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low-nanomolar scale. In all cases, LA-based hybrids exhibited a 
remarkable preference for the 1R subtype since their experimental 
affinities are in the range of low-nanomolar concentration with a 
selectivity ratio against the 2R greater than at least 19 times. 
New compounds were then functionally characterized at 1R. The general 
consensus is that 1R antagonists provoke a high cytotoxic effect leading 
to cell death, whereas 1R agonists promote cell survival.141 For defining 
the agonist/antagonist profile of the new derivatives we tested their 
cytotoxicity on the SH-SY5Y neuroblastoma cell line by adapting the 
approach originally proposed by Zeng et al. based on the MTT assay.142 
To this aim, the cytotoxicity of the novel 1R ligands was tested in SH-
SY5Y cells and compared to that measured for NE-100 and pentazocine, 
two commonly accepted 1R antagonist and agonist, respectively. 
Figure 1.7 shows cytotoxicity data of 1R ligands at 50 µM, expressed as 
a percent relative to the cytotoxicity of NE-100 at the same 
concentration, as obtained from the cell viability assay. Conversely, at 
the same concentration, pentazocine showed only limited toxicity (2%) to 
the SH-SY5Y cells. As inferred from figure 3, the moderate or low 
cytotoxicity of all lipoic-based hybrids is more consistent with a 1R-
agonist, rather than with a 1R-antagonist activity. Both DBMA 
derivatives (R,S)-15 and (R,S)-17 could be define as full agonists, as 
demonstrated by a cytotoxic level under 10%, comparable to the 
prototypical agonist pentazocine. Instead, the NBP derivative (R,S)-11 
and its pure enantiomers (R)-12 and (S)-13 behaved as partial agonists 
with a cytotoxicity comprised between 40-60%, in any case lower 
compared to the antagonist NE-100. This fact could be ascribed to their 
smaller selectivity against the 1R subtype as illustrated in table 1.2. 
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Figure 3. Cytotoxicity of 1R ligands as obtained from the MTT assay. SH-SY5Y 
cells were treated with different 1R ligands (50 μM) for 48h. MTT assay was 
then performed, cytotoxicity of compounds was determined, and data were 
reported as % of NE-100 cytotoxicity at 50 μM (100%). The bars represent the 
mean ± SD from three independent experiments performed in triplicate 
Neurogenic Studies. These studies were performed to assess the 
potential ability of new LA-based compounds to promote differentiation of 
brain stem-cells into a neuronal phenotype. Derivatives 1.12 and 1.17 
were selected for these studies, covering different structural features and 
biological activities. The LA-NBP compound 1.12 showed inhibition of h-
ChEs and h-BACE1, an ORAC value similar to vitamin E, and was found 
to be the most potent 1R agonist of this work. In contrast, the LA-DBA 
hybrid 1.17 showed worse inhibition of h-ChEs, no activity at h-BACE1, 
an ORAC value under the trolox value, but displayed the most selective 
1R agonism compared to 2R. Adult mice neural stem-cells were isolated 
from the SGZ of the dentate gyrus of the hippocampus, and cultured as 
neurospheres (NS) following described protocols.143-145 NS were incubated 
in the presence of 1.12 and 1.17 during 7 days and then adhered on a 
substrate to allow differentiation for 3 days. Immunocytochemical 
analysis using β-III-tubulin (clone TuJ1) and MAP-2 (microtubule-
associated protein 2) antibodies were used to visualize early proliferation 
and neuronal maturation, respectively. 
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Figure 1.8 In vitro neurogenic effect of compounds 1.12 and 1.17 on murine 
hippocampal SGZ-derived spheres. Neural stem-cells enriched spheres (NS) were 
grown for 7 days in culture in the presence of compounds 1.12 and 1.17 (10 
µM). Later on, NS were adhered on a substrate to allow differentiation for 3 days 
in the presence of compounds. Representative images show the expression of β-
III-tubulin (TuJ clone; green) and MAP-2 (red) inside the NS (inner part) and in 
the distal area (outer part). DAPI was used for nuclear staining. Scale bar, 
200µm. 
  
Chapter 1 
46 
 
As shown in figure 1.8, treatment with 12 and 17 clearly enhanced 
neurogenic activity on cultured NS. Both compounds were able to induce 
the expression of early neurogenesis markers like β-III-tubulin and also 
promoted neuronal maturation, increasing the number of MAP-2 
expressing cells. Interestingly, compound 12 appeared to be more 
effective not only promoting early neurogenesis but also stimulating 
neuronal maturation, showing a great neurogenic effect.  
Parallel Artificial Membrane Assay (PAMPA). Derivatives 11, 12 and 17 
were next selected as representative compounds of the two families to 
evaluate their ability to cross the blood-brain barrier in the PAMPA assay 
Table 1.3 Permeability (Pe 10-6 cm s-1) in the PAMPA-BBB Assay of 10 
Commercial Drugs Used in the Experiment Validation 
Compd Bibl.a Exp.b 
Testosterone 17.0 30.97 ± 3.78 
Verapamil 16.0 31.56 ± 3.89 
Imipramine 13.0 21.55 ± 3.03 
Desipramine 12.0 23.74 ± 3.17 
Promazine 8.8 22.31 ± 1.69 
Corticosterone 5.1 12.65 ± 0.14 
Piroxicam 2.5 9.12 ± 0.04 
Hydrocortisone 1.9 10.47 ± 0.03 
Caffeine 1.3 7.56 ± 0.15 
Ofloxacin 0.8 6.17 ± 0.31 
aTaken from Ref. 145. bData are the mean ± SD of three independent experiments 
The values of permeability were validated by comparison with previously 
reported values for several commercial drugs. All evaluated compounds 
were predicted to reach the CNS according to this in vitro model (Table 3). 
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Figure 1.9 describes the relation between bibliographic and experimental 
values of permeability summarized in table 3; as well as the calculated 
range of permeability values to determine whether or not any given 
compound is able to reach CNS. Compounds with values greater than 
11.9 are interpreted as positive to cross the BBB.  
 
 
Figure 1.9 Correlation of permeability values of the standard compounds used 
in PAMPA 
Modeling Studies 
Modeling Studies in h-BACE1.  
BACE1 is an aspartic protease, which functions in the first step of the 
pathway leading to the production and deposition of Aβs. It is a 
structurally challenging protein target, which displays a pronounced 
induced-fit conformational adjustment upon ligand interaction. Indeed, a 
detailed comparison of the available X-ray structures suggests that both 
the flap open region of the enzyme (residues 68–74 forming a β hairpin 
loop) and the 10s-loop (residues 9–14) located near the S3 site undergo a 
substantial rearrangement upon ligand binding.146,147 Accordingly, 
BACE1 adopts a bilobal structure with the inhibitor binding in the 
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substrate binding pocket between the N-terminal and C-terminal lobes of 
the enzyme. Catalytic aspartates D32 and D228 are located at the center 
of this pocket, and form part of an extensive hydrogen bonding network 
within the protein active site.27 
A challenge in the design and discovery of BACE1 inhibitors is posed by 
the large size of its substrate pocket. However, the development of large 
inhibitors is of poor practical use, given the known pharmacokinetics and 
pharmacodynamics problems such drugs may encounter in vivo. 
Concomitantly, small-molecule inhibitors would hardly fill the binding 
pocket adequately and, as such, are not endowed with great inhibitory 
potency. A way to overcome this issue can consist of increasing the 
affinity of a given inhibitor for the BACE1 active site by potentiating its 
interactions with the residues lining the enzyme binding cavity. In this 
context, we have carried out a molecular modeling study aimed at 
providing insights into the binding mode of the new LA-NBP and LA-
DBMA hybrids onto BACE1.  
 
Table 1.4 Binding Free Energies Gbind and its Components for 1.12, 1.13, (R)-
1.17 and (S)-1.17 in Complex with the BACE1a 
Compd. 
H 
(kcal/mol) 
TS 
(kcal/mol) 
Gbind 
(kcal/mol) 
(R)-1.12 -47.50 (0.21) -29.16 (0.27) -18.34 (0.35) 
(S)-1.13 -47.26 (0.23) -29.10 (0.26) -18.16 (0.33) 
(R)-1.17 -32.11 (0.21) -23.42 (0.29) -8.69 (0.37) 
(S)-1.17 -32.09 (0.19) -23.28 (0.28) -8.81 (0.44) 
aValues are expressed in kcal/mol and errors are given in parenthesis as 
standard errors of the mean. 
A three-step computational procedure was followed. In the first stage, we 
performed docking studies on the whole target protein surface. In a 
second stage, the best determined binding mode was further refined by 
molecular dynamics (MD) simulations. Finally, binding free energy 
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(Gbind) calculations in the MM-PBSA framework of theory148 were carried 
out to gain insight into thermodynamics and the nature of the stabilizing 
interactions for each drug/protein complex (table 4). 
 
Analysis of the binding mode of (R)-1.12 and (S)-1.13 into the BACE1 
enzyme revealed that the NBP scaffold locates below the flap region, 
allowing the protonated nitrogen of the piperidine to interact with both 
catalytic aspartic acids D32 and D228,27,149,150 and with T231 via 
electrostatic and H-bond interactions (figure. 1.10).  
 
 
Figure 1.10 Details of compound (S)-1.13 (in atom-colored sticks-and-balls: 
gray, C; blue, N; red, O; yellow, S) in the binding pocket of BACE1. The 
secondary structure of the protein is portrayed as a light-blue ribbon. Hydrogen 
bonds are highlighted as black dotted lines. Hydrogen atoms, water molecules, 
ions and counterions are omitted for clarity. 
 
The benzylic group establishes favorable - stacking contacts with the 
side chain of Y198 (S2’ pocket) and hydrophobic interactions with V332, 
I226, and T329 in the entry region of the binding pocket. The piperidine 
ring sits in the S1’ subsite, defined by residues D32, D228, G34, S35 and 
T231.  
The hydrophobic side chains of L30, Y71, F108, W115, and L118 in the 
S1 site nicely accommodate the linker portion of the compounds, with a 
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hydrogen bond formed between the amide carbonyl and the flap 
backbone NH of Q73. This is an important finding since hydrogen bonds 
to the backbone NH of the flap are essential to exhibit activity.151-155 
Additionally, the amide proton is hydrogen bonded to the backbone 
nitrogen of G230. Also in this case, the presence of an amide moiety that 
occupies the S1/S3 pockets of BACE1 and engages G230 proved to be a 
successful strategy to significantly increase BACE1 potency.156 The chain 
of the LA fragment extends deep into the S3 pocket, thereby establishing 
hydrophobic contacts with I110, W115, G11, G13, and Q12 side chains, 
while the dithiolane ring docks in the hydrophobic subpocket formed by 
the side chains of Y14, S229, T232, and A335. All together, these 
interactions may account for the micromolar inhibitory potency of (R)-
1.12 and (S)-1.13. Traditionally, appropriate substituents in S3 
contribute significantly to potency;157-160 moreover, the S3 pocket can 
accommodate large hydrophobic ligands.161,162 Thus, the chirality on the 
LA fragment is expected to have a minor impact. In fact, and in line with 
the experimentally determined IC50 values, we did not detect any 
significant difference in the binding mode of the two enantiomers (R)-
1.12 and (S)-1.13. 
In all complexes analyzed, BACE1 assumes a closed conformation; the 
flap adopts a conformation complementary to the shape and nature of 
the ligand bound in the active site, while Y71 is hydrogen bonded to W76 
side chain, which physically separates the S1 and S2′ sites. However, 
some differences have been found regarding the DBMA derivative 1.17 
(figure 1.11). The protonated nitrogen of the ligand is able to reach the 
acid environment formed by the catalytic dyad D32 and D228, but less 
efficiently (larger and, hence, weaker H-bonds, see figure 1.11, right 
panel) than 1.12/1.13, whereas the N-benzyl ring establishes  
interaction with Y198, its position inside the active site resembling that 
of 1.12/1.13. Nevertheless, the presence of the rigid aromatic core 
induces a severe clash with the flap: indeed, the flap residue Y71 breaks 
the hydrogen bond with W76 that is not counterbalanced in energy by 
Chapter 1 
51 
 
the formation of  interactions with the aromatic ring of the ligand. 
Moreover, as a consequence of this flap conformational change, the H-
bond between the amide and Q73 is weaker than for 1.12/1.13, as 
revealed by the corresponding per residue binding enthalpy 
deconvolution (figure 1.11, right panel). Overall, the complex is less 
stable and, accordingly, shows a higher Gbind value than the NBP 
derivatives. Thus, even if the ligand somehow interacts with both key 
catalytic aspartic acids and the LA is also well accommodated in the 
hydrophobic cavity S3, the opening and destabilization of the flap due to 
the aromatic core could account for the lower potency of the DBMA 
derivatives. 
 
 
Figure 1.11 (Left) Comparison between the optimized MD binding conformations 
within the BACE1 receptor putative binding site of compounds (S)-1.13 (blue) 
and (S)-1.17 (pink). (Right) Per residue enthalpy decomposition for the same 
system. 
 
Finally, we noted that the presence of a basic amine group (pKa ≥ 6) as in 
NBP or DBMA, seems crucial for BACE1 inhibition since the replacement 
by a 1,2-dimethoxybenzene group (Compound 1.18) results in a drop of 
activity. Indeed, our calculations were unable to isolate a stable complex 
along the pertinent MD simulation trajectory. 
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Modeling Studies in Sigma-1 Receptor 
During the past years several three-dimensional (3D) pharmacophore 
models for 1R ligands have been published,163-167 and all these models 
propose a basic amino group and at least two hydrophobic substituents 
at the N-atom. However, the last-generation of 1R pharmacophore 
models165,166 are characterized by an additional requirement: a 
heteroatom, such as O or S, in the scaffold of the molecule that can form 
hydrogen bond interactions with a counterpart in the receptor binding 
cavity. From a qualitative point of view, both NBP and DBMA scaffolds 
match the pharmacophore requirements to efficiently bind the 1R. 
Actually, all tested derivatives demonstrated low nanomolar affinities for 
the 1R (table 2). As for the BACE1 receptor, to describe at molecular 
level the binding mechanism of these new derivatives, compounds (R)-
1.12 and (S)-1.13 as well as both enantiomers of compounds 1.15 and 
1.17 were docked in the putative binding site of our well validated 3D-
model of 1R.54,168 Consequently, the corresponding ligand/receptor free 
energies of binding (Gbind) were calculated by applying a validated MD 
procedure168,169 based on MM/PBSA calculations148 (table 4). Lastly, to 
investigate in detail the binding mode of the inhibitors to the target, a 
deconvolution of the enthalpic component (Hbind) of Gbind into 
contributions from each protein residue was carried out.168 
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Table 1.5 Gbind and its Components for (R)-1.12, (S)-1.13, (R)-1.15, (S)-1.15, 
(R)-1.17 and (S)-1.17 in Complex with the 1Ra 
Compd. 
H 
(kcal/mol) 
TS 
(kcal/mol) 
Gbind 
(kcal/mol) 
(R)-1.12 -39.07 (0.19) -28.62 (0.26) -10.45 (0.32) 
(S)-1.13 -39.42 (0.21) -28.76 (0.28) -10.66 (0.35) 
(R)-1.15 -37.95 (0.21) -27.68 (0.26) -10.27 (0.34) 
(S)-1.15 -38.41 (0.17) -27.98 (0.25) -10.43 (0.33) 
(R)-1.17 -38.23 (0.20) -27.84 (0.27) -10.39 (0.34) 
(S)-1.17 -38.39 (0.18) -27.88 (0.29) -10.51 (0.34) 
aValues are expressed in kcal/mol and errors are given in parenthesis as 
standard errors of the mean. 
The results of our computational methodology confirmed the 
experimental data about the binding capability of the new LA-based 
hybrids. As shown in Table 4, NBP and DBMA derivatives established a 
stable complex with 1R and this is translated in a favorable Gbind 
values, less than -10 kcal/mol for each complex.  
Taking compound (S)-1.13 as a proof of concept, the analysis of the 
binding mode revealed the classical main interactions involved in the 
stabilization of the ligand/receptor complexes, in line with our previous 
findings on other similar 1R ligands.141,166,168-170 As we can see from 
figure 1.12A, during the MD simulation (S)-1.13 performed stable salt 
bridge and H-bond interaction with the side chain group of residue D126 
and T151 respectively. Additionally, the N-benzyl ring established  
interactions with R119 and W121 while the bulky dithiolanpentanamide 
moiety is perfectly encased in the typical hydrophobic pocket of 1R 
surrounding residues I128, F133 Y173 and L186 in which also the 
aliphatic portion of the piperidine group plays a role in the stabilization 
of the complex. 
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Figure 1.12. (A) Details of compound (S)-1.13 (in stick-and-ball representation) 
in the binding pocket. Salt bridge and hydrogen bond are highlighted as black 
broken lines. (B) Per residue binding free energy decomposition for the 1R in 
complex with (S)-1.13. Only 1R amino acids from position 100 to 200 are 
shown, as for all the remaining protein residues the contribution to ligand 
binding is irrelevant. 
Even the deconvolution of the free energy of binding (figure 1.12B) 
supported the binding mode of (S)-1.13: the interaction spectra, in fact, 
shows that the major contributions to the binding are afforded by the 
aforementioned 1R ligands. 
For the purpose to compare the results obtained for (S)-1.13 with the 
remaining compounds, we assessed the role of the chirality and the effect 
of the substitution of the NBP group with the DBMA moiety on the 
interactions in the 1R binding site. Concerning the first point, as 
expected from previous evidences on this topic,171,172 we did not detect 
any significant difference in the binding mode of the two enantiomers 
(figure 1.13A). In fact, the flexible nature of the 1R binding site enables 
the receptor to easily and efficiently accommodate the (R)-configuration of 
compound 1.12 that is able to perform similar interactions with the same 
1R residues (figure 1.13C). 
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Figure 1.13 (A) Comparison between the optimized MD binding conformations 
within the 1R putative binding site between compounds (R)-1.12 (cyan) and (S)-
1.13 (green). (B) Comparison between the optimized MD binding conformations 
within the 1R putative binding site between compounds (S)-1.13 (green) and 
(S)-17 (hot pink). (C) Per residue enthalpic contribution to binding for the 1R in 
complex with (R)-1.12, (S)-1.13, (R)-1.17 and (S)-1.17. Only 1R amino acids 
critical for receptor binding are shown. 
Even in the comparison between the NBP and DBMA derivatives our 
computational approach confirmed the experimental results, the N,N-
dibenzyl(N-methyl)amine group of compounds 1.15 and 1.17 can 
interact with the external part of the binding site in the same way as the 
N-benzylpiperidine scaffold without affecting the correct arrangement of 
the dithiolanpentanamide part of the molecule in the hydrophobic cavity 
of 1R (figures 1.13B and 1.13C). 
Conclusions 
In this section we have synthesized a new series of LA-based multitarget 
directed compounds with proved affinity for AChE, BACE1 and 1R, 
three important enzymes involved in the pathogenesis of AD. If these 
compounds acted in vivo as we have observed in our in vitro and in sílico 
studies, they could be able to affect the onset and progression of AD.  
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By their ability to inhibit BACE1, these LA-based hybrids could prevent 
the formation of the toxic beta-amyloid species, which are considered the 
molecular structure which unchains the cascade of events leading to 
neuronal death. At the same time, these compounds could alleviate the 
learning and memory symptoms, in a similar manner than the drugs 
currently used in AD treatment. Alternatively, since oxidative stress is 
accepted as an important factor in the neurodegenerative processes, 
these compounds could preserve neurons health through their 
antioxidant properties, as demonstrated in the ORAC model. 
In light of this, our compounds could be able to influence the 
development of AD acting on the basis of three of the most accepted 
hypothesis explaining AD pathogenesis. 
Given the importance of the communication between endoplasmic 
reticulum and mitochondria, and the homeostasis of the calcium levels to 
avoid excitotoxicity, processes mediated by 1R. The ability of these new 
hybrids to agonize this kind of receptors could help to preserve the health 
of neurons in CNS and contribute to slow the progress of several 
neurodegenerative diseases including AD. 
An important issue to be considered to evaluate the potential of these 
new LA-MTDl’s is the difference of affinities for each target; compound 
1.11 exhibit values ranging from low nanomolar to low micromolar (Ki-1 
= 8,9 nM, IC50-AChE = 390 nM, IC50-BACE1 = 5.6 μM); regarding to  
receptors, some studies have demonstrated that dose-response 
interaction describes a bell-shaped curve,173-175 according to the hormetic 
model,176 it means that at high concentrations of the ligand, the 
pharmacological effect could be significantly reduced or even disappear. 
Considering these differences of affinities, we must assume that a low 
concentration will be required to inhibit 1R and a higher concentration 
might be needed to inhibit BACE1; therefore, the question of what level of 
dose should be considered to use in AD patients arises. In this regard, 
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even though, more experiments are required to determine how our 
compounds behave, we believe they have a great potential for several 
reasons; despite the relationship between level of BACE1 inhibition, 
amyloid burden and cognitive impairments is not fully understood, some 
genetic studies have demonstrated that a modest reduction of Aβ 
production may exert protective effects against AD;177 on the other hand, 
BACE1 inhibition might be important in early stages of AD, when Aβ 
burden is not significant; in late stages, when senile plaques are largely 
distributed, inhibiting BACE1 might be useless or at least high 
percentages of inhibition may be required to avoid the progress of 
plaques deposition, although dead neurons will never be recovered. In 
this way, we consider these new hybrids could combine neuroprotective 
effects by agonizing 1R and by preventing amyloid production in mild to 
moderate AD patients.  
On the other hand, it has been demonstrated that targeting 
simultaneously cholinergic system and 1R could be a successful 
strategy, for example, ANAVEX 2-73 combining 1 and muscarinic 
agonist effects (0.86 μM and 5.2 μM respectively)95, has successfully 
completed phase 1 studies and have demonstrated to be effective 
improving the cognitive markers in electrophysiological studies in a 
phase 2a clinical trial with AD patients. Additionally, according to 
ANAVEX Company, ANAVEX PLUS, a combination of ANAVEX 2-73 and 
a low dose of donepezil has been tested in some AD models and is 
planned to be evaluated in the same phase 2a study.178 The compounds 
obtained in this work, combine advantageously the same abilities in a 
single small molecule. 
As demonstrated in our predictive permeability studies, these 
compounds are able to cross the blood brain barrier and reach the CNS, 
which is necessary to act over their targets and exert their protective 
effects. 
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Through our molecular modeling studies at BACE1 and 1R, we have 
obtained a sensible molecular rationale for the interactions of our 
hybrids with these fundamental proteins and interesting clues for 
improving the potency and affinity of these new multifunctional 
compounds and possibly their ability to reduce Aβ species and increase 
neuroprotective effects. 
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Experimental Section 
Chemical Synthesis 
General Procedure 1.1. Synthesis of N-Benzylpiperidine-lipoic acid 
hybrids: 100 mg of (±)-LA (0.49 mmol) and 86 mg (0.53 mmol) of N,N-
carbonyldiimidazole (CDI) were mixed into a microwave tube under 
nitrogen (N2) atmosphere. Once the tube was sealed, 5 mL of anhydrous 
THF were added using a syringe to dissolve the mixture (CO2 evolution 
was observed). This solution of activated LA was heated into a microwave 
reactor at 120 °C during 1.5 min to complete the activation. Afterward, a 
solution of 0.56 mmol of the corresponding amine in 2 mL of THF was 
added with a syringe into the sealed tube; this final solution was heated 
during 3 min at 120 °C to obtain the desired amide. After completion of 
the reaction, the THF was evaporated under reduced pressure; the crude 
obtained was resolved in 25 mL of EtOAc and washed five times with 
water, dried over magnesium sulfate (MgSO4) and concentrated. The 
crude was purified by column chromatography using EtOAc/MeOH (9:1) 
as eluent. 
 
1-Benzylpiperidine-4-carbonitrile. (1.1)  
Piperidine-4-carbonitrile (5.1 mL, 45.4 mmol) was 
dissolved in 5 mL of toluene and 4 mL of pyridine; 
afterward, benzyl bromide (6.5 mL, 54. 5 mmol) 
was added to reflux for 3 h. After completion of reaction, toluene and 
pyridine were eliminated under reduced pressure and the crude dissolved 
in 100 mL of ethyl acetate (EtOAc) and washed with NaOH 0.5M (5x10 
mL), water (3x10 mL) and brine (2x10 mL); the organic phase was dried 
over MgSO4 and concentrated to obtain 1 pure enough to characterize 
and use in the subsequent reaction. Brown oil, 8.3 g (92%). 1H NMR (300 
MHz, MeOD) δ 7.39 – 7.24 (m, 5H, Ph), 3.55 (s, 2H, H), 2.87 – 2.75 (m, 
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1H, H4), 2.73 – 2.62 (m, 2H, H2eq), 2.45 – 2.31 (m, 2H, H2ax), 2.03 – 1.91 
(m, 2H, H3eq), 1.90 – 1.72 (m, 2H, H3ax). 13C NMR (75 MHz, MeOD) δ 
138.47 (Ci), 130.55 (Co), 129.34 (Cm), 128.43 (Cp), 122.96 (C1'), 64.07 (C), 
52.32 (C2), 29.67 (C3), 26.93 (C4). LC-MS m/z = 201.3 [M + H]+, calcd for 
[C13H16N2 + H]+ 201.2 HPLC (94%). 
 
(1-Benzylpiperidin-4-yl)methanamine. (1.2)  
Over an ice bath, 7 mL of dissolution of LiAlH4 1 
M in Et2O (7.0 mmol) were added to 1.0 g (5.0 
mmol) of 1 dissolved in 1 mL of ether under N2 
athmosphere. The mixture was allowed to reach 
rt and was stirred overnight. After completion of reaction, excess of 
LiAlH4 was eliminated adding water dropwise until end of effervescence; 
ether was eliminated under reduced pressure and the crude dissolved in 
50 mL of dichloromethane (DCM) washed with NaHCO3 (5x5 mL), water 
(3x10 mL) and brine (2x10 mL); the organic phase was dried over MgSO4 
and concentrated to obtain 2 as a mixture of a light yellow oil and a solid; 
this mixture was washed several times with cold hexane to obtain the 
product as white amorphous solid, 0.86 g (85%) mp. 106-109 °C. 1H NMR 
(300 MHz, MeOD) δ 7.41 – 7.19 (m, 5H, Ph), 3.51 (s, 2H, H), 2.97 – 2.84 
(m, 2H, H2), 2.52 (d, J = 6.4 Hz, 2H, H1’), 2.08 – 1.94 (m, 2H, H2’), 1.83 – 
1.64 (m, 2H, H3), 1.45 – 1.14 (m, 3H, H3’,4). 13C NMR (75 MHz, MeOD) δ 
138.41 (Ci), 130.83 (Co), 129.25 (Cm), 128.37 (Cp), 64.33 (C), 54.44 (C2), 
48.26 (C1’), 39.47 (C4), 30.56 (C3). LC-MS m/z = 205.2 [M + H]+, calcd for 
[C13H20N2 + H]+ 205.2 HPLC (97%). 
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3-(1-Benzylpiperidin-4-yl)propanenitrile. (1.3)  
1-Benzylpiperidine-4-carbaldehyde 200 mg 
(0.98 mmol) and cyanoacetic acid 100 mg 
(0.12 mmol) were refluxed during 3 hours in 
2 mL of pyridine under N2 atmosphere. After 
completion of reaction, 20 mL of EtOAc were added and the remaining 
acid washed out with NaOH 0.5M (5x5 mL), water (3x5 mL) and brine 
(2x5 mL); the organic phase was dried over MgSO4 and concentrated. The 
crude was dissolved in 20 mL of EtOH and a catalytic amount of Pd over 
charcoal (Pd-C) 5% was added; the air was replaced by hydrogen (H2), the 
flask sealed with a septum and the mixture stirred overnight at 30 °C 
under H2 balloon. Finally, the catalyst was eliminated by filtration and 
the solvent evaporated. Purification was developed by column 
chromatography using EtOAc/MeOH 9:1 as eluent. Yellow oil (87%). 1H 
NMR (300 MHz, MeOD) δ 7.45 – 7.17 (m, 5H, Ph), 3.53 (s, 2H, H), 2.93 
(dt, J = 11.8, 3.4 Hz, 2H, H2eq), 2.47 (td, J = 7.3, 3.3 Hz, 2H, H2’), 2.09 – 
1.96 (m, 2H, H2ax), 1.79 – 1.68 (m, 2H, H3eq), 1.60 (q, J = 7.3 Hz, 2H, H3’), 
1.48 – 1.36 (m, 1H, H4), 1.35 – 1.20 (m, 2H, H3ax). 13C NMR (75 MHz, 
MeOD) δ 138.35 (Ci), 130.85 (Co), 129.27 (Cm), 128.41 (Cp), 121.20 (C1’), 
64.29 (C), 54.45 (C2), 36.04 (C4), 32.86 (C3’), 32.18 (C3), 14.83 (C2’). 
HRMS [ESI+] m/z =229.1703 [M]+, calcd for [C15H20N2]+ 229.1699. HPLC 
purity 100%. 
3-(1-Benzylpiperidin-4-yl)propan-1-amine. (1.4)  
1-Benzylpiperidine-4-carbaldehyde 2 g 
(9.84 mmol) and cyanoacetic acid 1.17 g 
(13.75 mmol) were refluxed for 4 h in 100 
mL of pyridine under N2 atmosphere. After 
completion of reaction, pyridine was evaporated until half of the initial 
volume and 200 mL of EtOAc were added. This mixture was washed with 
NaOH 0.5M (5x50 mL), water (3x50 mL) and brine (2x50 mL); the organic 
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phase was dried over MgSO4 and concentrated. The crude obtained was 
dissolved in 200 mL of EtOH, a catalytic amount of Pd-C (5%) was added 
and the mixture stirred overnight at 30 °C under H2 40 psi, afterward, 
the catalyst was eliminated by filtration and the solvent evaporated; 
subsequently, 200 mL of DCM were added, air was replaced by N2 and 
the mixture cooled to 0 °C to add 13.5 mL of LiAlH4 1M and stirred 
overnight at rt. The final mixture was washed with water (5x25 mL), 
brine (2x25 mL), dried over MgSO4 and concentrated under reduced 
pressure. Purification was developed by column chromatography using 
EtOAc/MeOH 9:1 as eluent. Yellow oil (75%). 1H NMR (500 MHz, MeOD) 
δ 7.35 – 7.23 (m, 5H, Ph), 3.52 (s, 2H, H), 2.95 – 2.85 (m, 2H, H2eq), 2.75 
(t, J = 7.6 Hz, 2H, H1’), 2.08 – 1.97 (m, 2H, H2ax), 1.74 – 1.66 (m, 2H, 
H3eq), 1.57 (p, J = 7.6 Hz, 2H, H2’), 1.36 – 1.18 (m, 5H, H3’, H4,, H3ax). 13C 
NMR (126 MHz, MeOD) δ 138.25 (Ci), 130.93 (Co), 129.26 (Cm), 128.43 
(Cp), 64.39 (C), 54.72 (C2), 41.86 (C1’), 36.59 (C3’), 34.50 (C4), 32.82 (C3), 
28.47 (C2’). HRMS [ESI+] m/z =232.1946 [M]+, calcd for [C15H24N2]+ 
232.1939. HPLC purity 96%. 
 
N-Benzyl-N-methyl-1-(3-nitrophenyl)methanamine. (1.5)  
Equimolar quantities of N-benzylmethylamine 
and 3-nitrobenzyl bromide (23.1 mmol) 
dissolved in 50 mL of toluene and 8.1 mL 
(57.9 mmol) of triethylamine were refluxed 
during 3h. After completion of reaction, the solvent was eliminated under 
reduced pressure; afterward, 20 mL of a saturated solution on NaHCO3 
were added, subsequently, NaOH 2M dropwise until basic pH. The 
organic phase was extracted with EtOAc (3x15 mL), dried over MgSO4 
and concentrated under reduced pressure; brown oil, 5.6g (95%). 1H 
NMR (300 MHz, MeOD) δ 8.33 (t, J = 2.2 Hz, 1H, H2), 8.20 (dd, J = 7.8, 
2.2 Hz, 1H, H6), 7.84 (d, J = 7.8 Hz, 1H, H4), 7.65 (t, J = 7.8 Hz, 1H, H5), 
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7.50 – 7.20 (m, 5H, Ph), 3.72 (s, 2H, H), 3.65 (s, 2H, Hβ), 2.29 (s, 3H, H). 
13C NMR (75 MHz, MeOD) δ 149.76 (C1), 142.95 (C3), 139.81 (Ci), 136.23 
(C4), 130.47 (C5), 130.17 (Co), 129.35 (Cm), 128.29 (Cp), 124.52 (C2), 
123.05 (C6), 62.89 (Cβ), 61.62 (C), 42.45 (C).The crude was analyzed by 
LC-MS and was used for the subsequent reactions without any further 
purification. HPLC-MS (Water-ACN 15→95%, g.t. 5 min), retention time 
1.55 min, m/z = 257.3 [M + H]+, calcd for [C15H16N2O2 + H]+ 257.3. 
 
N-Benzyl-N-methyl-1-(4-nitrophenyl)methanamine. (1.6)  
A mixture of equimolar quantities of N-
benzylmethylamine and 4-nitrobenzylbromide 
(23.1 mmol) in 50 mL of toluene and 8.1 mL 
(58.5 mmol) of triethylamine was refluxed during 3h. After completion of 
reaction, the solvent was eliminated under reduced pressure, 20 mL of a 
saturated solution on NaHCO3 were added and subsequently, NaOH 2M 
dropwise until basic pH. The organic phase was extracted with EtOAc 
(3x15 mL), dried over MgSO4 and concentrated under reduced pressure; 
brown oil, 5.6g (97%). 1H NMR (300 MHz, CDCl3) δ 8.18 (d, J = 8.4 Hz, 
2H), 7.55 (d, J = 8.4 Hz, 2H), 7.45 – 7.21 (m, 5H), 3.61 (s, 2H), 3.57 (s, 
2H), 2.22 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 147.53, 147.18, 138.75, 
129.39, 128.93, 128.46, 127.33, 123.60, 62.19, 60.98, 42.46. LC-MS 
m/z = 257.3 [M + H]+, calcd for [C15H16N2O2 + H]+ 257.3. 
 
3-((Benzyl(methyl)amino)methyl)aniline. (1.7)  
Into a round-bottom flask containing 5 (5.6 g 
24.19 mmol) in 50 mL of MeOH, was added a 
catalytic amount of Pd-C (5%). Air was 
replaced by hydrogen (H2), the flask was sealed with a rubber septum 
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and the reaction mixture was stirred overnight at rt under H2. The 
catalyst was eliminated by filtration and the solvent evaporated, 
obtaining 7 pure enough to be characterized and used in the next 
reactions; yellow oil 4.8 g (98%). 1H NMR (300 MHz, MeOD) δ 7.31 – 7.21 
(m, 4H, Ho, m), 7.21 – 7.14 (m, 1H, Hp), 7.01 (t, J = 7.7 Hz, 1H, H5), 6.73 – 
6.67 (m, 1H, H4), 6.65 – 6.56 (m, 2H, H2,6), 3.41 (s, 2H, Hβ), 3.33 (s, 2H, 
H), 2.08 (s, 3H, H). 13C NMR (75 MHz, MeOD) δ 148.56 (C1), 140.36 (C3), 
139.59 (Ci), 130.37 (Co), 129.92 (C5), 129.21 (Cm), 128.15 (Cp), 120.30 
(C2), 117.42 (C4), 115.50 (C6), 62.84 (C), 62.57 (Cβ), 42.43 (C10). HRMS 
[ESI+] m/z =226.1474 [M]+, calcd for [C15H18N2]+ 226.1470. HPLC purity 
96%. 
 
4-((Benzyl(methyl)amino)methyl)aniline. (1.8)  
 
Into a round-bottom flask containing 1.6 (6.2 
g 24.19 mmol) in 50 mL of MeOH, was added 
a catalytic amount of Pd-C (5%). Air was 
replaced by H2, the flask was sealed with a rubber septum and the 
reaction mixture was stirred overnight at rt under H2 (2 balloons). The 
catalyst was eliminated by filtration and the solvent evaporated, 
obtaining 1.8 pure enough to be characterized and used in the next 
reactions. Light brown oil 97%. 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.23 
(m, 5H, Ph ), 7. 16 (d, J = 8.2 Hz, 2H, H2), 6.67 (d, J = 8.2 Hz, 2H, H3), 
3.52 (s, 2H, Hβ), 3.46 (s, 2H, H), 2.19 (s, 3H, H). 13C NMR (75 MHz, 
CDCl3) δ 145.45 (C1), 139.35 (Ci), 130.27 (C2), 129.15 (Co), 129.00 (C4), 
128.31 (Cm), 127.02 (Cp), 115.09 (C3), 61.64 (Cβ), 61.48 (C), 42.07 (C). 
LC-MS m/z = 227.2 [M + H]+, calcd for [C15H18N2 + H]+ 227.2 HPLC (98%) 
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N-(1-Benzylpiperidin-4-yl)-5-(1,2-dithiolan-3-yl)pentanamide. (1.9)  
 According to the general 
procedure 1.1, 1.9 was obtained 
from 100 mg of (±)-LA (0.49 
mmol), 86 mg (0.52 mmol) of CDI 
and 106 mg (0.57 mmol) of 1-benzylpiperidin-4-amine as a light yellow 
oil, 145 mg (80%). 1H NMR (300 MHz, MeOD) δ 7.35 - 7.22 (m, 5H, Ph), 
3.72 - 3.55 (m, 2H, Ha, 4’ ), 3.54 (s, 2H, H), 3.22 - 3.02 (m, 2H, Hc), 2.88 
(dt, J = 12.5, 3.6 Hz, 2H, H2’eq), 2.45 (dtd, J = 13.2, 6.6, 5.4 Hz, 1H, Hb), 
2.27 - 2.08 (m, 4H, H2, 2’ax), 1.94 – 1.78 (m, 3H, Hb’, 3’eq), 1.77 – 1.37 (m, 
8H, H3, 4, 5, 3’ax). 13C NMR (75 MHz, MeOD) δ 175.38(C1), 138.22(Ci), 
130.82(Co), 129.34(Cm), 128.52(Cp), 63.94(C), 57.57(Ca), 53.31(C2’), 
47.78(C4’), 41.30(Cb), 39.35(Cc), 36.85(C2), 35.73(C5), 32.30(C3’), 
29.81(C4), 26.77(C3). HRMS [ESI+] m/z =378.1816 [M]+, calcd for 
[C20H30N2SO2]+ 378.1800. HPLC purity 100% 
 
N-((1-Benzylpiperidin-4-yl)methyl)-5-(1,2-dithiolan-3-yl)pentanamide. 
(1.10)  
1.10 was synthesized from 55 
mg (±)-LA (0.27 mmol), 48 mg 
(0.29 mmol) CDI and 63 mg 
(0.31 mmol) of (1-
benzylpiperidin-4-yl) methanamine (General procedure 1.1). The crude 
was purified by column chromatography using EtOAc/MeOH (9:1) as 
eluent, obtaining 1.10 as a yellow oil; however a poor yield of 10% was 
achieved. In a second assay, the crude obtained after evaporation of the 
THF was purified with no further treatment; EtOAc/MeOH (9:1), 
improving the yield up to 25% (26 mg). 1H NMR (500 MHz, CDCl3) δ 7.32 
– 7.28 (m, 4H, Ho, m), 7.25 – 7.21 (m, 1H, Hp), 5.47 (t, J = 6.5 Hz, 1H, NH), 
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3.56 (dq, J = 8.6, 6.5 Hz, 1H, Ha), 3.49 (s, 2H, H), 3.20 – 3.06 (m, 4H, H, 
c), 2.94 – 2.81 (m, 2H, H2’eq), 2.45 (dtd, J = 13.0, 6.5, 5.4 Hz, 1H, Hb), 2.21 
– 2.15 (m, 2H, H2), 1.98 – 1.86 (m, 3H, Hb’, 2’ax), 1.70 – 1.58 (m, 6H, H4, 5, 
3’eq), 1.53 – 1.41 (m, 3H, H3, 4’), 1.26 (m, 2H, H3’ax). 13C NMR (126 MHz, 
CDCl3) δ 172.84 (C1), 138.43 (Ci), 129.34 (Co), 128.31 (Cm), 127.12 (Cp), 
63.47 (C), 56.57 (Ca), 53.44 (C2’), 45.15 (C), 40.39 (Cb), 38.63 (Cc), 36.73 
(C2), 36.15 (C4’), 34.77 (C5), 30.03 (C3’), 29.06 (C3), 25.60 (C4). HRMS 
[ESI+] m/z =392.1956 [M]+, calcd for [C21H32N2SO2]+ 392.1961. HPLC 
purity 100% 
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-5-(1,2-dithiolan-3-yl)pentanamide. 
(1.11)  
According to the general 
procedure 1.1, 1.11 was 
obtained from 100 mg of (±)-
LA (0.49 mmol), 86 mg (0.53 
mmol) of CDI and 121 mg 
(0.56 mmol) of 2-(1-benzylpiperidin-4-yl)ethan-1-amine as a light yellow 
oil 183 mg (93%). 1H NMR (300 MHz, CDCl3) δ 7.36 – 7.21 (m, 5H, Ph), 
5.46 (t, J = 5.7 Hz, 1H, NH), 3.63 – 3.49 (m, 3H, H, Ha), 3.26 (dt, J = 7.6, 
5.7 Hz, 2H, H), 3.22 – 3.06 (m, 2H, Hc), 2.92 (dt, J = 12.7, 3.1 Hz, 2H, 
H2’eq), 2.45 (dtd, J = 12.9, 6.8, 5.4 Hz, 1H, Hb), 2.15 (t, J = 7.1Hz, 2H, H2), 
2.00 (t, J = 11.1 Hz, 2H, 1H2’ax), 1.90 (dq, J = 12.8, 6.8 Hz, 1H, Hb’), 1.74 
– 1.59 (m, 6H, H3, 5, 3’eq), 1.50 – 1.31 (m, 7H, H4, β, 3’ax, 4’). 13C NMR (75 
MHz, CDCl3) δ 172.71 (C1), 137.20 (Ci), 129.62 (Co), 128.39 (Cm), 127.44 
(Cp), 63.21 (C), 56.59 (Ca), 53.62 (C2’), 40.37 (Cb), 38.58 (Cc), 37.25 (C), 
36.62 (C2), 36.39 (Cβ), 34.73 (C5), 33.39 (C4’), 31.81 (C3’), 20.00 (C4), 25.53 
(C3). HRMS [ESI+] m/z =406.2114 [M]+, calcd for [C22H34N2OS2]+ 
406.2112. HPLC purity 100% 
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 (R)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-5-(1,2-dithiolan-3-
yl)pentanamide. (1.12)  
 
1.12 was synthesized as 
described in the general 
procedure1.1 from 100 mg of 
(R)-LA (0.49 mmol), 86 mg 
(0.53 mmol) of CDI and 121 mg (0.56 mmol) of 2-(1-benzylpiperidin-4-
yl)ethan-1-amine. Yellow oil, 179 mg (91%). 1H NMR (500 MHz, CDCl3) δ 
7.31 – 7.27 (m, 4H, Ho, m), 7.26 – 7.20 (m, 1H, Hp), 5.36 (bs, 1H, NH), 
3.56 (dq, J = 8.6, 6.5 Hz, 1H, Ha), 3.48 (s, 2H, H), 3.25 (ddd, J = 8.6, 7.4, 
5.9 Hz, H), 3.20 – 3.08 (m, 2H, Hc), 2.90 – 2.81 (m, 2H, H2’eq), 2.45 (dtd, 
J = 12.9, 6.5, 5.4 Hz, 1H, Hb), 2.22 – 2.10 (m, 2H, H2), 2.06 – 1.85 (m, 
3H, H2’ax, Hb’), 1.75 – 1.55 (m, 6H, H3, 5, 3’eq), 1.53 – 1.37 (m, 4H, H4, Hβ), 
1.33 – 1.19 (m, 3H, H4’, 3’ax). 13C NMR (126 MHz, CDCl3) δ 172.66 (C1), 
138.49 (Ci), 129.37(Co), 128.27 (Cm), 127.06 (Cp), 63.59(C), 56.59 (Ca), 
53.85 (C2’), 40.39 (Cb), 38.61 (Cc), 37.36 (C), 36.69 (C2), 36.55 (Cβ), 34.76 
(C5), 33.65 (C4’), 32.32 (C3’), 29.04 (C4), 25.56 (C3). HRMS [ESI+] m/z 
=406.2114 [M]+, calcd for [C22H34N2OS2]+ 406.2112. HPLC purity 99% 
 
(S)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-5-(1,2-dithiolan-3-
yl)pentanamide. (1.13)  
1.13 was synthesized as 
described in the general 
procedure 1.1 from 100 mg of 
(S)-LA (0.49 mmol), 86 mg 
(0.53 mmol) of CDI and 121 mg (0.56 mmol) of 2-(1-benzylpiperidin-4-
yl)ethan-1-amine. Yellow oil, 180 mg (92%). 1H NMR (400 MHz, CDCl3) δ 
7.36 – 7.28 (m, 4H, Ho, m), 7.27 – 7.21 (m, 1H, Hp), 5.39 (t, J = 5.6 Hz, 
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1H, NH), 3.56 (dq, J = 8.5, 6.5 Hz, 1H, Ha), 3.48 (s, 2H, H), 3.26 (ddd, J = 
8.6, 7.3, 5.9 Hz, H), 3.21 – 3.07 (m, 2H, Hc), 2.91 – 2.84 (m, 2H, H2’eq), 
2.45 (dtd, J = 13.0, 6.5, 5.4 Hz, 1H, Hb), 2.15 (td, J = 7.4, 1.5 Hz, 2H, H2), 
1.98 – 1.85 (m, 3H, H2’ax, Hb’), 1.79 – 1.59 (m, 6H, H3, 5, 3’eq), 1.52 – 1.38 
(m, 4H, H4, Hβ), 1.32 – 1.23 (m, 3H, H4’, 3’ax). 13C NMR (126 MHz, CDCl3) δ 
172.69 (C1), 138.35 (Ci), 129.41(Co), 128.27 (Cm), 127.08 (Cp), 63.54(C), 
56.57 (Ca), 53.80 (C2’), 40.38 (Cb), 38.59 (Cc), 37.33 (C), 36.67 (C2), 36.51 
(Cβ), 34.75 (C5), 33.60 (C4’), 32.24 (C3’), 29.03 (C4), 25.54 (C3). HRMS 
[ESI+] m/z =406.2135 [M]+, calcd for [C22H34N2OS2]+ 406.2112. HPLC 
purity 100%. 
 
(R, S)-N-(3-(1-Benzylpiperidin-4-yl)propyl)-5-(1,2-dithiolan-3-
yl)pentanamide. (1.14)  
According to the general 
procedure 1.1, 1.14 was 
obtained from 100 mg of 
(±)-LA (0.49 mmol), 86 mg 
(0.53 mmol) of carbonyldiimidazol and 129 mg (0.56 mmol) of 1.4 as a 
light yellow oil  189 mg (93%). 1H NMR (500 MHz, MeOD) δ 7.34 – 7.30 
(m, 4H, Ho, m), 7.29 – 7.25 (m, 1H, Hp), 3.60 – 3.54 (m, 1H, Ha), 3.53 (s, 
2H, H), 3.21 – 3.05 (m, 4H, H, c), 2.94 – 2.87 (m, 2H, H2’eq), 2.49 – 2.42 
(m, 1H, Hb), 2.18 (t, J = 7.3 Hz, 2H, H2), 2.07 – 2.01 (m, 2H, H2’ax), 1.91 – 
1.84 (m, 1H, Hb’), 1.74 – 1.59 (m, 6H, H3, 3’eq, 5), 1.54 – 1.38 (m, 4H, Hβ, 4 ), 
1.31 – 1.19 (m, 5H, H4’,, 3’ax). 13C NMR (126 MHz, MeOD) δ 175.91 (C1), 
137.96 (Ci), 130.99 (Co), 129.29 (Cm), 128.52 (Cp), 64.29 (C), 57.61 (Ca), 
54.71 (C2’), 41.31 (Cb), 40.49 (C), 39.34 (Cc), 36.90 (C2), 36.46 (C4'), 35.74 
(C5), 34.75 (C), 32.82 (C3’), 29.86 (C4), 27.66 (Cβ), 26.81 (C3). HRMS 
[ESI+] m/z =420.2264 [M]+, calcd for [C23H36N2OS2]+ 420.2269. HPLC 
purity 99% 
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(R, S)-N-(3-((Benzyl(methyl)amino)methyl)phenyl)-5-(1,2-dithiolan-3-
yl)pentanamide. (1.15)  
The general procedure 1.1, 
100 mg of (±)-LA (0.48 mmol), 
was followed until the 
addition of 126 mg (0.56 
mmol) of 3-((benzyl(methyl)amino)methyl)aniline; the final mixture was 
heated during 10 min at 120 °C to yield the desired amide. After 
completion of the reaction the THF was evaporated under reduced 
pressure; the crude obtained was purified with directly by column 
chromatography using EtOAc/MeOH (9:1) as eluent, obtaining 1.15 as a 
yellow oil, 185 mg (92%).  1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.6 
Hz, 1H, H5’), 7.46 (s, 1H, H2'), 7.38 – 7.22 (m, 6H, H6’, o, m, p), 7.11 (d, J = 
7.6 Hz, 1H, H4’), 3.57 (dq, J = 8.7, 6.6 Hz, 1H, Ha), 3.52 (s, 2H, Hβ), 3.49 
(s, 2H, H), 3.21 – 3.06 (m, 2H, Hc), 2.45 (dtd, J = 12.9, 6.6, 5.4 Hz, 1H, 
Hb), 2.36 (td, J = 7.4, 1.6 Hz, 2H, H2), 2.17 (s, 3H, H), 1.91 (dq, J = 12.9, 
6.6 Hz, 1H, Hb’), 1.82 – 1.67 (m, 4H, H3, 5), 1.52 (ddt, J = 16.0, 8.6, 6.2 
Hz, 2H, H4). 13C NMR (101 MHz, CDCl3) δ 171.07 (C1), 140.54 (C3’), 
139.26 (Ci), 137.97 (C1’), 129.05 (Co), 129.00 (C6’), 128.34 (Cm), 127.07 
(Cp), 124.89 (C4’), 120.18 (C2’), 118.59 (C5'), 62.07 (Cβ), 61.77 (C), 56.51 
(Ca), 42.34 (C), 40.37 (Cb), 38.60 (Cc), 37.59 (C2), 34.78 (C5), 29.00 (C4), 
25.37 (C3). HRMS [ESI+] m/z =414.1802 [M]+, calcd for [C23H30N2SO2]+ 
414.1799. HPLC purity 100% 
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(S)-N-(3-((Benzyl(methyl)amino)methyl)phenyl)-5-(1,2-dithiolan-3-
yl)pentanamide. (1.16)  
The general procedure 1.1, 
100 mg of (S)-LA (0.48 mmol), 
was followed until the 
addition of 126 mg (0.56 
mmol) of 3-((benzyl(methyl)amino)methyl)aniline; the final mixture was 
heated during 10 min at 120 °C to yield the desired amide. After 
completion of the reaction the THF was evaporated under reduced 
pressure; the crude obtained was purified directly by column 
chromatography using EtOAc:MeOH (9:1) as eluent, obtaining 1.16 as a 
yellow oil, 180 mg (90%).  1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.6 
Hz, 1H, H5’), 7.45 (s, 1H, H2’), 7.39 – 7.18 (m, 6H, H6’, o, m, p), 7.11 (d, J = 
7.6 Hz, 1H, H4’), 3.58 (dq, J = 8.7, 6.7 Hz, 1H, Ha), 3.52 (s, 2H, Hβ), 3.49 
(s, 2H, H), 3.23 – 3.07 (m, 2H, Hc), 2.46 (dtd, J = 13.4, 6.6, 5.4 Hz, 1H, 
Hb), 2.37 (td, J = 7.4, 1.7 Hz, 2H, H2), 2.17 (s, 3H, H), 1.92 (dq, J = 13.4, 
6.6 Hz, 1H, Hb’), 1.84 – 1.66 (m, 4H, H3, 5), 1.52 (ddt, J = 16.0, 8.9, 6.2 
Hz, 2H, H4). 13C NMR (101 MHz, CDCl3) δ 171.03 (C1), 140.55 (C3’), 
139.26 (Ci), 137.96 (C1’), 129.05 (Co), 129.02 (C6’), 128.35 (Cm), 127.08 
(Cp), 124.91 (C4’), 120.16 (C2’), 118.58 (C5’), 62.08 (Cβ), 61.76 (C), 56.51 
(Ca), 42.35 (C), 40.38 (Cb), 38.61 (Cc), 37.61 (C2), 34.79 (C5), 29.00 (C4), 
25.36 (C3). HRMS [ESI+] m/z =414.1795 [M]+, calcd for [C23H30N2SO2]+ 
414.1799. HPLC purity 100% 
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(R, S)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-5-(1,2-dithiolan-3-
yl)pentanamide. (1.17)  
The general procedure 1.1, 
100 mg of (±)-LA (0.49 
mmol), was followed until 
the addition of 126 mg (0.56 
mmol) of 4-
((benzyl(methyl)amino)methyl)aniline; this mixture was heated during 40 
min at 120 °C into a microwave reactor to yield the desired amide. After 
completion of the reaction the THF was evaporated under reduced 
pressure; the crude obtained was purified directly by column 
chromatography using EtOAc:MeOH (9:1) as eluent, obtaining 1.17 as a 
yellow oil, 167 mg (83%). 1H NMR (300 MHz, CDCl3) δ 7.48 (d, J = 8.4 Hz, 
2H, H3’), 7.36 – 7.29 (m, 6H, H2’, o, m), 7.27 – 7.18 (m, 1H, Hp), 3.57 (dt, J = 
8.6, 6.6 Hz, 1H, Ha), 3.51 (s, 2H, Hβ), 3.49 (s, 2H, H), 3.24 – 3.03 (m, 2H, 
Hc), 2.46 (td, J = 12.6, 6.6 Hz, 1H, Hb), 2.37 (t, J = 7.4 Hz, 2H, H2), 2.17 
(s, 3H, H), 1.91 (dq, J = 13.8, 6.6 Hz, 1H, Hb’), 1.82 – 1.65 (m, 4H, H3, 5), 
1.59 – 1.45 (m, 2H, H4). 13C NMR (75 MHz, CDCl3) δ 171.06 (C1), 139.15 
(Ci), 136.87 (C1’), 135.15 (C4'), 129.68 (C2’), 129.07 (Cm), 128.35 (Co), 
127.11 (Cp), 119.81 (C3’), 61.80 (Cβ), 61.36 (C), 56.51 (Ca), 42.22 (C), 
40.37 (Cb), 38.61 (Cc), 37.55 (C2), 34.78 (C5), 28.99 (C4), 25.39 (C3). HRMS 
[ESI+] m/z =414.1812 [M]+, calcd for [C23H30N2SO2]+ 414.1799. HPLC 
purity 100% 
 
Biochemical Studies.  
Inhibition of Human AChE and BuChE. The method of Ellman et al. 
was followed 135. The assay solution consisted of 0.1 M phosphate buffer 
pH 8.0, 400 M 5,5´-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman’s 
reagent), 0.05 U/mL h-AChE (human recombinant acetylcholinesterase, 
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Sigma Chemical Co.) or 0.024 U/mL h-BuChE (butyrylcholinesterase 
from human serum, Sigma Chemical Co.), and 800 M acetylthiocholine 
iodide, or 500 M butyrylthiocholine as the substrate of the enzymatic 
reaction, respectively. The compounds tested were added to the assay 
solution and preincubated with the enzyme for 5 min at 30 ºC. After that 
period, the substrate was added. The absorbance changes at 412 nm 
were recorded for 5 min with a UV/Vis microplate spectrophotometer, 
Multiskan Spectrum, Thermo-Electron Co. The reaction rates were 
compared and the inhibition percentage due to the presence of test 
compound was calculated. The IC50 is defined as the concentration of 
each compound that reduces at 50% the enzymatic activity without any 
inhibitor. 
Human BACE1 Inhibition Assay. This experiment was carried out using 
fluorescence resonance energy transfer (FRET), according to the protocol 
described by the manufacturer (Invitrogen).11 Briefly, an APP-based 
peptide substrate (rhodamine-EVNLDAEFK-quencher, Km of 20 μM) 
carrying the Swedish mutation and containing a rhodamine as a 
fluorescence donor and a quencher acceptor at each end was used. The 
intact substrate is weakly fluorescent and becomes highly fluorescent 
upon enzymatic cleavage. The assays were conducted in 50 mM sodium 
acetate buffer, pH 4.5, in a final enzyme concentration (1 U/mL). The 
mixture was incubated for 60 min at 25 °C under dark conditions and 
then stopped with 2.5 M sodium acetate. Fluorescence was measured 
with a FLUOstar Optima (BMG Labtechnologies GmbH, Offenburg, 
Germany) microplate reader at 545 nm excitation and 585 nm emission.  
 
In Vitro Blood–Brain Barrier Permeation Assay. Prediction of the brain 
penetration was evaluated using the PAMPA assay, in a similar manner 
as previously described.145,179-181 Pipetting was performed with a semi-
automatic robot (CyBi®-SELMA) and UV reading with a microplate 
spectrophotometer (Multiskan Spectrum, Thermo Electron Co.). 
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Commercial drugs, phosphate buffered saline solution at pH 7.4 (PBS), 
and dodecane were purchased from Sigma, Aldrich, Acros, and Fluka. 
Millex filter units (PVDF membrane, diameter 25 mm, pore size 0.45 μm) 
were acquired from Millipore. The porcine brain lipid (PBL) was obtained 
from Avanti Polar Lipids. The donor microplate was a 96-well filter plate 
(PVDF membrane, pore size 0.45 μm) and the acceptor microplate was an 
indented 96-well plate, both from Millipore. The acceptor 96-well 
microplate was filled with 200 μL of PBS : ethanol (70:30) and the filter 
surface of the donor microplate was impregnated with 4 μL of porcine 
brain lipid (PBL) in dodecane (20 mg mL-1). Compounds were dissolved in 
PBS: ethanol (70:30) at 100 μg mL-1, filtered through a Millex filter, and 
then added to the donor wells (200 μL). The donor filter plate was 
carefully put on the acceptor plate to form a sandwich, which was left 
undisturbed for 240 min at 25 ºC. After incubation, the donor plate is 
carefully removed and the concentration of compounds in the acceptor 
wells was determined by UV-Vis spectroscopy. Every sample is analyzed 
at five wavelengths, in four wells and at least in three independent runs, 
and the results are given as the mean ± standard deviation. In each 
experiment, 11 quality control standards of known BBB permeability 
were included to validate the analysis set. 
 
Oxygen Radical Absorbance Capacity Assay. The ORAC method was 
followed, using a Polarstar Galaxy plate reader (BMG Labtechnologies 
GmbH, Offenburg, Germany) with 485-P excitation and 520-P emission 
filters.136,182 The equipment was controlled by the Fluorostar Galaxy 
software (version 4.11-0) for fluorescence measurement. 2,2’-Azobis-
(amidinopropane) dihydrochloride (AAPH), (±)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (trolox) and fluorescein (FL) were 
purchased from Sigma-Aldrich. The reaction was carried out in 75 mM 
phosphate buffer (pH 7.4) and the final reaction mixture was 200 L. 
Antioxidant (20 L) and FL (120 L; 70 mM, final concentration) solutions 
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were placed in a black 96-well microplate (96F untreat, Nunc). The 
mixture was pre-incubated for 15 min at 37 ºC and then, AAPH solution 
(60 L, 12 mM, final concentration) was added rapidly using a 
multichannel pipette. The microplate was immediately placed in the 
reader and the fluorescence recorded every minute for 80 min. The 
microplate was automatically shaken prior each reading. Samples were 
measured at eight different concentrations (0.1-1M). A blank (FL + 
AAPH in phosphate buffer) instead of the sample solution and eight 
calibration solutions using trolox (1-8 M) were also carried out in each 
assay. All the reaction mixtures were prepared in duplicate, and at least 
three independent assays were performed for each sample. Raw data 
were exported from the Fluostar Galaxy Software to an Excel sheet for 
further calculations. Antioxidant curves (fluorescence vs. time) were first 
normalized to the curve of the blank corresponding to the same assay, 
and the area under the fluorescence decay curve (AUC) was calculated. 
The net AUC corresponding to a sample was calculated by subtracting 
the AUC corresponding to the blank. Regression equations between net 
AUC and antioxidant concentration were calculated for all the samples. 
ORAC-FL values were expressed as trolox equivalents by using the 
standard curve calculated for each assay, where the ORAC-FL value of 
trolox was taken as 1.0. 
Binding Assays at 1 and 2 Receptor.168,169,171,183-185 For 1R assay, 
the thawed membrane preparation of guinea pig brain cortex (about 100 
ug of protein) were incubated for 120 min at 37°C with 2 nM [3H]-(+)-
pentazocine (PerkinElmer, specific activity 34.9 Ci/mmol) in 50 mM Tris-
HCl, pH 7.4, 0.5 mL final volume. Nonspecific binding was defined in the 
presence of 10 μM of unlabeled (+)-pentazocine. The reaction was 
stopped by vacuum filtration through GF/B glass-fiber filters presoacked 
with 0.5% polyethylenimine, followed by rapid washing with 2 ml ice-cold 
buffer. Filters were placed in 3 ml scintillation cocktail and the 
radioactivity determined by liquid scintillation counting.  
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For 2R assay, 150 μg of rat liver homogenate were incubated for 120 
min at rt with 3 nM [3H]-DTG (PerkinElmer, specific activity 58.1 
Ci/mmol) in 50 mM Tris-HCl, pH 8.0, 0.5 mL final volume. (+)-
Pentazocine (500 nM) was used to mask 1R and to define nonspecific 
binding, respectively.  
Competition studies were done using at least 11 different concentrations 
of the ligand under investigation. As internal control, three increasing 
concentrations of unlabelled (+)-pentazocine (1R) or DTG (2R) were 
always included. The compounds were prepared as 10 mM stock 
solutions in 100% DMSO and diluted with Tris-HCl buffer on the day of 
the experiment. The final DMSO concentration in the incubation tubes 
was maintained at 0.1%. 
IC50 values and Hill’s coefficients nH were calculated by nonlinear 
regression using a four parameters curve-fitting algorithm of the 
GraphPad Prism software (v.6, La Jolla California USA), and are reported 
as the mean ± SE of three separate determinations performed in 
duplicate. The corresponding Ki values were obtained by means of the 
Cheng-Prusoff equation, using the Kd values obtained in saturation 
experiments.  
 
Functional Characterization at 1 Receptor. SH-SY5Y (human 
neuroblastoma) cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) Glutamax (Life Technologies) supplemented with 10% 
(v/v) fetal bovine serum and 1x Antibiotic Antimycotic Solution (Sigma-
Aldrich, 100 U penicillin, 100µg/ml streptomycin and 0.25µg/ml 
amphotericin B) at 37 °C in a humidified incubator with a 5% CO2/95% 
air atmosphere. The cytotoxicity of the 1R ligands was evaluated by MTT 
test on SH-SY5Y cell cultures. Cells were plated in 96-well plates (1x103 
cells/well) for 24 h prior to compounds addition. 1R ligands were 
dissolved in DMSO and serially diluted in culture medium to achieve the 
desired final concentrations. All compounds were assayed in triplicates, 
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and the results were derived from three independent experiments. 
Statistical analysis was done using one-way ANOVA Test (GraphPad 
Prism; GraphPad Software, La Jolla, CA). Cell viability was determined by 
calculating the mean absorbance of treated samples (A595 subtracted by 
A655) divided by the mean absorbance of respective control (DMSO), and 
expressed as percentage of the reference compound. Cell cytotoxicity was 
determined by the simple formula % Cytotoxicity = 100 - cell viability (%), 
and expressed as 1R ligand cytotoxicity with respect to that obtained for 
the reference compound NE-100 at 100µM (=100%). 
 
Neurogenic Assays. Adult (3 months old) male C57BL/6 mice were used 
for neurogenesis determination. All animal experimental procedures were 
previously approved by the Ethics Committee for Animal Experimentation 
of the CSIC following national (normative 1201/2005) and international 
recommendations (Directive 2010/63 from the European Communities 
Council). Special care was taken to minimize animal suffering. Neural 
stem cells were isolated from the SGZ of the dentate gyrus of the 
hippocampus of adult mice and cultured as NS as previously 
described.144,186 After treatment of NS with compounds 12 and 17 at 10 
µM, the expression of neuronal markers was analyzed by 
immunocytochemistry according to published protocols,144 using two 
well-known neurogenesis-associated markers: β-III-tubulin linked to 
early stages of neurogenesis and microtubule-associated protein type 2 
(MAP-2), a classical marker of late neuronal maturation. A rabbit anti-β-
III-tubulin (TuJ clone; Abcam) polyclonal antibody coupled to an Alexa-
488-fluor-labeled secondary antibody (Molecular Probes) and a mouse 
anti-MAP-2 (Sigma) monoclonal antibody coupled to an Alexa-546-fluor-
labeled secondary antibody (Molecular Probes) were used. DAPI staining 
was used as a nuclear marker. Fluorescent representative images were 
acquired with a Nikon fluorescence microscope 90i coupled to a digital 
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camera Qi. The microscope configuration was adjusted to produce the 
optimum signal-to-noise ratio. 
Computational Binding Studies. The ligands were optimized using the 
Gaussian09 software (Gaussian, Inc. Wallingford, CT) at the B3LYP/6-
31G* level of theory and partial atomic charges were assigned using a 
standard restricted electrostatic potential fit (RESP) method187 with the 
tertiary nitrogen considered in a protonated state. The molecular 
structure of BACE1 was obtained from the Protein Data Bank (pdb code: 
2b8l).188 The protein target was converted to AutoDock 4.2189 format files 
using AutoDockTools 1.5.6 generating automatically all other atom 
values. The docking area has been centred on the catalytic residue D228 
and grids points of 60 x 60 x 60 with 0.375 Å spacing were calculated 
around the docking area for all the ligand atom types using AutoGrid4. 
100 separate docking calculations were performed for each binder. Each 
docking calculation consisted of 25 x 106 energy evaluations using the 
Lamarckian genetic algorithm local search (GALS) method. A low-
frequency local search according to the method of Solis and Wets was 
applied to docking trials to ensure that the final solution represents a 
local minimum. The docking results from each of the 100 calculations 
were clustered and ranked on the basis of the free energy of binding. 
For the 1R, the optimized structure of selected compounds was docked 
into the putative binding pockets by applying a consolidated 
procedure168,169,171,183-185,190 with AutoDock. The resulting docked 
conformations for each complex were clustered and visualized; then, for 
each compound, only the molecular conformation satisfying the 
combined criteria of having the lowest (i.e., more favourable) Autodock 
energy and belonging to a highly populated cluster was selected to carry 
for further modeling.  
The ligand/receptor complexes obtained from the docking procedure for 
both protein targets, BACE1 and 1R, were further refined in Amber 12191 
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and 14192 using the quenched molecular dynamics (QMD) method as 
previously described.168,169,183 According to QMD, the best energy 
configuration of each complex resulting from this step was subsequently 
solvated by a cubic box of TIP3P193 water molecules extending at least 10 
Å in each direction from the solute. The system was neutralized and the 
solution ionic strength was adjusted to the physiological value of 0.15 M 
by adding the required amounts of Na+ and Cl- ions. Each solvated 
system was relaxed by 500 steps of steepest descent followed by 500 
other conjugate-gradient minimization steps and then gradually heated 
to a target temperature of 300 K in intervals of 50 ps of NVT MD, using a 
Verlet integration time step of 1.0 fs. The Langevin thermostat was used 
to control temperature, with a collision frequency of 2.0 ps-1 The protein 
was restrained with a force constant of 2.0 kcal/(mol Å), and all 
simulations were carried out with periodic boundary conditions. 
Subsequently, the density of the system was equilibrated via MD runs in 
the isothermal-isobaric (NPT) ensemble (with isotropic position scaling 
and a pressure relaxation time of 1.0 ps), for 50 ps with a time step of 1 
fs. All restraints on the protein atoms were then removed, and each 
system was further equilibrated using NPT MD runs at 300 K, with a 
pressure relaxation time of 2.0 ps. Three equilibration steps were 
performed, each 2 ns long and with a time step of 2.0 fs. To check the 
system stability, the fluctuations of the root-mean-square-deviation 
(rmsd) of the simulated position of the backbone atoms of the receptor 
with respect to those of the initial protein were monitored. All 
chemophysical parameters and rmsd values showed very low fluctuations 
at the end of the equilibration process, indicating that the systems 
reached a true equilibrium condition. The equilibration phase was 
followed by a data production run consisting of 40 ns of MD simulations 
in the canonical (NVT) ensemble. Only the last 20 ns of each equilibrated 
MD trajectory were considered for statistical data collections. A total of 
1000 trajectory snapshots were analyzed the each ligand/receptor 
complex. The binding free energy, Gbind, between the two ligands and the 
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1R was estimated by resorting to the MM/PBSA approach implemented 
in Amber 14. According to this well validated methodology,148 the free 
energy was calculated for each molecular species (complex, receptor, and 
ligand), and the binding free energy was computed as the difference: 
Gbind = Gcomplex – (Greceptor + Gligand) = EMM + Gsol - TS 
in which EMM represents the molecular mechanics energy, Gsol includes 
the solvation free energy and TS is the conformational entropy upon 
ligand binding. The per residue binding free energy decomposition was 
performed exploiting the MD trajectory of each given compound/complex, 
with the aim of identifying the key residues involved in the 
ligand/receptor interaction. This analysis was carried out using the 
MM/GBSA approach,194,195 and was based on the same snapshots used 
in the binding free energy calculation. All simulations with 1R were 
carried out using the Pmemd modules of Amber 14, running on the 
EURORA-CPU/GPU calculation cluster of the CINECA (Bologna, Italy). 
The entire MD simulation and data analysis procedure was optimized by 
integrating Amber 14 in modeFRONTIER, a multidisciplinary and 
multiobjective optimization and design environment.196 
Studies of Cell viability and Neuroprotection. Culture of SH-SY5Y 
Cells. SH-SY5Y cells, at passages between 3 and 16 after de-freezing, 
were maintained in a Dulbecco’s modified Eagle’s medium (DMEM) 
containing 15 non-essential amino acids and supplemented with 10% 
fetal calf serum (FCS), 1 mM glutamine, 50 units/mL penicillin, and 50 
μg/mL streptomycin (reagents from GIBCO, Madrid, Spain). Cultures 
were seeded into flasks containing supplemented medium and 
maintained at 37 ºC in 5% CO2/humidified air. Stock cultures were 
passaged 1:4 twice weekly. For assays, SH-SY5Y cells were sub-cultured 
in 48-well plates at a seeding density of 105 cells per well. For the 
cytotoxicity experiments, cells were treated with drugs before confluence 
in DMEM free of serum.  
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Cell Viability Experiments. To study the cytotoxic effects of compounds 
alone, cells were plated at a density of 105 cells per well at least 48 h 
before the toxicity measurements. Cells were exposed for 24 h to the 
compound at 1 μM, and the quantitative assessment of cell death was 
made by measurement of the percent of the intracellular enzyme lactate 
dehydrogenase (LDH) released to the extracellular medium (cytotoxicity 
detection kit, Roche). The quantity of LDH was evaluated in a microplate 
reader (Anthos 2010 or Labsystems iMES Reader MS) at 492 nm (λ 
excitation) and 620 nm (λ emission). 
 
Neuroprotection Studies. To study the cytoprotective action of the 
compounds against cell death induced by the mixture of rotenone (30 
μM) and oligomycin A (10 μM), drugs were given at time zero and 
maintained for 24 h. Then, the media were replaced by fresh media still 
containing the drug plus the cytotoxic insult, which was left for an 
additional 24 h period. Thereafter, cell survival was assessed measuring 
MTT activity. 
 
Measurement of Cell Viability by MTT Assay. Cell viability was also 
measured by quantitative colorimetric assay with 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) (Sigma Aldrich), as 
described previously.197 Briefly, 50 µL of the MTT labeling reagent, at a 
final concentration of 0.5 mg/mL, was added to each well at the end of 
the incubation period and the plate was placed in a humidified incubator 
at 37 ºC with 5 % CO2 and 95 % air (v/v) for an additional 2 h period. 
Then, the insoluble formazan was dissolved with dimethylsulfoxide; 
colorimetric determination of MTT reduction was measured at 540 nm. 
Control cells treated with 0.1% DMSO were taken as 100 % viability. 
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New Antioxidant AChE-MAO Dual 
Inhibitors Based on the Chromone 
Scaffold 
Introduction 
Monoamine Oxidase (MAO)  
Monoamine oxidase (MAO) catalyzes the oxidative deamination of dietary 
amines such as tyramine or phenethylamine and biogenic amines, 
including neurotransmitters dopamine (DA), epinephrine, norepinephrine 
(NE) and serotonin (5-HT). Almost all mammalian tissues express two 
isoforms of MAO (MAO-A and MAO-B), they were initially distinguished 
by their susceptibility to different inhibitors as well as by their affinity for 
different substrates, MAO-A catalyzes deamination of 5-HT and NE and 
is potently inhibited by clorgiline. On the other hand, MAO-B is inhibited 
by deprenyl or selegiline and shows affinity for phenylethyl amine and 
benzyl amine.198 Distribution of each isoenzyme varies depending on the 
organ; in peripheral nervous system (PNS) and CNS, neuronal MAO 
protects against exogenous amines and regulates the levels of amine 
neurotransmitters.  
In human brain, 75% of MAO activity corresponds to MAO-B; it has been 
detected in serotonergic neurons where contributes to the purity of 5-HT 
degrading other biogenic or exogenous amines, and in micro-vessels of 
the BBB199 as part of the protecting system against foreign substances.  
MAO-A has been detected in catecholaminergic neurons (locus coeruleus, 
substantia nigra or paraventricular nucleus of hypothalamus, among 
others) involved in different processes such as stress response, attention, 
emotions or movement. In astrocytes and glial cells, both isoforms are
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 present and participate in degradation of neurotransmitters released 
into the synaptic cleft. 
MAO and Alzheimer’s disease  
Oxidative deamination catalyzed by MAO produces hydrogen peroxide 
(H2O2), the corresponding aldehyde and ammonia in the case of primary 
amines or a substituted amine in the case of secondary amines. H2O2 is 
considered a source of hydroxyl radicals which in turn contributes to 
generate an oxidative environment. In agreement with this mechanism, it 
is expectable that augmented levels of MAO-B observed AD brain,16,200 
mainly in glial cells associated to senile plaques,201 potentiate the 
oxidative stress typical of neurodegenerative processes, by production of 
radical species.  
On the other hand, changes in MAO-A levels in AD patients seem to be 
more intricate. While elevated activity of MAO-A has been reported in 
several regions of AD brain such as neocortex and locus coeruleus,202,203 
other studies have determined a decreased amount of intra-neuronal 
MAO-A in nucleus basalis of Meynert. Additionally, it has been proposed 
that some metabolites of catecholamines catabolized preferentially by 
MAO-A are potentially neurotoxic, one example is the aldehyde and 
alcohol resulting from dopamine oxidation, which have been 
demonstrated to be apoptotic agents, and oxidative stressors.204  
MAO inhibitors as therapeutic agents for AD 
Commonly, AD patients exhibit neuropsychiatric symptoms such as 
depression, psychosis and aggressive behavior.205,206 Depression is 
associated with low levels of 5-HT and could be considered a risk factor 
to develop AD,207 on the other hand, aggressive behavior in AD has been 
related to low levels of NE in some brain regions.18,208 Assuming that NE 
and 5-HT are both substrates of MAO-A, inhibiting this isozyme could be 
beneficial in some cases of AD. 
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Additionally, as stated above, MAO-B activity is exacerbated in AD; 
mainly in glial cells associated to senile plaques, this increased activity 
contributes to the neuronal death through the production of oxidative 
stress and toxic metabolites.209,210 
Benefits of MAO isoforms inhibition in AD could include increase of 5-HT 
levels, reduction of oxidative stress caused by radical species17 and 
restoration of the unbalanced amounts of amine neurotransmitters.13,211 
In agreement with these facts, MAO inhibitors might be an interesting 
and complementary tool for the treatment of neurodegenerative diseases 
including PD and AD.  
In spite of all stated above, the use of drugs which exclusively act over 
MAO enzymes in AD remains controversial; one example is selegiline, 
there are some studies which have demonstrated that this MAO-B 
inhibitor affects positively learning and memory in animal models,212 
however, it has not demonstrated any beneficial effect in AD patients,213 
in light of this, a different strategy must be envisioned to take advantage 
of MAO inhibition in AD treatment, the design of multifunctional 
molecules with the potential of acting in different processes related to the 
disease.214  
Chromones 
The chromone ring is the central core of several naturally occurring 
substances, such as flavonoids, responsible for the antioxidant 
properties of red wine and numerous fruits.215 The interesting biological 
properties of natural chromones have led to the synthesis of hundreds of 
new derivatives with a wide variety of activities, proving the chromone 
framework as a privileged scaffold useful in the search for new bioactive 
compounds.216,217 Drugs based on the chromone scaffold (Blue in figure 
2.1) currently used in humans, include sodium cromoglicate and 
nedocromil which act as mast cell stabilizer drugs, iguratimode, an anti-
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inflammatory agent, diosmin an anti-hemorroidal drug, and flavoxate, a 
muscle relaxant. (Figure 2.1) 
 
Figure 2.1 Chromone scaffold containing drugs 
The use of the chromone ring as part of new potential drugs for 
neurodegenerative diseases is based on the diversity of biological effects 
reported for synthetic and natural chromone derivatives, such as 
antioxidant, anti-inflammatory, AChE inhibition and MAO inhibition, 
among others.216-220 
In this chapter we intend to take advantage of the affinity demonstrated 
by different chromone derivatives towards MAO enzymes, as well as their 
antioxidant properties to combine this scaffold with the NBP and DBMA 
fragments in order to obtain potential multifunctional molecules acting 
as dual AChE-MAO inhibitors with antioxidant properties. 
In order to generate a diverse set of target compounds and evaluate the 
structure-activity relationship, we decided to carry out modifications in 
the nature and place of the substituents in the aromatic ring of the 
chromone scaffold (H, OMe, OH, NO2 and NH2), being preferred those 
able which potentiate the antioxidant properties; changes in the nature 
of the bond linking the chromone system to the moiety bearing the 
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tertiary amine, (amide or ester); changes in the aliphatic chain in the 
case NBP (n=1-3) and changes in the position of the amine group in the 
case of DBMA derivatives. 
Results and Discussion 
Synthesis of Chromone-NBP and Chromone-DMBA hybrids 
The synthesis of the methoxylated chromone-2-carboxlic acids (2.1-2.6) 
was achieved from the corresponding phenols and dimethyl 
acetylenedicarboxylate, according to the method of Stoermer et al.221 
However, since this methodology is widely known and the intermediate 
diesters and dicarboxylic acids have been previously reported, we did not 
isolate them and carried out the synthesis in a continuous process until 
the desired acids as described in the experimental section. 
  
Scheme 2.1 Reagents and conditions. (a)Et2O, Et3N, overnight, rt; (b) Acethyl 
chloride, H2SO4, reflux 30 min; (c) NaOH, reflux 30 min; (d) HNO3:H2SO4 (1:6), 
70 °C, 3h.  
The nitro derivative 2.6 was obtained as a sole product by a classical 
nitration of the commercially available chromone-2-carboxylic acid in a 
mixture of nitric and sulphuric acids (scheme 2.1).222 
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NBP and DMBA amine intermediates (1.2 and 1.4) were synthesized as 
described in chapter 1, (scheme 1.1). Alcohol 2.7, was synthesized as 
described in scheme 2.2 from commercially available 2-(piperidin-4-
yl)ethan-1-ol and benzyl bromide; amines where n= 0, 2 and alcohols 
where n= 0, 1 are commercially available. 
 
Scheme 2.2 Reagents and conditions. (a)ACN, K2CO3, Tetrabutyl ammonium 
iodide (TBAI), reflux 24h; (b) DMF, CDI, mw 120 °C; (c) BOP, Et3N, DMF, 
overnight, rt. (d) BBr3, THF, overnight, rt. (e) H2/Pd(5%), EtOH, overnight, rt.  
The synthesis of the chromone-based hybrids was developed by reaction 
between the corresponding alcohols or amines with acids 2.1-2.6 or 
chromone-2-carboxylic acid (commercially available). Two different 
methods where used according to the availability of the coupling agent. A 
microwave assisted reaction with CDI as activating agent and a coupling 
reaction at room temperature (rt) with BOP and Et3N (CDI is preferred 
due to the easier work up; see experimental section). In both cases the 
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best solvent was DMF due to the low solubility of the chromone 
carboxylic acids in less polar solvents, although when activation is 
carried out with BOP, other solvents could be used (i.e. THF or DCM) 
because the Et3N helps to solubilize the acids. Deprotection of 
methoxylated derivatives was carried out by overnight treatment with 
boron tibromide (BBr3) at rt. It is worth to mention that 1 equivalent for 
each ether group and one additional equivalent for each heteroatom 
present in the molecule was used to obtain good yields (70-90 %).140,223 
Regarding to characterization of final compounds, it is important to 
mention the case of nitro derivative 2.26. Although the exact mass 
corresponds to the desired product; the CH group at position 3 of the 
chromone system was not observed either in 13C or 1H NMR spectra. 
However, amine derivative 2.27, obtained by hydrogenation of 2.26 
exhibited all the expected signals and exact mass, allowing us to confirm 
the structure of 2.26. 
Biological Evaluation 
All derivatives were evaluated initially as inhibitors of human 
cholinesterases (AChE and BuChE), as described in chapter one. In order 
to establish their ability to reach the CNS and to determine whether or 
not they exhibit antioxidant properties, they were evaluated 
simultaneously in ORAC and PAMPA assays. Results are gathered in 
tables 2.1 and 2.2 for DBMA and NBP series respectively. 
AChE inhibition test, demonstrated that both series (chromone-NBP and 
chromone-DBMA) are selective inhibitors of AChE with IC50 values 
between the low micromolar and two-digit nanomolar range. Chromone-
DBMA hybrids are weaker AChE inhibitors and totally lack of affinity for 
BuChE, consequently a shorter series was prepared. (Table 2.1)  
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Table 2.1 Inhibition of h-AChE, h-BuChE (IC50, µM) and prediction of CNS-
Permeation by the PAMPA-BBB Assay.a 
aResults are expressed as mean ± SD (n =3). bCNS+: compounds predicted to 
reach CNS. 
As seen in table 2.2, the most potent AChE inhibitors belong to 
chromone-NBP series, showing more potency when the linker chain holds 
2 or 3 methylene groups.  
The nature of the substituent in the chromone system did not exert a 
significant effect on the potency, 6.7-diMeO, 6-OH, 6-NO2, and 6-NH2 
substituted compounds showed IC50 values in the low nanomolar range, 
as long as the substituted positions are 6 and 7. Replacement of the 
amide by an ester bong did not affect significantly the inhibitory potency 
as evident comparing compounds 2.21 and 2.30, with IC50 values in the 
same range, 56 nM and 46 nM respectively. 
  
 
   IC50 (μM) PAMPAb 
Comp. R Subst. h-AChE h-BuChE Pe 10-6 cm s-1 
2.8 6,7-diOMe 3 4.5±0.8 >10 30.6±0.8 CNS + 
2.9 5,7-diOMe 4 3.2±0.4 >10 31.4±0.9 CNS + 
2.10 5,7-diOH 4 1.9±0.6 >10 25.3±1.7 CNS + 
2.11 6,7-diOMe 4 0.99±0.3 >10 31.0±0.1 CNS + 
2.12 6-OMe 4 1.5±0.2 >10 28.4±1.1 CNS + 
2.13 6-OH 4 1.3±0.3 >10 12.6±0.3 CNS + 
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Table 2.2 Inhibition of h-AChE, h-BuChE (IC50, µM) and prediction of CNS-
Permeation by the PAMPA-BBB Assay.a 
aResults are expressed as mean ± SD (n =3). bCNS+: compounds predicted to 
reach CNS. nd: not determined. 
 
    
IC50 (μM) PAMPAb 
Comp. X n R h-AChE h-BuChe Pe 10-6 cm s-1 
2.14 NH 0 6-OMe 0.97±0.14 >10 17.4±1.1 CNS + 
2.15 NH 0 6-OH 2.36±0.54 >10 8.8±0.9 CNS - 
2.16 NH 0 6,7-diOMe 0.66±0.09 >10 18.0±0.4 CNS + 
2.17 NH 1 6-OMe 3.61±0.09 >10 16.1±0.5 CNS + 
2.18 NH 1 6,7-diOMe 1.46±0.17 >10 nd 
2.19 O 1 6,7-OMe 0.30±0.06 >10 10.7±0.8 CNS ± 
2.20 O 1 6-OMe 7.49±0.12 >10 15.1±0.4 CNS + 
2.21 O 2 6,7-diOMe 0.056±0.015 >10 14.3±0.4 CNS + 
2.22 NH 2 5-OMe 0.87±0.14 >10 nd 
2.23 NH 2 6-OMe 0.17±0.01 6.5±0.7 20.9±0.3 CNS + 
2.24 NH 2 5,7-diOMe 0.32±0.02 6.3±0.5 11.5±0.7 CNS ± 
2.25 NH 2 H 0.11±0.03 5.2±0.4 16.0±0.8 CNS + 
2.26 NH 2 6-NO2 0.021±0.009 9.3±0.7 18.2±0.2 CNS + 
2.27 NH 2 6-NH2 0.041±0.006 4.3±0.4 11.3±0.3 CNS ± 
2.28 NH 2 6-OH 0.091±0.014 >10 10.1±0.6 CNS ± 
2.29 NH 2 5,7-diOH 0.58±0.04 >10 19.1±0.7 CNS + 
2.30 NH 2 6,7-OMe 0.046±0.007 >10 14.8±1.2 CNS + 
2.31 NH 2 6,7-diOH 4.13±0.79 >10 10.7±0.4 CNS ± 
2.32 NH 2 7-OMe 0.033±0.009 9.9±0.99 nd 
2.33 NH 3 6,7-diOMe 0.11±0.04 >10 13.4±0.5 CNS + 
2.34 NH 3 6-OMe 0.37±0.13 5.8±0.5 21.8±0.2 CNS + 
2.35 NH 3 6-OH 0.023±0.012 >10 12.7±0.5 CNS + 
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In chromone-NBP series, the best dual profile combining AChE inhibition 
and antioxidant properties was shown by compounds 2.27 (6-NH2, n=2 
IC50=41 nM), 2.28 (6-OH, n=2, IC50=91 nM) and 2.35 (6-OH, n=3, 
IC50=23 nM), they were selected besides to 2.30 (6,7-diMeO, n=2, IC50=46 
nM) and 2.9 (6,7-diOMe-4’-DBMA, IC50=0.99 μM), to determine the 
mechanism of the inhibition of AChE. For example, Lineweaver-Burk 
plots for several compounds (fig 2.3), show how 1/Vmax (y intercept) and 
1/Km (x intercept) increase with increasing concentrations of inhibitor; 
the prototypical pattern of a mixed-type of inhibition (competitive and 
non-competitive); possibly due to the interaction of compounds with both 
catalytic anionic site (CAS) and peripheral anionic site (PAS) of AChE.  
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Fig 2.3 Lineweaver-Burk plot of reciprocals for velocity and increasing 
concentrations of inhibitor. Lines were derived from a weighted least-squares 
analysis of data. 
 
According to PAMPA assay results, most of nanomolar AChE inhibitors 
are able to cross the BBB. In the case of 2.27 and 2.28, permeability 
values in the upper limit of the calculated range of uncertainty (8.9-11.5; 
figure 2.4) were obtained, 11.3 and 10.1 respectively.  
Table 2.3 Permeability values (Pe 10-6 cm s-1) for commercial drugs used in the 
PAMPA-BBB Validation Experiment.  
Compound Bibl.a Exp.b 
Testosterone 17.0 26.5 ± 0.3 
Verapamil 16.0 29.5 ± 0.2 
Imipramine 13.0 20.6 ± 1.0 
Desipramine 12.0 22.9 ± 1.7 
Promazine 8.8 20.8 ± 0.5 
Corticosterone 5.1 11.0 ± 0.2 
Piroxicam 2.5 10.0 ± 0.1 
Hydrocortisone 1.9 10.2 ± 0.1 
Caffeine 1.3 7.9± 0.3 
Ofloxacin 0.8 6.1 ± 0.1 
aTaken from Ref 225 bData are the mean ± SD of three independent experiments 
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In general, chromone-DBMA hybrids exhibited higher values of 
permeability than chromone-NBP derivatives and hydroxy-substituted 
hybrids showed lower permeability than methoxylated compounds. 
 
Figure 2.4 Correlation of permeability of experimental and theoretical values of 
standard compounds used in PAMPA assay in PBS:EtOH (70:30) as solvent and 
the calculated range of permeability values to determine whether or not a given 
compound is able to reach CNS. 
 
Inhibition of human MAO’s and BACE and the antioxidant properties 
To continue the assessment of the multitarget profile of these new 
hybrids, we evaluated their ability to inhibit both isoforms of human 
recombinant MAO, expressed in baculovirus infected BTI insect cells.  
Table 2.4 summarizes the results of those compounds which exhibited 
activity towards MAO-A and MAO-B. Interestingly, most potent MAO 
inhibitors belong to chromone-DBMA series. Compounds 2.12 and 2.13 
inhibit MAO-A, with comparable potency than iproniazide, and higher 
potency than moclobemide; drugs which exert antidepressant effects with 
potencies in the micromolar range (in vitro) and have been clinically used 
in humans to treat depression.  
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Table 2.4 IC50 values for the inhibitory effects new compounds and reference 
inhibitors on the enzymatic activity of human recombinant MAO isoforms 
expressed in baculovirus infected BTI insect cells. 
IC50 values shown in this table are the mean ± SEM. from five experiments. Level 
of statistical significance: aP < 0.01 versus the corresponding IC50 values 
obtained against MAO-B, as determined by ANOVA/Dunnett´s. bPercent of 
inhibition at 10 uM. *Maximum inhibition achieved with compound was about 
50% of total enzymatic activity. ** Inactive at 200 µM (highest concentration 
tested). *** Inactive at 1 mM (highest concentration tested).NA: not antioxidant. 
nd: not determined 
  
  IC50 (μM)  
 Comp. MAO-A  MAO-B 
BACE1 
(% Inhb) 
ORAC 
Trolox Equiv. 
N
B
P
 
2.26 20.5±1.3 ** (3.5) NA 
2.27 *** ** (5.1) 0.9±0.1 
2.28 39.3±2.8* 51.2±4.3 (0.2) 1.2±0.1 
2.31 70.5±8.6* 37.9±4.2* (14.8) 1.7±0.2 
2.35 *** ** ND 1.3±0.1 
D
B
M
A
 
2.8 ** ** 6.7±0.8 μM NA 
2.9 ** ** (30.9) ND 
2.10 22.8±1.5 ** (20.6) 1.2±0.1 
2.11 ** ** (27.4) NA 
2.12 1.6±0.4 59.8±3.7* (22.1) ND 
2.13 7.0±0.8 9.7±1.6 (3.3) 1.6±0.1 
 R-Deprenyl 68.7±4.2a 0.017±0.002 nd nd 
 Iproniazide 6.6±0.8 7.5±0.36 nd nd 
 Moclobemide 361.4±19.4 * nd nd 
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Regarding to BACE1 inhibition, we observed that chromone-NBP hybrids 
completely lack of affinity for the enzyme, while chromone-DBMA series 
are poor BACE1 inhibitors with inhibition percentages around 30% at 10 
μM, except compound 2.8, in this case we observed a notorious effect of 
changing the position of the amide group linking the DBMA fragment to 
the chromone scaffold, shifting from 27% of inhibition at 10 μM in the 
case of 2.11 to an IC50 value of 6.7 μM in the case of 2.8.  
The antioxidant activities of selected chromone-based hybrids were 
evaluated by ORAC assay. As expected, compounds bearing methoxy or 
nitro groups in the chromone scaffold were inactive, while hybrids with 
amine, or better hydroxyl groups, exhibited interesting antioxidant 
capacities, ranging from 0.9 to 1.7-fold the trolox value. In the NBP 
series, the best antioxidant agent was 2.31 with two hydroxyl groups in 
positions 6 and 7 of the chromone core, but moderated AChE inhibitory 
potency. On the other hand, 2.35 combines a good value of antioxidant 
capacity (1.3 trolox equivalents.) and a potent inhibitory activity towards 
AChE (IC50 23 nM). Among the DBMA-based hybrids, the best radical 
scavenger was 2.13 (6-hydroxy substituted), a dual AChE-MAO inhibitor 
in the low micromolar range.  
Inhibition of Aβ42 and tau aggregation in intact Escherichia coli 
cells 
A selection of compounds, including 2.12 and 2.13 (chromone-DBMA), 
with a good dual profile AChE-MAO and the potent AChE inhibitors 2.28 
and 2.30 (chromone-NBP) were evaluated as anti-aggregating agents in 
independent assays on cells overexpressing Aβ42 and tau protein. In the 
NBP series, very low anti-aggregating activities were found, and only the 
nanomolar AChE inhibitor 2.30 showed percentages of inhibition around 
10%. By contrast, the chromone-DBMA hybrids 2.12 and 2.13, which 
also showed a good dual inhibition of hAChE – hMAO, displayed a 
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moderated anti-aggregating effect of 21% and 19% for Aβ42 and 33% and 
27% for tau protein respectively. (Table 2.5)  
Table 2.5 Inhibitory activities of chromone-based hybrids (20 µM) monitored by 
Th-S staining of bacterial cells overexpressing Aβ42 peptide 
  
 Comp. R X 
n 
or 
subst. 
% Inhibitiona 
Aβ42 aggr. tau aggr. 
NBP 
2.14 6-OMe NH 0 <10 <10 
2.16 6,7-diOMe NH 0 <10 <10 
2.19 6,7-diOMe O 1 <10 <10 
2.28 6-OH NH 2 <10 <10 
2.29 5,7-diOH NH 2 <10 <10 
2.30 6,7-diOMe NH 2 11.9 ± 4.9 9.6 ± 5.4 
DBMA 
2.12 6-OMe NH 4 21.8 ± 3.4 33.5 ± 7.5 
2.13 6-OH NH 4 19.3 ± 5.8 27.0 ± 2.2 
aValues are expressed as mean ± SEM of four independent experiments (n = 4). 
Inhibitor concentration: 20 µM 
 
Neuro-protectant properties of some selected compounds including 2.13 
with an antioxidant capacity of 1.2 trolox equivalents and 2.30 inactive 
in ORAC but a potent AChE inhibitor, were evaluated in a cell viability 
test using SH-SY5Y cells co-cultured with a toxic mixture of rotenone-
oligomycin during 24 hours.  
Unexpectedly, 2.30 with negative results in ORAC exhibited the better 
neuro-protective profile in a concentration-dependent manner, increasing 
concentrations from 0.1 to 3 μM protected between 11% and 22% of cells 
(table 2.6, figure 2.5). Melatonin, with antioxidant capacity of 2.8 trolox 
equivalents, was used as a positive control, protecting 38 % of cells at 10 
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nM. 2.13 exhibited a statistically significant protection of 17 % at 0.3 μM 
and 2.19 at 0.1 and 0.3 μM. 
Table 2.6 Percentage of neuroprotection in the human neuroblastoma cell line 
SH-SY5Y against the combination of rotenone (30 µM) and oligomycin A (10 µM) 
by selected chromene-based hybrids at indicated concentrations. 
  
   Neuroprotection (%)a 
 
Comp. n/sust. 0.1 µM 0.3 µM 1 µM 3 µM 
NBP 
2.14 0 9.8±1.1ns 13.9±3.1ns 14.6±1.2ns 8.6±1.7ns 
2.16 0 5.73.6ns 18.03.1ns 12.32.5ns 12.63.1ns 
2.19 1 19.40.7* 19.63.0* 6.81.2ns 12.43.6 ns 
2.28 2 15.0±2.9ns 18.8±3.8ns 8.6±3.0ns 15.2±4.9ns 
2.30 2 11.5±1.5* 18.1±1.6** 17.1±1.9* 22.4±2.5** 
DBMA 2.13 4 13.5±2.6ns 17.4±1.1* 12.2±2.6ns 15.3±2.4ns 
aCell viability was measured as MTT reduction and data were normalized as % 
control. Data are expressed as the means ± SEM of triplicate of at least three 
different cultures. All compounds were assayed at increasing concentrations 
(0.1-3 μM). **P< 0.01 and *P<0.05 with respect to control group. Comparisons 
between drugs and control group were performed by one-way ANOVA followed by 
the Newman–Keuls post-hoc test. 
According to these results, it is probable that the protection exerted by 
2.30 could involve a mechanism different than the radical scavenging 
capacity. Even though the rest of compounds did not exhibited neuro-
protectant properties, it is worth to mention that in any case, they 
potentiated the toxicity of rotenone/oligomycin.  
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Figure 2.5 Cell viability was measured as MTT reduction and data were 
normalized as % of control. Data are expressed as the means ± SEM. of triplicate 
of at least three different cultures. All compounds were assayed at increasing 
concentrations (0.1-3 µM). 
 
Preliminary evaluation in vivo of MAO-B inhibitory properties in the 
model of reversion of hypokinesia induced by reserpine  
Taking into account that inhibition of MAO’s could exert antidepressant 
or antiparkinsonian effects in vivo. We decided to evaluate some of the 
most potent MAO inhibitors in the murine model of reserpine. This model 
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is based on the monoaminergic hypothesis which states that depression 
and extrapyramidal symptoms of PD are caused by an unbalance in the 
levels of monoamine neurotransmitters, i.e serotonin or dopamine.224-226  
Reserpine, an indole based alkaloid with antihypertensive and 
antipsychotic properties, has ability to deplete catecholamines by 
inhibition of vesicular monoamine transporter (VMAT). Free 
catecholamines are introduced by VMAT from the cytosol to presynaptic 
vesicles for subsequent exocytosis. As a consequence of VMAT inhibition, 
free intracellular unprotected amines are metabolized by MAO’s and 
never reach the synaptic cleft and consequently the postsynaptic neuron. 
These undesired effects are believed to be responsible for the depressant 
and parkinsonian effects of reserpine, and are the basis of the model of 
hypokinesia induced by reserpine.227,228  
In this preliminary evaluation, a single dose of 100 mg/Kg of compounds 
2.12, 2.13 (MAO-B IC50 9.7 μM) and 2.30 (it was introduced in this 
experiment as a control since it does not inhibit MAO’s) were 
administered intraperitoneally (i.p.) to ICR albino mice to counteract the 
hypokinetic effects of reserpine (3mg/Kg) as described by Tadaiesky et. al 
(2006), with minor adaptations.229 
The spontaneous locomotion of the animals was measured 2 h and 24 h 
after administration of compounds. As described in figure 2.6, control 
animals did not recover the mobility; even after 24 hours because of the 
long lasting effects of reserpine. 
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Figure 2.6 Locomotion measured 2 and 24 hours after administration of 
compounds (100 mg/Kg), control (vehicle) and selegiline (10 mg/Kg). All animals 
were administered with reserpine (3 mg/Kg). Statistical significance (p<0.05) 
 
However, compound 2.13 (100 mg/Kg) and MAO-B inhibitor, selegiline 
(10 mg/Kg), reverted significantly the effects, allowing to the animals to 
recover the natural locomotion. In future experiments it will be 
determined whether or not these effects are dose dependent. 
The capacity of 2.13 to counteract the hypokinesia in a similar manner 
to selegiline corroborates the MAO-B inhibitory effects observed in the 
previous in vitro assays.  
1R Agonist radioligand displacement 
The most potent AChE inhibitors in the series of chromone-NBP hybrids 
and chromone-DBMA derivative 2.8, with dual AChE-BACE1inhibitory 
activity, were selected to evaluate their ability to displace [3H]pentazocine 
from 1R at a concentration of 10 μM.  
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Table 2.7 [3H]pentazocine binding inhibition by newly synthesized compounds 
Compound 
% Inhibition of agonist radioligand binding to 1R 
(10 μM) 
2.8 39  
2.26 95 
2.27 88 
2.30 83 
2.35 83 
Percent values obtained by CEREP Co. at a single dose of 10 μM230  
 
High inhibition percentages (83-95%) (table 2.7) were obtained in the 
series of chromone-NBP hybrids. The nitro-derivative 2.26, was the most 
potent displacing 95%, of agonist radioligand; while the chromone-DBMA 
derivative 2.8 displaced a moderated 39% of [3H]pentazocine. 
Determination of affinity constants and the agonist or antagonist 
character of each compound remain to be determined, in order to learn 
about their potential to exert neuroprotective effects trough 1R 
modulation. 
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Conclusions 
In this chapter we have synthesized and evaluated as multitarget 
compounds several hybrids based on the chromone scaffold combined 
with the NBP and DBMA fragments. We have obtained potent and 
selective inhibitors of AChE with IC50 values in the low nanomolar range. 
Although these new compounds reminds the structure and activity of 
donepezil, especially di-methoxy substituted compound 2.30, they 
exhibit additional pharmacological properties such as neuroprotection, 
radical scavenging capacity, MAO inhibition. 
Chromone-NBP derived compounds substituted with hydroxyl and amino 
groups, exhibited the better antioxidant properties, among them, 2.27 
and 2.35, demonstrated to be effective in three targets of interest in this 
work, AChE, anti-oxidation and affinity 1R. In agreement with these 
results, and the fact that they were predicted to reach the CNS, we can 
argue that these new hybrids have the potential to become useful drugs 
in AD treatment. They could be able to restore the cholinergic 
homeostasis and therefore alleviate the cognitive symptoms in a manner 
similar to currently used cholinergic drugs including donepezil, but with 
the advantage of their radical scavenging properties and their potential 
activity as agonists of 1R, which activation is essential for mitochondrial 
health and neuronal survival. 
The chromone-NBP series yielded three moderated MAO inhibitors, 2.28, 
2.31 and the multitarget compound 2.26 with affinity for 1R and the 
ability to inhibit potently AChE. Even though, IC50 values for MAO 
enzymes are in the low micromolar range, it is worth to mention that 
high potencies (in vitro) for MAO-A are not required to exert therapeutic 
antidepressant effects (in vivo). Some drugs such as moclobemide or 
iproniazide exhibit IC50 values in the low micromolar range but 
significant antidepressant effects in humans.  
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On the other hand, in the series of chromone-DBMA hybrids, 2.12 and 
2.13, which behave as MAO-A inhibitors with potencies comparable to 
the reference drugs, are at the same time, moderated inhibitors of AChE 
in the low micromolar range (IC50=1.5 μM). Results in the rest of targets 
could be considered moderated, inhibiting 20% of BACE activity at 10 
μM, 21% and 33% of Aβ and tau aggregation at 20 μM. In the case of 
2.13, their potent antioxidant properties (1.6 trolox equivalents) acting 
synergistically with its ability to inhibit MAO-B (IC50 = 9.7 μM) could be 
able to reduce oxidative stress, distinctive of neurodegenerative disorders 
such as AD and PD. These results are in agreement with those observed 
in vivo in the model of reserpine. They corroborate the MAO-B inhibitory 
activity and the ability to reach the CNS predicted in PAMPA. 
These findings support the continuation of the investigation of these new 
hybrids with further in vivo experiments in order to determine the 
antidepressant effects which could give an additional value to their 
pharmacological profile. 
Finally, we present in this work, 2.8, a new dual hit with activity in AChE 
and BACE1; even though, this compound inhibits both enzymes with 
moderated potency (IC50 = 6.7 μM AChE, 4.5 μM BACE1). We can argue 
that these values are susceptible to be improved by structural 
modifications, similar to those made in chromone-NBP hybrids; the 
substituents in the chromone ring, the length of the chain linker and 
introduction of new substituents in the DBMA rings.  
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Experimental section 
Chemical Synthesis 
General procedure 2.1 Synthesis of 4-oxo-4H-chromene-2-carboxylic 
acids (2.1-2.5) A mixture of the corresponding phenol (24 mmol) 
dissolved in 50 mL of Et2O with an equimolar quantity of dimethyl 
acetylenedicarboxylate and 29 mmol of Et3N, was stirred overnight at 
room temperature. After completion of reaction, this mixture was washed 
with HCl (1N) (3 x 5 mL), water (3 x 5 mL) and brine (3 x 5 mL), dried 
over MgSO4 and concentrated under reduced pressure to yield the 
corresponding mixture of isomers (Z and E) of dimethyl 2-(phenoxy)but-2-
enedioates. To the flask containing the intermediate esters, 20 mL of 
NaOH 2M (40 mmol) were added and the mixture was refluxed during 30 
min ; afterward, the reaction mixture was cooled into an ice bath and 
concentrated HCl was added dropwise until pH 1 to precipitate the 
corresponding dicarboxylic acid which was separated by filtration and 
washed with distilled water. Once the solid got dried, it was dissolved in 
20 mL of acetyl chloride (290 mmol) and cooled to 0 °C. To this mixture, 
4 mL of concentrated H2SO4 (77 mmol) were added carefully to 
subsequently reflux during 30 min. The crude was cooled again and 
water was added dropwise under gentle stirring to precipitate the desired 
product (2.1-2.5). The dried solid was partially dissolved in EtOAc and 
precipitated again with hexane, filtrated and washed again several times 
with hexane, obtaining the desired products pure enough to 
characterization and to be used in the next reactions. 
General Procedure 2.2. Synthesis of chromone-NBP and chromone-
DBMA hybrids 1.0 mmol of the corresponding 4-oxo-4H-chromene-2-
carboxylic acid and 1.3 mmol of CDI were mixed into a 10 mL microwave 
vial under N2 atmosphere. The vial was sealed and 5 mL of anhydrous 
DMF were added using a syringe to dissolve the mixture (CO2↑). This 
solution was heated into a mw reactor at 120 °C during 10 min to 
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complete the activation of the acid. Afterward, a solution of 1.2 mmol of 
the corresponding amine in 2 mL of DMF was added with a syringe; this 
final solution was heated during 10 min at 150 °C to obtain the desired 
amide. After completion of the reaction, the DMF was evaporated under 
reduced pressure; the crude was re-dissolved in 25 mL of EtOAc and 
washed five times with water, dried over MgSO4 and concentrated. The 
crude was purified by column chromatography using EtOAc:MeOH (9:1) 
as eluent. 
General Procedure 2.3. Synthesis of chromone-NBP and chromone-
DBMA hybrids 
Into a round bottom flask, 1.0 mmol of the corresponding acid were 
mixed with 10 mL of anhydrous DCM under N2 atmosphere; to this 
mixture, 3 mmol of BOP were added to stir during 5 min; subsequently, 
2.5 mmoL of triethylamine were added to dissolve utterly the reagents. 
The mixture was stirred again during 5 min and finally, 1.1 mmol of the 
amine was added to stir overnight at room temperature. The mixture of 
reaction was washed with HCl (0.5 M) (3 x 5 mL), saturated solution of 
NaHCO3 (3 x 5 mL) and brine (3 x 5 mL), dried over MgSO4, filtered and 
concentrated. The crude was purified by column chromatography using 
EtOAc/MeOH (9:1) as eluent. 
General procedure 2.4 Deprotection of methoxy-substituted hybrids  
To the corresponding methoxy-derivative (0.1 mmol) dissolved in 3 mL of 
anhydrous THF, was added slowly under magnetic stirring, 1 equivalent 
of BBr3 per each heteroatom present in the molecule; air was displaced 
by N2 and the mixture was allowed to react overnight at room 
temperature. Reaction was quenched with MeOH (dropwise until end of 
effervescence) and the solvent evaporated under reduced pressure to 
eliminate the remaining BBr3, this process was repeated several times 
depending on the quantity of BBr3 used, until no fumes were observed 
when adding MeOH. When necessary, purification was carried out by 
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column chromatography using a gradient of EtOAc/MeOH 0→10% as 
eluent. 
 
5-methoxy-4-oxo-4H-chromene-2-carboxylic acid. (2.1) 
Acid 2.1 was obtained as a secondary product in the 
synthesis of 2.5, as described in the general 
procedure 2.1. 3 g (24 mmol) of 3-methoxyphenol 
and 3.4 g (24 mmol) of dimethyl 
acetylenedicarboxylate, 0,5 g (10%). White 
amorphous solid. 1H NMR (500 MHz, DMSO-d6) δ 7.73 (t, J = 8.4 Hz, 1H, 
H7), 7.18 (dd, J = 8.5, 0.9 Hz, 1H, H6), 7.03 (dd, J = 8.5, 0.9 Hz, 1H, H8), 
6.70 (s, 1H, H3), 3.86 (s, 3H, H51).13C NMR (126 MHz, DMSO-d6) δ 176.69 
(C4), 161.51 (C9), 159.21 (C5), 157.37 (C8a), 151.08 (C2), 135.27 (C7), 
115.20 (C3), 114.34 (C4a), 110.13 (C6), 107.60 (C8), 56.25 (C61). HPLC-MS 
(Water-ACN 15→95%, g.t. 5 min), retention time 2.82 min, m/z = 221.2 
[M + H]+, calcd for [C11H8O5 + H]+ 221.18 
 
5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid. (2.2) 
Compound 2.2 was obtained from 3 g of 3,5-
dimethoxyphenol (19.5 mmol) and 2.76 (19.5 mmol) 
of dimethyl acetylenedicarboxylate, as described in 
the general procedure 2.1. Light brown solid, 5.3 g 
(75%).  1H NMR (500 MHz, DMSO-d6) δ 6.72 (d, J = 
2.3 Hz, 1H, H8), 6.64 (s, 1H, H3), 6.54 (d, J = 2.3 Hz, 1H, H6), 3.89 (s, 3H, 
H71), 3.83 (s, 3H, H51). 13C NMR (126 MHz DMSO-d6) δ 175.53 (C4), 
164.41 (C7), 161.46 (C9), 160.38 (C5), 159.07 (C8a), 150.71 (C2), 115.33 
(C3), 109.08 (C4a), 96.72 (C6), 93.37 (C8), 56.21 (C51), 56.15 (C71). HPLC-
MS (Water-ACN 15→95%, g.t. 5 min), retention time 3.17 min, m/z 
=251.2 [M + H]+, calcd for [C12H10O6 + H]+ 251.2 
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6-Methoxy-4-oxo-4H-chromene-2-carboxylic acid. (2.3) 
According to the general procedure 2.1, compound 
2.3 was synthesized from 3 g (24 mmol) of 4-
methoxyphenol and 3.4 g (24 mmol) of dimethyl 
acetylenedicarboxylate. Light yellow amorphous 
solid, 5.01 g (78%). 1H NMR (300 MHz, DMSO-d6) δ 
7.70 (d, J = 9.1 Hz, 1H, H8), 7.46 (dd, J = 9.1, 3.1 Hz, 1H, H7), 7.40 (d, J = 
3.1 Hz, 1H, H5), 6.88 (s, 1H, H3), 3.87 (s, 3H, H61). 13C NMR (75 MHz, 
DMSO-d6) δ 177.27 (C4), 161.47 (C9), 156.99 (C6), 152.96 (C2), 150.18 
(C8a), 124.55 (C4a), 124.42 (C7), 120.56 (C8), 112.56 (C3), 104.53 (C5), 
55.82 (C61). HPLC-MS (Water-ACN 15→95%, g.t. 5 min), retention time 
3.62 min, m/z = 221.2 [M + H]+, calcd for [C11H8O5 + H]+ 221.2 
 
5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid. (2.4) 
2.4 was obtained from 3 g (19.5 mmol) of 3,4-
dimethoxyphenol and 2.76 (19.5 mmol) of dimethyl 
acetylenedicarboxylate, as described in the general 
procedure. Brown amorphous solid, 4.9 g (69%). 1H 
NMR (300 MHz, DMSO-d6) δ 7.33 (s, 1H, H5), 7.23 
(s, 1H, H8), 6.72 (s, 1H, H3), 3.92 (s, 3H, H71), 3.86 (s, 3H, H61). 13C NMR 
(75 MHz, DMSO-d6) δ 176.96 (C4), 161.79 (C9), 157.35 (C2), 154.70 (C7), 
151.72 (C8a), 147.57 (C6), 117.07 (C4a), 111.22 (C3), 103.44 (C5), 100.81 
(C8), 56.43 (C61), 55.79 (C71). HPLC-MS (Water-ACN 15→95%, g.t. 5 min), 
retention time 3.13 min, m/z =251.2 [M + H]+, calcd for [C12H10O6 + H]+ 
251.2 
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7-methoxy-4-oxo-4H-chromene-2-carboxylic acid. (2.5) 
2.5 was obtained from 3 g (24 mmol) of 3-
methoxyphenol and 3.4 g (24 mmol) of dimethyl 
acetylenedicarboxylate. White amorphous solid, 
4.25 g (80%). 1H NMR (500 MHz, DMSO-d6) δ 7.91 
(d, J = 8.9 Hz, 1H, H5), 7.16 (d, J = 2.4 Hz, 1H, H8), 
7.06 (dd, J = 8.9, 2.4 Hz, 1H, H6), 6.82 (s, 1H, H3), 3.90 (s, 3H, H71). 13C 
NMR (126 MHz, DMSO-d6) δ 176.62 (C4), 164.52 (C7), 161.45 (C9), 157.40 
(C8a), 152.87 (C2), 126.33 (C5), 117.63 (C4a), 115.54 (C6), 113.70 (C3), 
100.96 (C8), 56.27 (C71). HPLC-MS (Water-ACN 15→95%, g.t. 5 min), 
retention time 4.26 min, m/z = 221.2 [M + H]+, calcd for [C11H8O5 + H]+ 
221.18. 
 
6-Nitro-4-oxo-4H-chromene-2-carboxylic acid. (2.6) 
Over an ice bath, 1 g (5.26 mmol) of 4-oxo-4H-
chromene-2-carboxylic acid was dissolved in 1.5 
mL of HNO3 (34.2 mmol), to this solution 10 mL 
of concentrated H2SO4 (190 mmol) were carefully 
added; the reaction mixture was first heated until 
75 °C during 3 hours and then cooled over an ice bath to add water 
dropwise to precipitate 2.6 as a white amorphous solid, 1.1 g (90%). mp: 
273 - 275 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.71 (d, J = 2.8 Hz, 1H, H5), 
8.61 (dd, J = 9.2, 2.8 Hz, 1H, H7), 8.00 (d, J = 9.2 Hz, 1H, H8), 7.02 (s, 
1H, H3). 13C NMR (75 MHz, DMSO-d6) δ 176.88 (C4), 160.96 (C9), 158.47 
(C6), 153.99 (C2), 144.65 (C8a), 129.16 (C7), 123.73 (C4a), 121.23 (C8), 
120.93 (C5), 113.72 (C3). HPLC-MS (Water-ACN 15→95%, g.t. 10 min), 
retention time 5.75 min, m/z =236.1 [M + H]+, calcd for [C10H5NO6 + H]+ 
236.1 
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2-(1-Benzylpiperidin-4-yl)ethan-1-ol. (2.7) 
4-Piperidineethanol (0.3 g, 2.32 mmol) and 
benzyl bromide (276 µL, 1 eq), were dissolved 
in 20 mL of acetonitrile. Then, anhydrous 
K2CO3 (320.65 mg, 1 eq) and 
tetrabutylammonium iodide (TBAI, 8.6 mg, 0.01 eq) were added. The 
reaction mixture was refluxed for 24 h. The inorganic salt was filtered 
and washed with MeOH, the filtrate was evaporated and purified by 
column chromatography using a mixture of DCM: MeOH. 1H NMR (300 
MHz, 1H NMR (300 MHz, CDCl3) δ 7.51 – 7.15 (m, 5H, Ph), 3.80 – 3.57 
(m, 4H, H β), 3.51 (s, 1H, H), 2.90 (d, J = 11.6 Hz, 2H, H2eq), 1.99 (dt, J = 
12.4, 6.2 Hz, 2H, H2ax), 1.73 – 1.58 (m, 2H, H3eq), 1.52 (q, J = 6.2 Hz, 1H, 
H4), 1.31 (qd, J = 11.1, 10.2, 3.6 Hz, 1H, H3ax). 13C NMR (75 MHz, CDCl3) 
δ 138.05 (Ci), 129.50 (Co), 128.31 (Cm), 127.19 (Cp), 70.70 (C), 63.51 (C), 
60.66 (Cβ), 53.86 (C2), 32.36 (C4), 32.26 (C3). 
 
N-(3-((Benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide. (2.8) 
(2.8) was obtained as 
described in the general 
procedure 2.2, from 0.12 g 
(0.48 mmol) of (2.4) and 0.13 g 
(0.58 mmol) of 1.7. Light 
brown amorphous solid, 0.2 g (90%), mp: 105 -108 °C. 1H NMR (400 
MHz, MeOD) δ 7.79 (bs, 1H, H2’), 7.71 (dd, J = 8.2, 1.6 Hz, 1H, H6’), 7.46 
(s, 1H, H5), 7.39 – 7.31 (m, 6H, Ho, m, p, 8), 7.29 – 7.21 (m, 1H, H5’), 7.20 
(dt, J = 8.2, 1.5 Hz, 1H, H4’), 7.03 (s, 1H, H3), 4.01 (s, 3H, H61), 3.92 (s, 
3H, H71), 3.55 (bs, 4H, H, β), 2.19 (s, 3H, H). 13C NMR (101 MHz, MeOD) 
δ 179.43 (C4), 159.40 (C9), 157.41 (C6), 156.94 (C2), 153.48 (C8a), 150.11 
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(C7), 140.93 (Ci), 139.68 (C3’), 138.69 (C1’), 130.40 (Co), 129.89 (Cp), 
129.34 (Cm), 128.29 (C5’), 127.37 (C4’), 123.17 (C2’), 121.27 (C6’), 118.50 
(C4a), 111.78 (C3), 104.68 (C5), 101.45 (C8), 62.79 (C), 62.57 (Cβ), 57.10 
(C61), 56.67 (C71), 42.42 (C). HRMS [ESI+] m/z =458.1840 [M]+, calcd for 
[C27H26N2O5]+ 458.1841. HPLC purity 100%  
 
N-(4-((Benzyl(methyl)amino)methyl)phenyl)-5,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide. (2.9) 
 According to the general 
procedure, 2.9 was obtained 
from 0.2 g (0.8 mmol) of 2.2 
and 0.22 g (0.96 mmol) of 1.8 
White amorphous solid (70%), 
mp: 99.3-101.2 ºC. 1H NMR (300 MHz, CDCl3) δ 8.81 (s, 1H, NH), 7.88 (d, 
J = 8.4 Hz, 2H, H2’), 7.60 (d, J = 8.4 Hz, 2H, H3’), 7.56 – 7.41 (m, 5H, Ph), 
7.26 (s, 1H, H3), 6.75 (d, J = 2.3 Hz, 1H, H6), 6.58 (d, J = 2.3 Hz, 1H, H8), 
4.11 (s, 3H, H71), 4.09 (s, 3H, H51), 3.73 (s, 2H, Hβ), 3.72 (s, 2H, H), 2.39 
(s, 3H, H). 13C NMR (75 MHz, CDCl3) δ 176.96 (C4), 164.84 (C7), 161.28 
(C5), 159.02 (C8a), 157.16 (C9), 152.57 (C2), 139.22 (Ci), 136.85 (C1’), 
135.48 (C4’), 129.81 (C3’), 129.05 (Co), 128.38 (Cm), 127.13 (Cp), 120.47 
(C2’), 114.39 (C3), 109.85 (C4a), 96.86 (C6), 93.03 (C8), 61.94 (Cβ), 61.37 
(C), 56.55 (C51), 56.05 (C71), 42.34 (C). HRMS [ESI+] m/z =458.1863 
[M]+, calcd for [C27H26N2O5]+ 458.1842. HPLC purity 99% 
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N-(4-((Benzyl(methyl)amino)methyl)phenyl)-5,7-dihydroxy-4-oxo-4H-
chromene-2-carboxamide. 2.10 
2.10 was obtained as 
described in the above C, from 
0.1 g (0.25 mmol) of 2.9 and 
0.3 g (1.2 mmol) BBr3. Bright 
yellow solid, 0.84 g (90%), mp: 
199 - 233 °C. 1H NMR (500 MHz, MeOD) δ 7.75 (d, J = 8.5 Hz, 2H, H2’), 
7.41 (d, J = 8.5 Hz, 2H, H3’), 7.39 – 7.33 (m, 4H, Ho, m), 7.30 – 7.26 (m, 
1H, Hp), 6.94 (s, 1H, H3), 6.63 (d, J = 2.1 Hz, 1H, H8), 6.28 (d, J = 2.1 Hz, 
1H, H6), 3.59 (s, 4H, H, β), 2.22 (s, 3H, H). 13C NMR (126 MHz, MeOD) δ 
183.60 (C4), 167.44 (C7), 163.42 (C5), 159.15 (C9), 159.00 (C8a), 157.45 
(C2), 139.22 (Ci), 137.77 (C1’), 136.59 (C4’), 130.98 (C3’), 130.48 (Co), 
129.40 (Cm), 128.46 (Cp), 122.50 (C2’), 111.22 (C3), 106.32 (C4a), 100.92 
(C6), 95.94 (C8), 62.60 (C), 62.07 (Cβ), 42.22 (C). HRMS [ESI+] m/z 
=430.1517 [M]+, calcd for [C25H22N2O5]+ 430.1529. HPLC purity 100%  
 
N-(4-((Benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide. 2.11 
2.11 was obtained as described 
in the general procedure 2.2, 
from 0.2 g (0.80 mmol) of 2.4 
and 0.18 g (0.88 mmol) of 1.8. 
White amorphous solid, 0.29 g 
(80%), mp: 119.5-120.3 ºC. 1H NMR (300 MHz, MeOD) δ 7.89 (d, J = 8.6 
Hz, 2H, H2’), 7.53 – 7.35 (m, 9H, Ph, H3’, 5, 8), 7.06 (s, 1H, H3), 4.04 (s, 3H, 
H61), 3.98 (bs, 4H, H, β), 3.95 (s, 3H, H71), 2.49 (s, 3H, H). 13C NMR (75 
MHz, MeOD) δ 179.39 (C4), 159.50 (C9), 157.48 (C6), 156.76 (C2), 153.49 
(C8a), 150.17 (C7), 139.17 (C1’), 136.52 (C4’), 134.41 (Ci), 131.99 (C3’), 
Chapter 2 
115 
 
131.33 (Co), 129.93 (Cm), 129.84 (Cp), 122.53 (C2’), 118.53 (C4a), 111.87 
(C3), 104.71 (C5), 101.48 (C8), 61.77 (C), 61.30 (Cβ), 57.14 (C61), 56.69 
(C71), 40.87 (C). HRMS [ESI+] m/z =458.1848 [M]+, calcd for 
[C27H26N2O5]+ 450.1842. HPLC purity 100% 
 
N-(4-((Benzyl(methyl)amino)methyl)phenyl)-6-methoxy-4-oxo-4H-
chromene-2-carboxamide. (2.12)  
According to the general 
procedure 2.2, 2.12 was 
obtained from 0.2 g (0.91 
mmol) of 2.3 and 0.27 g (1.18 
mmol) of 1.8. White 
amorphous solid, 0.3 g (77%), 
mp: 145.7-146.7 ºC. 1H NMR (300 MHz, CDCl3) δ 8.55 (s, 1H, NH), 7.67 
(d, J = 8.5 Hz, 2H, H2’), 7.59 (d, J = 3.1 Hz, 1H, H5), 7.54 (d, J = 9.1 Hz, 
1H, H7), 7.42 (d, J = 8.5 Hz, 2H, H3’), 7.39 – 7.29 (m, 5H, H8, o, m), 7.28 – 
7.23 (m, 2H, H3, p), 3.91 (s, 3H, H61), 3.54 (s, 2H, Hβ), 3.53 (s, 2H, H), 
2.20 (s, 3H, H).13C NMR (75 MHz, CDCl3) δ 178.02 (C4), 157.78 (C6), 
157.06 (C9), 154.52 (C2), 150.02 (C8a), 139.28 (Ci), 137.14 (C1’), 135.26 
(C4’), 129.86 (C3’), 129.05 (Cm), 128.39 (Cp), 127.13 (Co), 125.24 (C4a), 
124.90 (C8), 120.47 (C2’), 119.60 (C7), 111.84 (C3), 105.34 (C5), 61.99 (Cβ), 
61.37 (C), 56.16 (C61), 42.37 (C). HRMS [ESI+] m/z =428.1754 [M]+, 
calcd for [C26H24N2O4]+ 428.1736. HPLC purity 99% 
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N-(4-((Benzyl(methyl)amino)methyl)phenyl)-6-hydroxy-4-oxo-4H-
chromene-2-carboxamide. 2.13 
2.13 was obtained as 
described in the general 
procedure C, from 0.05 g (0.1 
mmol) of 2.12 and 0.3 g (1.2 
mmol) BBr3. Yellow solid, 
0.043 g (90%), mp: 186 -189 °C. 1H NMR (500 MHz, MeOD) δ 7.77 (d, J = 
8.6 Hz, 2H, H2’), 7.73 (d, J = 9.1 Hz, 1H, H8), 7.45 (d, J = 2.9 Hz, 1H, H5), 
7.41 (d, J = 8.6 Hz, 2H, H3’), 7.38 – 7.31 (m, 5H, H7, o, m), 7.29 – 7.25 (m, 
1H, Hp), 7.05 (s, 1H, H3), 3.56 (s, 4H, H, β), 2.20 (s, 3H, H).13C NMR (126 
MHz, MeOD) δ 180.41 (C4), 159.57 (C9), 157.38 (C2), 157.29 (C8a), 151.03 
(C6), 139.51 (Ci), 137.75 (C1’), 136.84 (C4’), 130.92 (Co), 130.42 (C3’), 
129.36 (Cm),  128.36 (Cp), 126.09 (C4a), 125.57 (C7), 122.39 (C2’), 121.32 
(C8), 111.16 (C3), 108.72 (C5), 62.65 (Cβ), 62.13 (C), 42.30 (C).HRMS 
[ESI+] m/z =414.1583 [M]+, calcd for [C25H22N2O4]+ 414.1580. HPLC 
purity 100%  
 
N-(1-Benzylpiperidin-4-yl)-6-methoxy-4-oxo-4H-chromene-2-
carboxamide.  2.14 
2.14 was obtained as described in 
the general procedure method A, 
from 0.20 g (0.91 mmol) of 2.3 and 
0.19 g (1 mmol) of 1-
benzylpiperidin-4-amine. White 
amorphous solid, 0.25 g (70%), mp: 196 -199 °C. 1H NMR (300 MHz, 
MeOD) δ 7.72 (d, J = 9.2 Hz, 1H, H8), 7.53 (d, J = 3.1 Hz, 1H, H5), 7.46 
(dd, J = 9.2, 3.1 Hz, 1H, H7), 7.38 – 7.28 (m, 5H, Ph), 6.96 (s, 1H, H3), 
3.92 (s, 4H, H4’, 61’), 3.58 (s, 2H, H), 2.99 (d, J = 11.9 Hz, 2H, H2’eq), 2.20 
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(td, J = 11.9, 2.5 Hz, 2H, H2’ax), 2.03 – 1.88 (m, 2H, H3’eq), 1.78 (tt, J = 
13.3, 6.6 Hz, 2H, H3’ax).  13C NMR (75 MHz, MeOD) δ 180.23 (C4), 160.81 
(C9), 159.21 (C6), 157.30 (C2), 151.86 (C8a), 138.52 (Ci), 130.73 (Co), 
129.33 (Cm), 128.47 (Cp), 125.88 (C7), 125.83 (C4a), 121.37 (C8), 111.08 
(C3), 105.68 (C5), 63.93 (C), 56.42 (C61), 53.53 (C2’), 49.17 (C4’) 32.04 (C3’). 
HRMS [ESI+] m/z =392.1742 [M]+, calcd for [C23H24N2O4]+ 392.1736. 
HPLC purity 100% 
 
N-(1-Benzylpiperidin-4-yl)-6-hydroxy-4-oxo-4H-chromene-2-
carboxamide. 2.15 
2.15 was obtained as described in 
the general procedure from 0.05 g 
(0.013 mmol) of 2.14 and 0.1 mmol 
of BBr3. white amorphous solid, 
0.013 g (70%), mp: 302 - 304 °C. 
1H NMR (500 MHz, MeOD) δ 7.65 (d, J = 9.1 Hz, 1H, H8), 7.56 – 7.51 (m, 
5H, Ph), 7.43 (d, J = 3.0 Hz, 1H, H5), 7.34 (dd, J = 9.1, 3.0 Hz, 1H, H7), 
6.94 (s, 1H, H3), 4.35 (s, 2H, H), 4.25 – 4.15 (m, 1H, H4’), 3.66 – 3.50 (m, 
2H, H2’eq), 3.25 – 3.13 (m, 2H, H2’ax), 2.29 – 2.17 (m, 2H, H3’eq), 2.09 – 1.96 
(m, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 180.33 (C4), 161.28 (C9), 
157.26 (C8a), 156.84 (C2), 150.97 (C6), 132.35 (Co), 131.33 (Cp), 130.44 
(Cm), 130.44 (Ci) 126.06 (C4a), 125.59 (C7), 121.13 (C8), 110.96 (C3), 
108.72 (C5), 61.88 (C), 52.86 (C2’), 29.75 (C3’). HRMS [ESI+] m/z 
=378.15814 [M]+, calcd for [C22H22N2O4]+ 378.1579. HPLC purity 97% 
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N-(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-4-oxo-4H-chromene-2-
carboxamide. 2.16 
2.16 was obtained as described in 
the general procedure 2.3, from 
0.05 g (0.2 mmol) of 2.4 and 0.42 g 
(0.22 mmol) of 1-benzylpiperidin-4-
amine. White solid, 0.04 g (54%), 
mp: 183-185 °C. 1H NMR (300 MHz, MeOD) δ 7.45 (s, 1H, H8), 7.42 – 
7.29 (m, 5H, Ph), 7.26 (s, 1H, H5), 6.93 (s, 1H, H3), 4.01 (s, 3H, H71), 3.98 
– 3.83 (m, 4H, H4’, 61), 3.65 (s, 2H, H), 3.05 (d, J = 11.9 Hz, 2H, H2’eq), 
2.36 – 2.21 (m, 2H, H2’ax), 2.06 – 1.93 (m, 2H, H3’eq), 1.90 – 1.70 (m, 2H 
H3’ax). 13C NMR (75 MHz, MeOD) δ 179.42 (C4), 160.78 (C9), 157.36 (C7), 
156.75 (C2), 153.43 (C8a), 150.02 (C6), 137.96 (Ci), 130.85 (Co), 129.41 
(Cm), 128.67 (Cp), 118.40 (C4a), 111.38 (C4’), 104.68 (C8), 101.31 (C5), 
63.76 (C), 57.07 (C71), 56.66 (C61), 53.44 (C2’), 31.89 (C3’). HRMS [ESI+] 
m/z =422.1850 [M]+, calcd for [C24H26N2O5]+ 422.1842. HPLC purity 97% 
 
N-((1-Benzylpiperidin-4-yl)methyl)-6-methoxy-4-oxo-4H-chromene-2-
carboxamide.  2.17 
2.17 was obtained as described in 
the general procedure 2.2, from 
0.05 g (0.23 mmol) of 2.3 and 
0.051 g (0.25 mmol) of 1.2. White 
amorphous solid, 0.055 g (60%). 
mp: 116.1-118.3 ºC. 1H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 3.1 Hz, 1H, 
H5), 7.42 (d, J = 9.1 Hz, 1H, H8), 7.31 – 7.20 (m, 6H, Ph, H7), 7.12 (s, 1H, 
H3), 6.90 (t, J = 6.2 Hz, 1H, NH), 3.88 (s, 3H, H61), 3.48 (s, 2H, H), 3.37 
(t, J = 6.2 Hz, 2H, H), 2.90 (d, J = 11.4 Hz, 2H, H2’eq), 1.96 (dt, J = 11.4, 
6.1 Hz, 2H, H2’ax), 1.71 (d, J = 12.7 Hz, 2H, H3’eq), 1.67 – 1.50 (m, 1H, H4’), 
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1.45 – 1.26 (m, 2H, H3’ax). 13C NMR (126 MHz, CDCl3) δ 178.14 (C4), 
159.58 (C9), 157.65 (C6), 154.59 (C2), 150.08 (C8a), 138.42 (Ci), 129.33 
(Co), 128.34 (Cm), 127.17 (Cp), 125.23 (C4a), 124.77 (C7), 119.56 (C8), 
111.46 (C3), 105.28 (C5), 63.45 (C), 56.16 (C61), 53.36 (C3’), 45.56 (C), 
36.17 (C4’), 30.12 (C2’). HRMS [ESI+] m/z =406.1908 [M]+, calcd for 
[C24H26N2O4]+ 406.1893. HPLC purity 98% 
 
N-((1-Benzylpiperidin-4-yl)methyl)-6,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide.  2.18 
2.18 was obtained as described in 
the general procedure 2.3, from 
0.20 g (0.80 mmol) of 2.4 and 
0.18 g (0.88 mmol) of 1.2. White 
amorphous solid, 0.17 g (50%), 
mp: 172 - 174 °C. 1H NMR (500 MHz, MeOD) δ 7.44 (s, 1H, H5), 7.35 – 
7.24 (m, 5H, Ph), 7.20 (s, 1H, H8), 6.92 (s, 1H, H3), 3.99 (s, 3H, H71), 3.92 
(s, 3H, H61), 3.56 (s, 2H, H), 3.33 (bs, 2H, H), 2.97 (dt, J = 12.0, 3.2 Hz, 
2H, H2’eq), 2.08 (td, J = 12.0, 2.5 Hz, 2H, H2’ax), 1.84 – 1.76 (m, 2H, H3’eq), 
1.72 (tq, J = 7.6, 3.7 Hz, 1H, H4’), 1.43 – 1.32 (m, 2H, H3’ax). 13C NMR (126 
MHz, MeOD) δ 179.44 (C4), 161.50 (C9), 157.37 (C7), 156.74 (C2), 153.41 
(C8a), 150.03 (C6), 137.97 (Ci), 130.92 (Co), 129.32 (Cm), 128.55 (Cp), 
118.37 (C4a), 111.34 (C3), 104.68 (C5), 101.22 (C8), 64.17 (C), 57.06 (C71), 
56.66 (C61), 54.25 (C2’), 46.23 (C), 37.06 (C4’), 30.50 (C3’). HPLC-MS 
(Water-ACN 2→95%, g.t. 10 min), retention time 6.27 min, m/z =437.2 
[M + H]+, calcd for [C25H28N2O5 + H]+ 437.2. HPLC purity 100%. 
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(1-Benzylpiperidin-4-yl)methyl 6,7-dimethoxy-4-oxo-4H-chromene-2-
carboxylate. 2.19 
2.19 was synthesized as 
described in the general 
procedure 2.3, from 0.05 g (0.20 
mmol) of 2.4 and 0.05 g (0.24 
mmol) (1-benzylpiperidin-4-
yl)methanol. White solid, 0.035 g (40%), mp: 138 -140 °C. 1H NMR (500 
MHz, CDCl3) δ 7.65 – 7.60 (m, 2H, Ho), 7.48 (s, 1H, H8), 7.48 – 7.42 (m, 
3H, Hm, p), 7.33 (s, 1H, H5), 7.06 (s, 1H, H3), 4.30 (d, J = 5.4 Hz, 2H, H), 
4.18 (s, 2H, H), 4.06 (s, 3H, H71), 3.97 (s, 3H, H61), 3.59 – 3.53 (m, 2H, 
H2’eq), 2.75 – 2.63 (m, 2H, H2’ax), 2.49 – 2.34 (m, 2H, H H3’eq), 2.04 – 1.97 
(m, 1H, H4’), 1.97 – 1.91 (m, 2H, H3’ax).  13C NMR (126 MHz, CDCl3) δ 
177.34 (C4), 160.64 (C9), 155.79 (C7), 152.57 (C8a), 151.13 (C2), 148.55 
(C6), 131.63 (Co), 130.46 (Cp), 129.55 (Cm), 127.91 (Ci), 118.21 (C4a), 
114.71 (C3), 103.93 (C8), 101.00 (C5), 69.04 (C), 61.23 (C), 57.31 (C71), 
56.53 (C61), 51.97 (C2’), 33.78 (C4’), 25.69 (C3’). HRMS [ESI+] m/z 
=437.1859 [M]+, calcd for [C25H27NO6]+ 437.1838. HPLC purity 97%   
 
(1-Benzylpiperidin-4-yl)methyl 6-methoxy-4-oxo-4H-chromene-2-
carboxylate.  2.20 
2.20 was obtained as described in 
the general procedure 2.2, from 
0.05 g (0.23 mmol) of 2.3 and 
0.055 g (0.27 mmol) (1-
benzylpiperidin-4-yl)methanol. 
White amorphous solid, 0.11 g (12%), mp: 185 -188 °C. 1H NMR (500 
MHz, CDCl3) δ 7.64 – 7.60 (m, 3H, Ho, 8), 7.52 (d, J = 3.2 Hz, 1H, H5), 7.47 
– 7.44 (m, 3H, Hm, p), 7.34 (dd, J = 9.2, 3.2 Hz, 1H, H7), 7.05 (s, 1H, H3), 
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4.30 (d, J = 6.3 Hz, 2H, H), 4.17 (s, 2H, H), 3.89 (s, 3H, H61),3.54 (d, J = 
12.1 Hz, 2H, H2’eq), 2.70 – 2.61 (m, 2H, H2’ax), 2.38 – 2.24 (m, 2H, H3’eq), 
2.08 – 1.87 (m, 3H, H3’ax, 4’). 13C NMR (126 MHz, CDCl3) δ 178.26 (C4), 
160.46 (C9), 157.74 (C6), 151.49 (C2), 150.97 (C8a), 131.64 (Co), 130.43 
(Cp), 129.53 (Cm), 127.93 (Ci), 125.32 (C7), 120.59 (C8), 120.40 (C4a), 
114.17 (C3), 104.66 (C5), 69.30 (C), 61.23 (C), 56.12 (C61), 51.85 (C2’), 
33.85 (C4’), 25.76 (C3’). HRMS [ESI+] m/z =407.1741 [M]+, calcd for 
[C24H25NO5]+ 407.1733. HPLC purity 98% 
 
2-(1-Benzylpiperidin-4-yl)ethyl 6,7-dimethoxy-4-oxo-4H-chromene-2-
carboxylate. 2.21 
2.21 was obtained as described 
in the general procedure 2.3, 
from 0.2 g (0.80 mmol) of 2.4 
and 0.191 g (0.88 mmol) of 2-
(1-benzylpiperidin-4-yl)ethan-1-
amine. White amorphous solid, 0.29 g (80%), mp: 129 -130 °C. 1H NMR 
(500 MHz, CDCl3) δ 7.51 (s, 1H, H8), 7.39 – 7.24 (m, 5H, Ph), 7.06 (s, 1H, 
H3), 7.03 (s, 1H, H5), 4.43 (t, J = 6.6 Hz, 2H, H), 3.99 (s, 3H, H71), 3.98 
(s, 3H, H61), 3.60 (s, 2H, H), 2.99 (s, 2H, H2’eq), 2.15 – 1.99 (m, 2H, H2’ax), 
1.82 – 1.67 (m, 4H, H3’eq, β), 1.53 – 1.24 (m, 3H, H3’ax, 4’). 13C NMR (126 
MHz, CDCl3) δ 177.49 (C4), 160.77 (C9), 155.52 (C7), 152.42 (C8a), 151.46 
(C2), 148.48 (C6), 129.70 (Co), 129.14 (Ci), 128.51 (Cm), 126.20 (Cp), 
118.31 (C4a), 114.61 (C3), 104.19 (C8), 100.33 (C5), 64.83 (C), 63.15 (C), 
56.80 (C71), 56.57 (C61), 53.50 (C2’), 35.00 (Cβ), 32.53 (C4’), 29.85 (C3’). 
HRMS [ESI+] m/z =451.2005 [M]+, calcd for [C26H29NO6]+ 451.1995. HPLC 
purity 96% 
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N-(2-(1-Benzylpiperidin-4-yl)ethyl)-6-methoxy-4-oxo-4H-chromene-2-
carboxamide. 2.23 
According to the general 
procedure 2.2, 2.23 was 
obtained from 0.15 g (0.7 
mmol) of 2.3 and 0.18 g (0.82 
mmol) of 2-(1-benzylpiperidin-
4-yl)ethan-1-amine. White amorphous solid, 0.23 g (80%), mp: 136.7-
138.8 ºC. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 3.1 Hz, 1H, H5), 7.57 
(d, J = 9.2 Hz, 1H, H7), 7.47 – 7.32 (m, 6H, Ph, H8), 7.26 (s, 1H, H3), 7.00 
(t, J = 5.0 Hz, 1H, NH), 4.02 (s, 3H, H61), 3.69 – 3.59 (m, 4H, H, ), 3.02 
(d, J = 10.7 Hz, 2H, H2’eq), 2.10 (t, J = 10.7 Hz, 2H, H2’ax), 1.84 (d, J = 9.5 
Hz, 2H, H3’eq), 1.73 (p, J = 6.1 Hz, 2H, Hβ), 1.57 – 1.38 (m, 3H, H3’ax, 4’). 13C 
NMR (75 MHz, CDCl3) δ 178.14 (C4), 159.39 (C9), 157.63 (C6), 154.65 (C2), 
150.09 (C8a), 138.28 (Ci), 129.40 (Co), 128.30 (Cm), 127.14 (Cp), 125.20 
(C4a), 124.72 (C8), 119.54 (C7), 111.33 (C3), 105.26 (C5), 63.52 (C), 56.13 
(C61), 53.74 (C2’), 37.91 (C), 36.29 (Cβ), 33.69 (C4’), 32.23 (C3’). HRMS 
[ESI+] m/z =420.2068 [M]+, calcd for [C25H28N2O4]+ 420.2049. HPLC 
purity 100% 
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-5,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide. 2.24 
According to the general 
procedure 2.2, 2.24 was 
obtained from 0.15 g (0.60 
mmol) of 2.2 and 0.157 g (0.72 
mmol) of 2-(1-benzylpiperidin-
4-yl)ethan-1-amine. White amorphous solid, 0.24 g (89%), mp: 82 - 84 
°C. 1H NMR (300 MHz, CDCl3) δ 7.37 – 7.21 (m, 5H, Ph), 6.95 (s, 1H, H3), 
6.83 (t, J = 5.9 Hz, NH), 6.48 (d, J = 2.3 Hz, 1H, H8), 6.37 (d, J = 2.3 Hz, 
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1H, H6), 3.92 (s, 3H, H71), 3.88 (s, 3H, H51), 3.53 – 3.44 (m, 4H, H,), 2.89 
(d, J = 10.7 Hz, 2H, H2’eq), 1.97 (t, J = 10.7 Hz, 2H, H2’ax), 1.70 (d, J = 9.5 
Hz, 2H, H3’eq), 1.63 – 1.54 (m, 2H, Hβ), 1.40 – 1.28 (m, 3H, H3’ax, 4’). 13C 
NMR (75 MHz, CDCl3) δ 177.05 (C4), 164.68 (C7), 161.29 (C5), 159.39 (C9), 
159.05 (C8a), 152.55 (C2), 138.25 (Ci), 129.39 (Co), 128.29 (Cm), 127.13 
(Cp), 113.91 (C3), 109.89 (C4a), 96.67 (C6), 92.94 (C8), 63.51 (C), 56.56 
(C71), 55.96 (C51), 53.73 (C2’), 37.84 (C), 36.29 (Cβ), 33.66 (C4’), 32.22 
(C3’). HRMS [ESI+] m/z =450.2169 [M]+, calcd for [C26H30N2O5]+ 450.2155. 
HPLC purity 100% 
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-4-oxo-4H-chromene-2-
carboxamide. 2.25 
2.25 was obtained as described 
in the general procedure 2.2, 
from 0.2 g (1 mmol) of 4-oxo-4H-
chromene-2-carboxylic acid and 
0.275 g (1.2mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-amine. White amorphous solid, 0.5 g (97%). 
mp: 163 - 165 °C. 1H NMR (300 MHz, MeOD) δ 8.14 (dd, J = 8.1, 1.7 Hz, 
1H, H5), 7.85 (ddd, J = 8.6, 7.1, 1.7 Hz, 1H, H6), 7.72 (dd, J = 8.6, 1.2 Hz, 
1H, H8), 7.52 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H, H7), 7.42 – 7.22 (m, 5H, Ph), 
6.97 (s, 1H, H3), 3.52 (s, 2H, H), 3.45 (t, J = 7.4 Hz, 2H, H), 2.91 (d, J = 
11.5 Hz, 2H, H2’eq), 2.05 (t, J = 11.4 Hz, 2H, H2’ax), 1.78 (d, J = 12.3 Hz, 
2H, H3’eq), 1.67 – 1.53 (m, 2H, Hβ), 1.45 – 1.18 (m, 3H, H3’ax, 4'). 13C NMR 
(126 MHz, MeOD) δ 180.43 (C4), 161.24 (C9), 157.52 (C2), 157.13 (C8a), 
138.01 (Ci), 136.31 (C6), 130.97 (Co), 129.29 (Cm), 128.51 (Cp), 127.29 
(C7), 126.37 (C5), 125.07 (C4a), 119.81 (C8), 111.88 (C3), 64.29 (C), 54.60 
(C2’), 38.64 (C), 36.90 (Cβ), 34.47 (C4’), 32.66 (C3’). HRMS [ESI+] m/z 
=390.1944 [M]+, calcd for [C24H26N2O3]+ 390.1943. HPLC purity 100% 
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N-(2-(1-Benzylpiperidin-4-yl)ethyl)-6-nitro-4-oxo-4H-chromene-2-
carboxamide. 2.26 
2.26 was obtained as 
described in the general 
procedure 2.2, from 0.2 g 
(0.85 mmol) of 2.6 and 0.23 g 
(1 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-amine. Light brown amorphous solid, 0.34 g 
(92%), mp: 173 - 175 °C. 1H NMR (500 MHz, MeOD) δ 8.94 (d, J = 2.8 Hz, 
1H, H5), 8.65 (dd, J = 9.2, 2.8 Hz, 1H, H7), 7.92 (d, J = 9.2 Hz, 1H, H8), 
7.35 – 7.31 (m, 5H, Ho, m, H3), 7.35 – 7.25 (m, 1H, Hp), 3.55 (s, 2H, H), 
3.48 (dd, J = 8.1, 6.7 Hz, 2H, H), 2.94 (dt, J = 12.0, 3.1 Hz, 2H, H2’eq), 
2.07 (td, J = 11.9, 2.5 Hz, 2H, H2’ax), 1.82 – 1.76 (m, 2H, H, H3’eq), 1.61 
(dt, J = 8.1, 6.7 Hz, 2H, Hβ), 1.41 (ddt, J = 12.9, 6.7, 3.4 Hz, 1H, H4’), 
1.38 – 1.27 (m, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 178.83 (C4), 
160.66 (C9), 159.84 (C6), 157.83 (C2), 146.65 (C8a), 137.98 (Ci), 130.97 
(Co), 130.13 (C7), 129.30 (Cm), 128.52 (Cp), 125.30 (C4a), 122.57 (C5), 
121.83 (C8), 64.28 (C), 54.58 (C2’), 38.71 (C), 36.87 (Cβ), 34.44 (C4’), 
32.65 (C3’). HRMS [ESI+] m/z =435.1795 [M]+, calcd for [C24H25N3O5]+ 
435.1794. HPLC purity 100% C-3 not observed 
 
6-Amino-N-(2-(1-benzylpiperidin-4-yl)ethyl)-4-oxo-4H-chromene-2-
carboxamide. 2.27 
2.26 0.2 g (0.46 mmol) was 
dissolved in 5 mL of EtOH 
into a 50 mL round bottom 
flask, to this dissolution a 
catalytic amount of 
Pd/charcoal 5% was added under N2 atmosphere; subsequently, N2 was 
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displaced by H2 and the flask was sealed up with a rubber septum; a 
balloon containing H2 was connected with a needle trough the septum to 
stir overnight at 30 °C; once reaction was completed, the catalyser was 
eliminated by filtration and the solvent evaporated under reduced 
pressure. Yellow amorphous solid, 0.18 g (98%). mp: 215 - 217 °C. 1H 
NMR (400 MHz, MeOD) δ 7.50 (dd, J = 8.9, 0.5 Hz, 1H, H8), 7.35 – 7.31 
(m, 4H, Ho, m), 7.31 – 7.26 (m, 1H, Hp), 7.25 (dd, J = 2.9, 0.5 Hz, 1H, H5), 
7.21 (dd, J = 8.9, 2.9 Hz, 1H, H7), 6.89 (s, 1H, H3), 3.55 (s, 2H, H), 3.44 
(t, J = 7.4 Hz, 2H, H), 2.94 (dt, J = 12.1, 3.2 Hz, 2H, H2’eq), 2.12 – 2.04 
(m, 2H, H2’ax), 1.83 – 1.75 (m, 2H, H3’eq), 1.64 – 1.54 (m, 2H, Hβ), 1.47 – 
1.25 (m, 3H, H3’ax, 4’). 13C NMR (101 MHz, MeOD) δ 180.68 (C4), 161.57 
(C9), 156.84 (C2), 150.04 (C6), 148.37 (Ci), 131.01 (Co), 129.32 (Cm), 
128.58 (Cp), 125.92 (C4a), 124.78 (C7), 120.42 (C8), 110.52 (C3), 106.95 
(C5), 64.21 (C), 54.57 (C2’), 38.56 (C), 36.90 (Cβ), 34.40 (C4’), 32.58 (C3’). 
HRMS [ESI+] m/z =405.2063 [M]+, calcd for [C24H27N3O3]+ 405.2054. 
HPLC purity 100%  
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-6-hydroxy-4-oxo-4H-chromene-2-
carboxamide. 2.28 
2.28 was obtained as 
described in the general 
procedure from 0.05 g (0.12 
mmol) of 2.23 and 0.3 g (1.2 
mmol) BBr3. Pale yellow solid, 
0.045 g (93%), mp: 204.5 (desc.) °C. 1H NMR (500 MHz, MeOD) δ 7.67 (d, 
J = 9.1 Hz, 1H, H8), 7.55 – 7.52 (m, 2H, Ho), 7.50 – 7.47 (m, 3H, Hm, p ), 
7.43 (d, J = 2.9 Hz, 1H, H5), 7.34 (dd, J = 9.1, 2.9 Hz, 1H, H7), 6.94 (s, 
1H, H3), 4.26 (s, 2H, H), 3.50 (t, J = 6.8 Hz, 2H, H), 3.43 (d, J = 12.5 Hz, 
2H, H2’eq), 2.97 (t, J = 12.5 Hz, 2H, H2’ax), 2.06 (d, J = 13.4 Hz, 2H, H3’eq), 
1.77 – 1.70 (m, 1H, H4’), 1.67 (q, J = 6.8 Hz, 2H, Hβ), 1.59 – 1.48 (m, 2H, 
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H3’ax). 13C NMR (126 MHz, MeOD) δ 180.43 (C4), 161.54 (C9), 157.21 (C8a), 
157.07 (C2), 150.98 (C6), 132.26 (Co), 131.19 (Ci), 130.94 (Cp), 130.23 
(Cm), 125.98 (C4a), 125.54 (C7), 121.21 (C8), 110.73 (C3), 108.71 (C5), 
61.73 (C), 53.51 (C2’), 38.09 (C), 36.09 (Cβ), 32.39 (C4’), 30.34 (C3’). 
HRMS [ESI+] m/z =406.1893 M]+, calcd for [C24H26N2O4]+ 406.1893. 
HPLC purity 99%  
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-5,7-dihydroxy-4-oxo-4H-
chromene-2-carboxamide. 2.29 
2.29 was obtained as 
described in the general 
procedure from 0.05 g (0.11 
mmol) of 2.24 and 0.3 g (1.2 
mmol) BBr3. Pale yellow solid, 
0.037 g (80%), mp: 267.0 (desc.) °C. 1H NMR (500 MHz, MeOD) δ 7.56 – 
7.52 (m, 2H, Ho), 7.51 – 7.47 (m, 3H, Hm, p), 6.83 (s, 1H, H3), 6.56 (d, J = 
2.2 Hz, 1H, H8), 6.26 (d, J = 2.2 Hz, 1H, H6), 4.27 (s, 2H, H), 3.48 (t, J = 
6.9 Hz, 2H, H), 3.44 (d, J = 12.6 Hz, 2H, H2’eq), 3.00 (t, J = 12.6 Hz, 2H, 
H2’ax), 2.06 (d, J = 14.3 Hz, 2H, H3’eq), 1.80 – 1.68 (m, 1H, H4’), 1.65 (q, J = 
6.9 Hz, 2H, Hβ), 1.57 – 1.47 (m, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 
183.66 (C4), 167.08 (C7), 163.41 (C5), 161.04 (C9), 158.90 (C8a), 157.15 
(C2), 132.30 (Co), 131.10 (Ci), 130.99 (Cp), 130.25 (Cm), 110.75 (C3), 
106.30 (C4a), 100.75 (C6), 95.68 (C8), 61.68 (C), 53.48 (C3’), 38.06 (C), 
36.03 (Cβ), 32.33 (C4’), 30.24 (C3’). HRMS [ESI+] m/z =422.1852 M]+, 
calcd for [C24H26N2O5]+ 422.1842. HPLC purity 98%  
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N-(4-((Benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide. 2.30 
2.30 was obtained as described 
in the general procedure 2.3, 
from 0.2 g (0.80 mmol) of 2.4 
and 0.191 g (0.88 mmol) of 2-
(1-benzylpiperidin-4-yl)ethan-1-
amine. White amorphous solid, 
0.28 (80%), mp: 129 - 132 °C. 1H NMR (300 MHz, CDCl3) δ 7.46 (s, 1H, 
H5), 7.32 – 7.18 (m, 5H, Ph), 7.05 (s, 1H, H8), 6.90 (s, 2H, NH, H3), 3.94 
(s, 3H, H71), 3.92 (s, 3H, H61), 3.53 – 3.38 (m, 4H, H, ), 2.88 (dd, J = 
11.5, 3.9 Hz, 2H, H2’eq), 1.97 (t, J = 11.5 Hz, 2H, H2’ax), 1.75 – 1.63 (m, 
2H, H3’eq), 1.63 – 1.44 (m, 2H, Hβ), 1.39 – 1.22 (m, 3H, H3’ax, 4’). 13C NMR 
(75 MHz, CDCl3) δ 177.30 (C4), 159.42 (C9), 155.19 (C7), 154.37 (C8a), 
151.39 (C2), 148.29 (C6), 137.73 (Ci), 129.46 (Co), 128.31 (Cm), 127.26 
(Cp), 117.97 (C4a), 111.61 (C8), 104.51 (C5), 99.77 (C3), 63.34 (C), 56.67 
(C61), 56.49 (C71), 53.60 (C2’), 37.85 (C), 36.20 (Cβ), 33.51 (C4’), 32.02 
(C3’). HRMS [ESI+] m/z =450.2176 [M]+, calcd for [C26H30N2O5]+ 450.2155. 
HPLC purity 100% 
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-6,7-dihydroxy-4-oxo-4H-
chromene-2-carboxamide. 2.31 
2.31 was obtained as 
described in the general 
procedure from 0.05 g (0.12 
mmol) of 2.23 and 0.3 g (1.2 
mmol) BBr3. Pale yellow solid, 
0.04 g (85%), mp: 204.5 (desc.) °C. 1H NMR (300 MHz, MeOD) δ 7.54 – 
7.46 (m, 2H, Ho), 7.45 – 7.39 (m, 3H, Hm, p), 7.32 (s, 1H, H8), 7.03 (s, 1H, 
H5), 6.81 (s, 1H, H3), 4.21 (s, 2H, H), 3.48 – 3.34 (m, 4H, H2’eq, ), 2.93 (td, 
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J = 12.5, 2.8 Hz, 2H, H2’ax), 2.00 (d, J = 13.8 Hz, 2H, H3’eq), 1.71 – 1.38 
(m, 5H, H3’ax, β, 4’). 13C NMR (75 MHz, MeOD) δ 179.57 (C4), 161.58 (C9), 
156.33 (C2), 155.69 (C7), 152.96 (C6), 146.97 (C8a), 132.34 (Co), 131.04 
(Cp), 130.80 (Ci), 130.24 (Cm), 117.87 (C4a), 110.85 (C3), 108.13 (C8), 
104.19 (C5), 61.55 (C), 53.41 (C2’), 38.02 (C), 35.98 (Cβ), 32.22 (C4’), 
30.12 (C3’ HRMS [ESI+] m/z =422.1852 M]+, calcd for [C24H26N2O5]+ 
422.1842. HPLC purity 97% 
 
N-(2-(1-Benzylpiperidin-4-yl)ethyl)-7-methoxy-4-oxo-4H-chromene-2-
carboxamide. 2.32 
2.32 was obtained as 
described in the general 
procedure 2.2, from 0.22 g 
(1 mmol) of 7-methoxy-4-
oxo-4H-chromene-2-
carboxylic acid and 0.26 g (1.2mmol) of 2-(1-benzylpiperidin-4-yl)ethan-
1-amine. White amorphous solid, 0.38 g (90%). mp: 141 - 143 °C. 1H 
NMR (500 MHz, MeOD) δ 7.99 (d, J = 8.9 Hz, 1H, H5), 7.32 – 7.29 (m, 4H, 
Ho, m), 7.25 (ddd, J = 8.9, 5.0, 3.8 Hz, 1H, Hp), 7.13 (d, J = 2.4 Hz, 1H, H8), 
7.06 (dd, J = 8.9, 2.4 Hz, 1H, H6), 6.88 (s, 1H, H3), 3.94 (s, 3H, H71), 3.51 
(s, 2H, H), 3.44 (dd, J = 8.1, 6.6 Hz, 2H, H), 2.90 (dt, J = 12.1, 3.3 Hz, 
3H, H2’eq), 2.03 (td, J = 11.7, 2.5 Hz, 2H, H2’ax), 1.77 (d, J = 12.9 Hz, 2H, 
H3’eq), 1.59 (dt, J = 8.1, 6.6 Hz, 2H, Hβ), 1.39 (ddtd, J = 16.4, 9.5, 6.6, 3.3 
Hz, 1H, H4’), 1.30 (qd, J = 12.1, 3.8 Hz, 2H, H3’ax). 13C NMR (126 MHz, 
MeOD) δ 178.24 (C4), 165.35 (C7), 159.75 (C9), 157.56 (C8a), 155.69 (C2), 
136.73 (Ci), 129.49 (Co), 127.85 (Cm), 127.03 (Cp), 126.30 (C5), 117.32 
(C4a), 115.30 (C6), 110.47 (C3), 100.34 (C8), 62.90 (C), 55.26 (C71), 53.18 
(C2’), 37.21 (C), 35.49 (Cβ), 33.06 (C4’), 31.28 (C3’).HRMS [ESI+] m/z 
=420.2090 [M]+, calcd for [C25H28N2O4]+ 420.2049. HPLC purity 100% 
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N-(3-(1-Benzylpiperidin-4-yl)propyl)-6,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide. 2.33 
2.33 was obtained as 
described in the general 
procedure 2.3, from 0.21 g (1 
mmol) of 2.4 and 0.22 g (1.1 
mmol) of 3-(1-
benzylpiperidin-4-yl)propan-1-amine 1.4. Light yellow amorphous solid, 
0.23 g (60%), mp: 98 - 102 °C. 1H NMR (500 MHz, MeOD) δ 7.46 (s, 1H, 
H5), 7.35 – 7.31 (m, 4H, Ho, m), 7.30 – 7.26 (m, 1H, Hp), 7.20 (s, 1H, H8), 
6.92 (s, 1H, H3), 3.99 (s, 3H, H61), 3.93 (s, 3H, H71), 3.58 (s, 2H, H), 3.40 
(t, J = 7.2 Hz, 2H, H), 2.95 (dt, J = 12.2, 3.1 Hz, 2H, H2’eq), 2.10 (td, J = 
12.2, 11.5, 2.5 Hz, 2H, H2’ax), 1.75 (d, J = 12.8 Hz, 2H, H3’eq), 1.67 (p, J = 
7.7 Hz, 2H, Hβ), 1.39 – 1.32 (m, 3H, H, 4’), 1.31 – 1.23 (m, 2H, H3’ax). 13C 
NMR (126 MHz, MeOD) δ 179.46 (C4), 161.29 (C9), 157.38 (C6), 156.80 
(C2), 153.42 (C8a), 150.04 (C7), 137.50 (Ci), 131.06 (Co), 129.35 (Cm), 
128.68 (Cp), 118.37 (C4a), 111.29 (C3), 104.70 (C5), 101.21 (C8), 64.12 (C), 
57.07 (C61), 56.67 (C71), 54.63 (C2’), 41.12 (C), 36.35 (C4’), 34.70 (C), 
32.64 (C3’), 27.53 (Cβ). HRMS [ESI+] m/z =464.2304 [M]+, calcd for 
[C27H32N2O5]+ 464.2311. HPLC purity 100% 
 
N-(3-(1-Benzylpiperidin-4-yl)propyl)-6-methoxy-4-oxo-4H-chromene-
2-carboxamide.  2.34 
2.34 was obtained as 
described in the general 
procedure for the synthesis of 
4-oxo-4H-chromene-2-
carboxamides (method B) 
from 0.25 g (1.11 mmol) of 2.3 and 0.29 g (1.25 mmol) of 3-(1-
benzylpiperidin-4-yl)propan-1-amine 1.4. Light yellow amorphous solid, 
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0.28 (59%), mp: 149 - 151 °C. 1H NMR (500 MHz, MeOD) δ 7.67 (d, J = 
9.3 Hz, 1H, H8), 7.53 (d, J = 3.1 Hz, 1H, H5), 7.45 (dd, J = 9.3, 3.1 Hz, 1H, 
H7), 7.35 – 7.30 (m, 4H, Ho, m), 7.30 – 7.25 (m, 1H, Hp), 6.96 (s, 1H, H3), 
3.91 (s, 3H, H61), 3.56 (s, 2H, H), 3.40 (t, J = 7.4 Hz, 2H, H), 2.94 (dt, J 
= 12.0, 3.3 Hz, 2H, H2’eq), 2.08 (td, J = 12.0, 11.4, 2.5 Hz, 2H, H2’ax), 1.74 
(d, J = 13.1 Hz, 2H, H3’eq), 1.67 (p, J = 7.4 Hz, 2H, Hβ), 1.37 – 1.25 (m, 
5H, H3’ax, 4’, ). 13C NMR (126 MHz, MeOD) δ 180.23 (C4), 161.29 (C9), 
159.21 (C6), 157.26 (C2), 151.82 (C8a), 137.68 (Ci), 131.03 (Co), 129.32 
(Cm), 128.61 (Cp), 125.90 (C7), 125.79 (C4a), 121.30 (C8), 110.98 (C3), 
105.68 (C5), 64.19 (C), 56.42 (C61), 54.65 (C2’), 41.15 (C), 36.38 (C4’), 
34.72 (C), 32.69 (C3’), 27.52 (Cβ). HRMS [ESI+] m/z =434.2214 [M]+, 
calcd for [C26H30N2O4]+ 434.2206. HPLC purity 100% 
 
N-(3-(1-Benzylpiperidin-4-yl)propyl)-6-hydroxy-4-oxo-4H-chromene-2-
carboxamide. 2.35 
2.35 was obtained as 
described in the general 
procedure from 0.05 g (0.09 
mmol) of 2.34 and 0.3 g 
(1.2 mmol) BBr3. Pale brown solid, 0.043 g (90%), mp: 208 - 210 °C. 1H 
NMR (500 MHz, MeOD) δ 7.65 (d, J = 9.1 Hz, 1H, H8), 7.56 – 7.52 (m, 2H, 
Ho), 7.49 – 7.47 (m, 3H, Hm, p), 7.41 (d, J = 3.0 Hz, 1H, H5), 7.33 (dd, J = 
9.1, 3.0 Hz, 1H, H7), 6.92 (s, 1H, H3), 4.30 (s, 2H, H), 3.47 – 3.40 (m, 4H, 
H2’eq, ), 3.02 (td, J = 12.8, 3.1 Hz, 2H, H2’ax), 2.02 – 1.97 (m, 2H, H3’eq), 
1.73 – 1.65 (m, 3H, H4’, β), 1.54 – 1.44 (m, 2H, H3’ax), 1.43 – 1.36 (m, 2H, 
H). 13C NMR (126 MHz, MeOD) δ 180.44 (C4), 161.47 (C9), 157.18 (C8a), 
157.13 (C2), 150.97 (C6), 132.36 (Co), 131.11 (Cp), 130.72 (Ci), 130.29 
(Cm), 125.95 (C4a), 125.54 (C7), 121.19 (C8), 110.69 (C3), 108.71 (C5), 
61.57 (C), 53.54 (C2’), 40.81 (C), 34.32 (C4’), 33.66 (C),  30.33 (C3’), 
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27.30 (Cβ). HRMS [ESI+] m/z =420.2045 M]+, calcd for [C25H28N2O4]+ 
420.2049. HPLC purity 99% 
Biochemical protocols used in this chapter but not described in the 
previous one are explained next.  
Biochemical Studies 
Inhibition of human monoamino oxidases (h-MAO-A and h-MAO-B) 
MAO inhibition measurements were evaluated following the general 
procedure previously described previously231. Briefly, test drugs and 
adequate amounts of recombinant hMAO-A or hMAO-B (Sigma-Aldrich 
Quıímica S.A., Alcobendas, Spain) required and adjusted to oxidize 165 
pmol of p-tyramine/min in the control group, were incubated for 15 min 
at 37 ºC in a flat-black-bottom 96-well microtest plate (BD Biosciences, 
Franklin Lakes, NJ) placed in the dark fluorimeter chamber. The reaction 
was started by adding 200 mM Amplex Red reagent (Molecular Probes, 
Inc., Eugene, OR), 1 U/mL horseradish peroxidase, and 1 mM p-
tyramine and the production of resorufin, was quantified at 37 ºC in a 
multidetection microplate fluorescence reader (FLX800, Bio-Tek 
Instruments, Inc., Winooski, VT) based on the fluorescence generated 
(excitation, 545 nm; emission, 590 nm). The specific fluorescence 
emission was calculated after subtraction of the background activity, 
which was determined from wells containing all components except the 
h-MAO isoforms, which were replaced by a sodium phosphate buffer 
solution. 
Antagonism of reserpine-induced hypokinesia. Adult ICR albino mice 
(10 weeks, 25-30 g) from the Department of Pharmarcy of Universidad 
Nacional de Colombia were group housed at 221 °C on a 12-hours 
light/dark cycle with ad libitum access to food and water until two hours 
prior to the experiment. All experiments were approved by an Ethical 
Committee and are in accordance with the current accepted methods of 
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research in the field. The procedure used is the same described by 
tadaievsky et al.229 
The animals were randomly distributed into the following groups: vehicle, 
selegiline and testing compounds; ten animals per group. The mice were 
orally administered with the corresponding treatment as follows, saline, 
0.1 mL/10g, selegiline, 10 mg/Kg and compounds 2.12, 1.13, 2.30, 100 
mg/Kg.  
2 and 24 hours after administration, the locomotor activity was evaluated 
in the open field test. The animals were located at the center of an acrylic 
box of 50 x 50 cm with 20 cm high walls and immediately the time of 
movement and inactivity was determined during five minutes. Statistical 
comparisons were carried out by a Kruskal-Wallis one way analysis of 
variance (ANOVA). Differences were considered statistically significant 
when P<0.05  
1R Radioligand displacement. Evaluation of the affinity of the 
derivatives obtained in this chapter was developed in JURKAT cells by 
CEREP co.230 Cell membrane homogenates (150 µg protein) are incubated 
for 120 min at 37°C with 15 nM [3H]pentazocine in the absence or 
presence of the test compound in a buffer containing 50 mM Tris-HCl 
(pH 8). Nonspecific binding is determined in the presence of 10 µM 
haloperidol. Following incubation, the samples are filtered rapidly under 
vacuum through glass fiber filters (GF/B, Packard) presoaked with 0.3% 
PEI and rinsed several times with ice-cold 50 mM Tris-HCl using a  
96-sample cell harvester (Unifilter, Packard). The filters are dried then 
counted for radioactivity in a scintillation counter (Topcount, Packard) 
using a scintillation cocktail (Microscint 0, Packard).  The results are 
expressed as a percent inhibition of the control radioligand specific 
binding. The standard reference compound is haloperidol, which is tested 
in each experiment at several concentrations to obtain a competition 
curve from which its IC50 is calculated.  
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Synthesis of Kynurenic Acid-based 
Hybrids, a Failed Attempt to Obtain 
NMDA Receptor Antagonists 
Introduction 
NMDA Receptor 
Glutamate is the main excitatory neurotransmitter in CNS, it is used by 
almost 70% of excitatory synapses, especially in cerebral tissue; 
Glutamate plays a key role in neural survival, differentiation and 
migration; at the same time, is the precursor of -aminobutyric acid 
(GABA), the main inhibitory neurotransmitter in the CNS. Glutamatergic 
neurons take part in important processes such as learning, memory and 
neuronal communication. Glutamate released from presynaptic cells 
binds receptors located on the cell membrane of postsynaptic neurons. 
These glutamate receptors are divided into ionotropic and metabotropic, 
depending on the mechanism of activation. Ionotropic glutamate 
receptors are cationic channels which respond to glutamate binding 
allowing the entrance of Na+, K+ or Ca2+. On the other hand, metabotropic 
glutamate receptors allow the flow of cations by a signal transduction 
system involving associated G-proteins and second messengers.  
Ionotropic glutamate receptors are named by their preferred agonists, 
kaynate, N-methyl-D-aspartate (NMDA), and -amino-3-hydroxy-5-
methyl-4-isoxazol propionic acid (AMPA). NMDA receptors participate in 
physiological processes such as long term potentiation (LTP) and in 
pathological ones, such as excitotoxicity. It is a ligand-gated and voltage-
dependent ion channel which simultaneously requires a co-ligand such 
as glycine, or D-serine to be activated. This activation leads to an increase 
of free intracellular Ca+2 levels required for LTP, neuronal plasticity,
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 learning and memory. Disruptions in glutamatergic system including 
NMDA receptors are implicated in several neurodegenerative processes 
such AD.232-234  
NMDA receptors in AD 
Excitotoxicity has been postulated to be the link between the glutamate 
signaling system and several neurodegenerative processes including AD. 
It is a phenomenon elicited by over-stimulation of NMDA receptors due to 
an excessive secretion or an impaired uptake of glutamate. This over-
stimulation entails an intense influx of calcium ions, which subsequently 
produces the signaling events resulting in ER stress and cell death.235,236  
It has been proved that Aβ is able to affect the homeostasis of the 
glutamatergic system. Enlarged release of glutamate from presynaptic 
neurons and inhibition of glutamate uptake/recycling in perisynaptic 
glial cells are some effects of toxic Aβ fragments.237-239 Aβ(25-35) increases 
glutamate levels and exerts toxicity in cultured neurons; interestingly, 
neurons with an enhanced glutamate uptake capacity are able to survive 
Aβ insult.240 Oxidative damage might be involved in these effects, it has 
been proved that Aβ impairs glutamate uptake increasing the 
conjugation of 4-hydroxy-2-nonenal (HNE), a product from lipid 
peroxidation, to glutamate transporters.241 Indeed, Aβ species are able to 
interact directly with the NMDA receptor; in cortical cultured neurons  
Aβ oligomeric species evoke an immediate rise of Ca2+ influx through 
activation of NMDA receptors.242 Moreover, these receptors seem to be 
required for Aβ oligomers to target synapses, since knocking-down of 
NMDA receptor abolishes Aβ1-42 oligomer binding to dendrites.243 
Although the mechanisms by Aβ species interact with NMDA receptors 
are not fully understood, it is widely accepted that they are valid targets 
in AD.236,244,245 Proof of this is memantine, an NMDAr antagonist 
currently used in clinical treatment of AD. Several studies have shown 
that memantine is capable to counteract the deleterious effects of Aβ 
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species; for instance, reduction of neurite outgrowth, cyclic relationship 
Aβ administration-NMDAr activation-Aβ production or Aβ induced 
ROS.246-248 Even though it is widely accepted that memantine effects are 
mediated by NMDA receptor, some studies suggest additional properties 
for this drug, such as enhancing of non amyloidogenic pathway, since 
memantine increases the levels of soluble APP in cultured human 
neuroblastoma cells, attenuation of tau phosphorylation and potentiation 
of the effects of donepezil in AD patients, according to different clinical 
trials.191,249,250 
Kynurenic acid and derivatives in AD 
Kynurenic acid (KA, figure 3.1) is a naturally occurring NMDAr 
antagonist, resulting from the normal metabolism of L-tryptophan. KA 
and several derivatives have been evaluated as antagonists of different 
glutamate receptors including NMDAr; furthermore KA derivatives are 
able to interact with the glycine binding site, especially 5- and 7- 
substituted derivatives.251,252 4-Benzylpiperidine amides of KA inhibit in 
the nanomolar range the influx of Ca+2 mediated by NMDA receptor in rat 
cortical cell cultures, proving that the acidic moiety is susceptible to be 
modified without losing activity.253 On this basis, we decided to combine 
the KA structure with NBP or DBMA fragments in a single small molecule 
aiming to obtain new NMDAr antagonists with affinity for the general 
targets evaluated in previous chapters (cholinesterases, BACE1, and 
oxidative stress). 
 
Fig 3.1 Kynurenic Acid 
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Results and discussion 
Synthesis of KA-based Hybrids 
Diesters 3.1-3.4 were synthesized from the corresponding methoxy 
aniline and dimethyl acetylenedicarboxylate at room temperature in 
Et2O; (Scheme 3.1). Subsequently, compounds 3.1-3.4 (100 mg) were 
heated in DMF at 225 °C into a microwave reactor to yield the desired 
products 3.5-3.8; however, when scaled up to 500 mg, this reaction 
allowed the isolation of byproducts 3.9-3.12 (10-12%). This methodology 
was selected instead the procedure used in the previous chapter because 
of the susceptibility of derivatives 3.1-3.4 to the acid-base hydrolysis.  
 
Scheme 3.1 Synthesis of starting products (a) Et2O, rt, overnight; (b) DMF, 
microwave, 225 °C, 30 min 
Additionally, 3.2 yielded a mixture of 3.7 (7-OMe) (55%) with the 5-OMe 
substituted derivative (13%) which was not isolated. However, a mixture 
of these two products was used to obtain final compounds 3.20 and 
3.23. 
Target compounds 3.13-3.26 were obtained by trimethylaluminium 
(Al(CH3)3) mediated amide formation between the corresponding methyl 
ester (3.2-3.8) and the proper amine (1.7, 1.8 or 2-(1-benzylpiperidin-4-
yl)ethan-1-amine) (Scheme 3.2). This procedure allowed us to obtain the 
desired products directly from the kynurenic methyl esters in 1.5 min 
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with good yields (50-90%). Hydroxy-substituted derivatives were obtained 
by treatment of the corresponding methoxy derivative with BBr3 in THF 
at rt as described previously. 
 
Scheme 3.2 Synthesis of KA-based hybrids (a) THF, 2-(1-benzylpiperidin-4-
yl)ethan-1-amine, Al(CH3)3, mw, 1.5 min, 120 °C; (b) THF, 1.7-1.8,  Al(CH3)3, 
microwave, 3 min, 120 °C; (c) THF, BBr3, r.t., overnight 
In regard to characterization of final products, it must be taken into 
account that unlike the chromone scaffold, the 4-quinolinone structure 
can exist in the tautomeric forms illustrated in the figure 3.2  
In tautomer B, H-3 possesses higher aromatic character compared to H-3 
in tautomer A; given the similarity of compounds 3.9-3.12 with tautomer 
B, we inferred that A is the favored tautomer in target compounds by 
comparison of the chemical shifts for H-3 in the pairs 3.6 – 3.10 and 
3.19 - 3.15. In most of cases H-3 presented chemical shifts around 6.8-
7.30 (when an accurate assignation of the corresponding peak was 
achieved, see experimental section).  
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Probably, because of this tautomerism, in some final compounds, 
quaternary carbons were not detected and the multiplicity of some 
signals corresponding to the aromatic protons in the quinolinone scaffold 
were not well defined, appearing as broad signals. However, high 
resolution mass spectroscopy confirmed the exact mass of the desired 
products. It is detailed in the experimental section, for each case. 
 
 
Fig 3.2 Tautomeric forms of starting esters and 1H-NMR chemical shifts for H-3 
in the target products 
Biological Evaluation 
As described above, the main objective of this chapter was the synthesis 
of multitarget ligands with affinity for NMDA receptors. In a first stage, 
we evaluated these new hybrids in the battery of assays available in our 
group, inhibition of cholinesterases and antioxidant capacity, in order to 
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select the most active compounds for further evaluation as NMDA 
receptor antagonists. Results are summarized in tables 3.1-2 
Table 3.1 Inhibition of h-AChE, h-BuChE, MAO-A/B (IC50, µM) 
 
  IC50 (μM) 
Comp. R h-AChEa h-BuChEa h-MAO-Ab h-MAO-Bb 
3.13 6-OMe 0.88±0.14 >10 ** ** 
3.14 6-OH 0.30±0.06 9.88±0.9 51.3±6.2* 59.9±6.7 
3.15 6,7-OMe 0.17±0.01 >10 ** ** 
3.16 7-OMe 0.45±0.05 >10 72.7±6.5* 56.4±4.5 
3.17 8-OMe 1.64±0.07 >10 52.4±3.1* 71.6±5.4* 
3.18 8-OH 1.15±0.41 >10 *** 13.6±0.9 
3.19 4,6,7-OMe 0.62±0.05 8.79±0.5 nd nd 
Results are expressed as mean ± SD (an =3, bn =5), **Inactive at 200 µM, *** 
inactive at 1 mM, nd: not determined 
Similarly to the chromone based hybrids in the former chapter, the most 
potent AChE inhibitors belong to the KA-NBP hybrids family. Compound 
3.15, bearing two methoxy groups at positions 6 and 7, was the most 
potent inhibitor with an IC50 value of 170 nM.  
Regarding to BuChE, only compounds 3.14 and 3.19 exhibited a modest 
inhibitory activity with IC50’s of 9.8 and 8.8 μM respectively; this 
represents selectivity for AChE of about two orders of magnitude. 
In the KA-DBMA family, the whole series inhibited selectively AChE in 
the low micromolar range, except compound 3.26; here, the change of 
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the amide bond position from 4’ (3.24) to position 3’, resulted in a 
complete loss of activity. The same was observed when 6,7-methoxy 
groups were reduced to obtain the corresponding di-hydroxy substituted 
compound 3.25. 
Table 3.2 Inhibition of h-AChE, h-BuChE, MAO-A/B (IC50, µM) 
 
  IC50 (μM) % at 10 μM % at 20 μM 
Comp. R--------- h-AChEa MAO-Bb h-BACE1a Aβa Taua 
3.20 5-OMe 4.0±0.4 15.2±1 10.4 nd nd 
3.21 6-OMe 2.3±0.1 ** 26.6 25.1 15.0 
3.22 6-OH 3.1±0.3 ** 26.5 26.3 27.4 
3.23 7-OMe 2.3±0.2 ** 33.5 nd nd 
3.24 6,7-OMe 4.5±0.3 nd 28.7 nd nd 
3.25 6,7-OH >10 ** 27.8 nd nd 
3.26 (3’)  6,7-OMe >10 ** 32.5 nd nd 
Results are expressed as mean ± SD (an =3, bn =5), **Inactive at 200 µM, nd: not 
determined 
 
Likewise to chromone based hybrids, 3.15 inhibited AChE with a mixed 
mechanism as inferred from figure 3.3  
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Fig 3.3 Lineweaver-Burk plot of reciprocals for velocity and different 
concentrations of 3.15, 0.5 - 1 μM. Lines were derived from a weighted least-
squares analysis of data. 
 
At this point, a selection of compounds (3.13, 3.16, 3.14, 3.15, 3.24, 
3.23, 3.21, 3.22), including the most potent AChE inhibitors, were 
tested in a radioligand displacement assay ([3H]CGP 39653,  CEREP 
Co.254) to determine whether or not they are able to antagonize NMDA 
receptor. Unfortunately, none of the selected compounds exhibited 
affinity for this receptor. Highest radioligand displacement percentage 
was reached by 3.13 with a poor 6%. 
Continuing with biological assessment of our compounds, we evaluated 
their MAO inhibitory activity. As shown in table 3.1, four of the newly 
synthesized KA-NBP hybrids displayed unselective MAO inhibitory 
activity (IC50’s = 52-72 μM). 3.18 (8-OH substituted) was the most potent 
and the unique selective towards MAO-B, IC50 = 13.6 μM. In the KA-
DBMA series, only 5-methoxy substituted compound 3.20, was able to 
inhibit selectively MAO-B with an IC50 value of 15.2 μM (table 3.2). The 
rest of the series was inactive towards both MAO isoforms. 
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Concerning to BACE1 inhibition, KA-NBP series was utterly inactive, 
while in KA-DBMA series, almost all derivatives inhibited modestly this 
enzyme with percentages around 30% at 10 μM. The highest inhibition 
was reached by 3.23 (7-OMe) with 33% (table 3.2). 
Complementary assays were carried out with some compounds 
depending on the availability. Anti-aggregating effect of compounds 3.13, 
3.15, 3.16 (KA-BP), 3.21, 3.22 (KA-DBMA) were evaluated in a culture of 
bacterial cells overexpressing Aβ42 peptide or tau protein. While KA-NBP 
compounds were completely inactive, KA-DBMA hybrid 3.22, inhibited 
modestly and simultaneously the self-aggregation of amyloid peptide and 
tau protein, 26 - 27% respectively (table 3.2). 
All derivatives were tested in PAMPA assay and were predicted to cross 
the BBB. On the other hand, all hydroxy substituted derivatives were 
evaluated as radical scavengers in ORAC assay, obtaining good 
antioxidant properties with values around 1 equivalent of trolox; 3.17 = 
0.97, 3.14 = 1.4, 3.25 = 0.5, 3.22 = 1.2. 
Finally, compound 3.14, with dual AChE-MAO inhibitory activity and the 
highest antioxidant capacity, exhibited neuroprotective properties in SH-
SY5Y cells treated with rotenone-oligomycin as described in the previous 
chapter; the highest cconcentration tested, 3 μM protected around 30% 
of the cells. 
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Figure 3.4 Cell viability was measured as MTT reduction and data were 
normalized as % of control. Data are expressed as the means ± SEM. of triplicate 
of at least three different cultures. All compounds were assayed at increasing 
concentrations (0.1-3 µM). 
Conclusions 
New hybrids based on the combination of KA and NBP or DBMA 
fragments were obtained and evaluated in several enzymes related to AD. 
This new molecules required a different approach in the synthesis 
compared to the chromone based derivatives described in chapter two. 
The susceptibility of intermediate diesters to hydrolysis demanded a 
more direct but less efficient method consistent in microwave assisted 
cyclization to obtain the corresponding kynurenic methyl esters.  
Taking into account that previous works have demonstrated the ability of 
KA containing compounds to antagonize the NMDA receptor,251,255-257 
here we attempted to combine this structure with NBP and DBMA 
fragments in order to obtain new multitarget anti-AD compounds. 
Although, we failed in our attempt to achieve molecules able to 
antagonize NMDA receptor, we obtained several compounds with 
antioxidant properties and dual affinity AChE/MAO-B. 
An interesting conclusion in regard to AChE inhibition could be drawn 
from the comparison between potencies of 3.15 (6,7-OMe) and the 
equivalent chromone based hybrid 2.30 (Chapter 2, IC50=41 nM). It 
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highlights the relevance of the endocyclic oxygen and/or the stability of 
the exocyclic carbonyl group (position 4) for the interaction with the 
enzyme, since the substitution by a group susceptible of tautomerization 
was detrimental for activity.  
In KA-DBMA series, the loss of activity observed in the changes from 
3.24 to 3.25 (6,7-diOMe→6,7-diOH) and from 3.24 to 3.26 
(4’subst.→3’subst.) reveal that the nature of the substituents in KA 
scaffold and the position of DBMA fragment contribute to the interaction 
with the enzyme. On the basis of these findings we believe that future 
modifications on the position, size and substitution of the intermediate 
ring could improve the potency towards AChE. 
In the case of MAO, either KA-NBP as KA-DBMA series gave inhibitors in 
the same order of magnitude, which could be interpreted as a 
dependence of the activity on the nature of substituents in the KA 
scaffold more than on the nature of the moiety bearing the tertiary amine 
and the benzyl group. Conversely, BACE1 inhibitory activity was 
independent of the kynurenic moiety (as well as the chromone scaffold in 
last chapter) but dependent on the fragment containing the tertiary 
amine, only DBMA derivatives were able to inhibit modestly this enzyme.   
Despite the fact that our results in NMDA receptor were negative and 
very modest in the rest of assays, we believe that there is still a region of 
the molecules that could be explored in the search for a better 
multitarget profile in KA-DBMA compounds, modifications in the position 
and substitution of the central ring could influence the interaction with 
the enzyme and exert better results in BACE1, and Aβ or tau 
aggregation; these modifications remain to be developed.  
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Experimental Part 
General Procedure 3.1 Synthesis of diesters (3.1-3.4) 1 mL (0.89 
mmol) of the corresponding methoxy aniline was dissolved in 20 mL of 
Et2O; to this solution, 0.10 mL (0.89  mmol) of dimethyl 
acetylenedicarboxylate and 0.11 mL (0.89 mmol) of Et3N were added, to 
stir overnight at room temperature. The reaction mixture was washed 
with HCl (1N) (3x5 mL), water (3x5 mL) and brine (3x5 mL), dried over 
MgSO4 and concentrated under reduced pressure. Purification was 
carried out recrystallizing the crude from a mixture of Et2O-Hexane, or 
column chromatography using a mixture of ethyl acetate in hexane 
(0→100%). 
General procedure 3.2 Synthesis of  KA-methyl esters (3.5-3.8). Into 
a 20 mL microwave vial, 0.2 g (0.76 mmol) of the corresponding dimethyl 
2-(phenylamino)but-2-enedioate were dissolved in 15 mL (193 mmol) of 
DMF; this dissolution was heated at 225 °C during 15 min in a 
microwave reactor. The solvent was evaporated under reduced pressure 
at 80 °C and purification was carried out by column chromatography 
using a gradient of methanol in EtOAc (0→10%) as eluent. The 
proportion between reagents and solvent is important to avoid undesired 
byproducts or decomposition. 
General Procedure 3.3 Synthesis of KA-amides. Into a 5 mL microwave 
vial, the corresponding esther (0.40 mmol) was dissolved in 2 mL of dry 
THF; to this dissolution, the corresponding amine (1 mmol) previously 
dissolved in 1.5 mL of THF, was added; air was displaced by N2 and the 
tube was sealed up; afterward, 3 mmol of Al(CH3)3 (2M in heptane) was 
injected with a syringe; this mixture was heated into a microwave reactor 
at 120 °C during 1.5 min. The crude was treated with HCl 2M (dropwise) 
until the end of effervescence, the mixture was neutralized with NaOH 
2M and the liquid phase evaporated until dryness; the solid was washed 
with EtOAc (5x5 mL) and methanol (2x5 mL), these fractions were mixed 
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and concentrated under reduced pressure. The product was purified by 
column chromatography using a gradient of EtOAc in hexane (0→65%) 
as eluent.  
General Procedure 3.4 Demethoxylation of KA-amides  To 3 mL of a 
solution of the corresponding KA-amide in anhydrous DCM was added 
slowly under magnetic stirring, 1 equivalent of BBr3 per each heteroatom 
present in the molecule; air was displaced by N2 and the mixture was 
allowed to react overnight at room temperature. Reaction was quenched 
with methanol (dropwise until end of effervescence) and the solvent 
evaporated under reduced pressure to eliminate the remaining BBr3, this 
process was repeated several times depending on the quantity of BBr3 
used, until no fumes were observed when adding methanol. When 
necessary, purification was carried out by column chromatography using 
a gradient of MeOH in EtOAc (0→10%) as eluent. 
 
Dimethyl 2-((2-methoxyphenyl)amino)but-2-enedioate. 3.1 
3.1 was obtained from equimolar quantities of 2-
methoxy aniline and dimethyl 
acetylenedicarboxylate (0.89 mmol) as described 
in the general procedure 3.1. HPLC-MS (Water-
ACN 15→95%, g.t. 5 min) was used to control the 
reaction, observing the majoritarian formation of one of the two possible 
isomers, retention time 4.17 min (3%), 4.90 min (97%). The main product 
was recrystallized from ether. Yellow crystals, 0.22 g (94%), mp:72 °C. 1H 
NMR (300 MHz, CDCl3) δ 9.66 (s, 1H, NH), 7.03 (ddd, J = 8.4, 7.1, 1.7 Hz, 
1H, H3’), 6.90 – 6.80 (m, 2H, H4’, 5’), 6.80 – 6.70 (m, 1H, H6’), 5.39 (s, 1H, 
H3), 3.84 (s, 3H, H21’), 3.74 (s, 3H, H41), 3.71 (s, 3H, H11). 13C NMR (75 
MHz, CDCl3) δ 169.96 (C4), 164.92 (C1), 150.62 (C2’), 147.84 (C2), 129.50 
(C1’), 124.56 (C3’), 120.74 (C4’), 120.16 (C6’), 111.12 (C5’), 92.80 (C3), 55.68 
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(C21’), 52.73 (C11), 51.26 (C41). HPLC-MS m/z =266.2 [M + H]+, calcd for 
[C13H15NO5 + H]+ 266.2 
 
Dimethyl 2-((3-methoxyphenyl)amino)but-2-enedioate. 3.2 
 3.2 was obtained from equimolar quantities of 3-
methoxy aniline and dimethyl 
acetylenedicarboxylate (0.89 mmol) as described 
in the general procedure 3.1. HPLC-MS (Water-
ACN 15→95%, g.t. 5 min) was used to control the 
reaction, observing the formation the two possible isomers. Retention 
time 4.17 min (20%), 4.88 min (80%) (Yield of mixture 95%), however, 
this proportion changed to 3%-97% after work up. The main product was 
purified by column chromatography, obtaining 3.2 as a brown oil, 0.21 g 
(90%). 1H NMR (300 MHz, CDCl3) δ 9.62 (s, 1H, NH), 7.21 – 7.10 (m, 1H, 
H5’), 6.71 – 6.56 (m, 1H, H4’), 6.48 – 6.39 (m, 2H, H2’, 6’), 5.37 (s, 1H, H3), 
3.75 (s, 3H, H31’), 3.72 (s, 3H, H41), 3.70 (s, 3H, H11). 13C NMR (75 MHz, 
CDCl3) δ 169.91 (C4), 165.01 (C1), 160.46 (C3’), 148.08 (C2), 141.57 (C1’), 
129.96 (C5’), 113.01 (C2’), 110.10 (C4’), 106.50 (C6’), 93.83 (C3), 55.34 
(C31’), 52.92 (C11),  51.31 (C41). HPLC-MS m/z =266.2 [M + H]+, calcd for 
[C13H15NO5 + H]+ 266.2 
 
Dimethyl 2-((4-methoxyphenyl)amino)but-2-enedioate. 3.3 
3.3 was obtained from equimolar quantities of 4-
methoxy aniline and dimethyl 
acetylenedicarboxylate (0.89 mmol) as described 
in the general procedure 3.1. HPLC-MS (Water-
ACN 15→95%, g.t. 5 min) was used to control the 
reaction, observing the formation of the two possible isomers, retention 
time 4.07 min (20%), 4.81 min (80%) (Yield of mixture of isomers 94%), 
the main product was isolated by column chromatography as a brown 
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oil, 0.19 g (80%). 1H NMR (300 MHz, CDCl3) δ 9.56 (s, 1H, NH), 6.93 – 
6.76 (m, 4H, H2’, 3’), 5.28 (s, 1H, H3), 3.75 (s, 3H, H41’), 3.70 (s, 3H, H41), 
3.64 (s, 3H, H11). 13C NMR (75 MHz, CDCl3) δ 170.09 (C4), 164.81 (C1), 
156.93 (C4’), 149.04 (C2), 133.43 (C1’), 122.98 (C2’), 114.39 (C3’), 91.69 
(C3), 55.42 (C41’), 52.69 (C11), 51.07(C41). HPLC-MS m/z =266.2 [M + H]+, 
calcd for [C13H15NO5 + H]+ 266.2 
 
Dimethyl 2-((3,4-dimethoxyphenyl)amino)but-2-enedioate. 3.4 
 3.4 was obtained from 1 g (6.53 mmol) of 3, 4-
dimethoxy aniline and 0.8 mL (6.53 mmol) of 
dimethyl acetylenedicarboxylate as described in 
the general procedure 3.1. HPLC-MS (Water-ACN 
15→95%, g.t. 5 min) was used to control the 
reaction, observing the majoritarian formation of one of the two possible 
isomers, retention time 3.74 min (10%), 4.49 min (90%) (Yield of isomers 
mixture 95%), the main product was isolated by column chromatography 
as a brown oil, 1.7 g  (87%). 1H NMR (300 MHz, CDCl3) δ 9.53 (s, 1H, 
NH), 6.70 (d, J = 8.5 Hz, 1H, H5’), 6.47 (d, J = 2.5 Hz, 1H, H2’), 6.40 (dd, J 
= 8.5, 2.6 Hz, 1H, H6’), 5.23 (s, 1H, H3), 3.78 (s, 3H, H41’), 3.77 (s, 3H, 
H31’), 3.66 (s, 3H, H41), 3.61 (s, 3H, H11). 13C NMR (75 MHz, CDCl3) δ 
169.93 (C4), 164.86 (C1), 149.28 (C3’), 148.90 (C2), 146.35 (C4’), 133.71 
(C1’), 113.24 (C6’), 111.35 (C5’), 105.96 (C2’), 91.91 (C3), 55.96 (C41’), 55.77 
(C31’), 52.67 (C11), 51.02 (C41). HPLC-MS m/z =296.3 [M + H]+, calcd for 
[C14H17NO6 + H]+ 296.3 
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Methyl 6-methoxy-4-oxo-1,4-dihydroquinoline-2-carboxylate. 3.5 
3.3, (0.2 g) was reacted as described in the 
general procedure 3.2. The crude was purified by 
column chromatography, obtaining 3.5 as brown 
needles, 0.105 (60%), mp: 254 °C 1H NMR (300 
MHz, MeOD) δ 7.80 (d, J = 9.2 Hz, 1H, H8), 7.62 
(d, J = 2.9 Hz, 1H, H5), 7.40 (dd, J = 9.2, 2.9 Hz, 1H, H7), 6.93 (s, 1H, H3), 
4.02 (s, 3H, H91), 3.91 (s, 3H, H61). 13C NMR (126 MHz, MeOD) δ 180.26 
(C4), 163.75 (C9), 158.97 (C6), 139.13 (C2), 136.49 (C8a), 128.32 (C4a), 
125.93 (C7), 122.37 (C8), 109.84 (C3), 104.31 (C5), 56.16 (C61), 54.02 (C91). 
HPLC-MS (Water-ACN 2→30%, g.t. 10 min), retention time 6.39 min, m/z 
=233.3 [M + H]+, calcd for [C12H11NO4 + H]+ 233.2 
 
Methyl 6,7-dimethoxy-4-oxo-1,4-dihydroquinoline-2-carboxylate. 3.6 
3.4 (0.2 g) was reacted as described in the 
general procedure 3.2. The crude was purified by 
column chromatography, obtaining 3.6 as a pale 
brown solid, 0.16 g (90%), mp: 267 - 269 °C. 1H 
NMR (300 MHz, MeOD) δ 7.55 (s, 1H, H8), 7.26 
(s, 1H, H5), 6.88 (s, 1H, H3), 4.01 (s, 3H, H91), 3.96 (s, 3H, H61), 3.92 (s, 
3H, H71).  13C NMR (126 MHz, MeOD) δ 179.38 (C4), 163.78 (C9), 156.59 
(C7), 150.23 (C6), 146.71 (C2), 138.04 (C8a), 121.71 (C4a), 110.25 (C3), 
104.46 (C8), 100.63 (C5), 56.72 (C71), 56.48 (C61), 53.96 (C91). HPLC-MS 
(Water-ACN 15→95%, g.t. 5 min), retention time 2.64 min HPLC-MS m/z 
=264.2 [M + H]+, calcd for [C13H13NO5 + H]+ 264.2 
  
Chapter 3 
154 
 
Methyl 7-methoxy-4-oxo-1, 4-dihydroquinoline-2-carboxylate. 3.7  
3.2 (0.2 g) was reacted as described in the 
general procedure 3.2. The crude was purified by 
column chromatography, obtaining 3.7 as pale 
brown needles, 0.097 g (55%), mp: 242 °C. 1H 
NMR (500 MHz, DMSO-d6) δ 11.84 (bs, 1H, NH), 
7.98 (d, J = 9.0 Hz, 1H, H5), 7.41 (d, J = 2.4 Hz, 1H, H8), 6.98 (dd, J = 9.0, 
2.4 Hz, 1H, H6), 6.56 (s, 1H, H3), 3.95 (s, 3H, H91), 3.85 (s, 3H, H71). 13C 
NMR (126 MHz, DMSO-d6) δ 176.88 (C4), 162.70 (C9), 162.46 (C7), 141.90 
(C8a), 137.44 (C2), 126.52 (C5),  120.43 (C4a), 114.34 (C6), 110.31 (C3), 
100.27 (C8), 55.49 (C71), 53.46 (C91). HPLC-MS (Water-ACN 15→95%, g.t. 
5 min), retention time 2.88 min, m/z =234.2 [M + H]+, calcd for 
[C12H11NO4 + H]+ 234.2 
 
Methyl 8-methoxy-4-oxo-1, 4-dihydroquinoline-2-carboxylate. 3.8 
3.1 (0.2 g) was reacted as described in the general 
procedure 3.2. The crude was purified by column 
chromatography, obtaining 3.8 as brown needles 
0.12 g (68%) mp: 132 °C. 1H NMR (300 MHz, 
CDCl3) δ 9.41 (s, 1H, NH), 7.89 (d, J = 8.1 Hz, 1H, 
H5), 7.36 – 7.23 (m, 1H, H6), 7.08 (dd, J = 8.1, 1.2 Hz, 1H, H7), 6.97 (d, J 
= 2.0 Hz, 1H, H3), 4.04 (s, 6H, H81,91). 13C NMR (75 MHz, CDCl3) δ 179.51 
(C4), 163.42 (C9), 148.46 (C8), 135.63 (C2), 130.59 (C8a), 127.22 (C4a), 
124.14 (C6), 117.50 (C5), 112.09 (C3), 111.33 (C7), 56.28 (O-CH3), 
53.87(O-CH3). HPLC-MS (Water-ACN 15→95%, g.t. 10 min), retention 
time 4.8 min, m/z =234.2 [M + H]+, calcd for [C12H11NO4 + H]+ 234.2  
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Methyl 4,6-dimethoxyquinoline-2-carboxylate. 3.9 
3.9 was obtained as a secondary product from 
the synthesis of 3.5 (starting from 0.5 g of 3.3 in 
15 mL of DMF), pale brown needles, 0.042 g 
(12%), mp: 135 °C. 1H NMR (300 MHz, CDCl3) δ 
8.13 (d, J = 9.2 Hz, 1H, H8), 7.59 (s, 1H, H3), 7.46 
(d, J = 2.9 Hz, 1H, H5), 7.40 (dd, J = 9.2, 2.9 Hz, 1H, H7), 4.13 (s, 3H, 
H41), 4.07 (s, 3H, H91), 3.96 (s, 3H, H61). 13C NMR (75 MHz, CDCl3) δ 
166.58 (C9), 162.18 (C4), 159.16 (C6), 146.72 (C2), 144.47 (C8a), 131.98 
(C8), 123.49 (C4a), 123.42 (C7), 100.67 (C3), 99.55 (C5), 56.18 (C41), 55.84 
(C61), 53.34 (C91). HPLC-MS (Water-ACN 15→95%, g.t. 10 min), retention 
time 6.42 min, m/z =248.2 [M + H]+, calcd for [C13H13NO4 + H]+ 248.2 
 
Methyl 4,6,7-trimethoxyquinoline-2-carboxylate. 3.10 
3.10 was obtained as a secondary product from 
the synthesis of 3.6 (starting from 0.5 g of 3.4 in 
15 mL of DMF), pale brown solid, 0.024 g (5%), 
mp: 255 - 258 °C 1H NMR (300 MHz, CDCl3) δ 
7.55 (s, 1H, H8), 7.54 (s, 1H, H3), 7.43 (s, 1H, H5), 
4.11 (s, 3H, H91), 4.06 (s, 3H, H41), 4.04 (s, 3H, H71), 4.02 (s, 3H, H61). 13C 
NMR (75 MHz, CDCl3) δ 166.62 (C9), 161.92 (C4), 153.19 (C6), 150.89 (C7), 
147.06 (C2), 145.63 (C4a), 117.53 (C8a), 109.07 (C8), 99.83 (C3), 99.61 (C5), 
56.41 (OCH3), 56.34 (OCH3), 56.12 (C91), 53.30 (C41). HPLC-MS (Water-
ACN 15→95%, g.t. 5 min), retention time 2.99 min, m/z =278.3 [M + H]+, 
calcd for [C14H15NO5 + H]+ 278.3 
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Methyl 4,7-dimethoxyquinoline-2-carboxylate. 3.11 
3.11 was obtained as a secondary product of the 
synthesis of 3.7 (starting from 0.5 g of 3.2 in 15 
mL of DMF). Pale yellow needles, 0.046 g (10%), 
mp: 157 °C 1H NMR (500 MHz, DMSO-d6) δ 8.06 
(d, J = 9.1 Hz, 1H, H5), 7.47 (d, J = 2.5 Hz, 1H, 
H8), 7.43 (s, 1H, H3), 7.30 (dd, J = 9.2, 2.6 Hz, 1H, H6), 4.09 (s, 3H, H41), 
3.93 (s, 3H, H91), 3.92 (s, 3H, H71). 13C NMR (126 MHz, DMSO-d6) δ 
165.66 (C9), 162.71 (C4), 161.08 (C7), 149.88 (C8a), 149.30 (C2), 122.76 
(C5), 120.30 (C6), 116.03 (C4a), 107.98 (C8), 99.08 (C3), 56.33 (C41), 55.64 
(C71), 52.61 (C91) HPLC-MS (Water-ACN 15→95%, g.t. 5 min), retention 
time 3.54 min, m/z =248.3 [M + H]+, calcd for [C13H13NO4 + H]+ 248.3 
 
Methyl 4,8-dimethoxyquinoline-2-carboxylate. 3.12 
3.12 was obtained as a secondary product from 
the synthesis of 3.8 (starting from 0.5 g of 3.1 in 
15 mL of DMF). White flakes, 0.056g (12%) mp: 
143 °C. 1H NMR (300 MHz, CDCl3) δ 7.77 (dd, J = 
8.1, 1.3 Hz, 1H, H5), 7.63 (s, 1H, H3), 7.51 (t, J = 
8.1 Hz, 1H, H6), 7.08 (d, J = 8.0 Hz, 1H, H7), 4.11 
(s, 3H, H41), 4.06 (s, 3H, H81), 4.04 (s, 3H, H91). 13C NMR (75 MHz, CDCl3) 
δ 166.50 (C9), 163.42 (C4), 155.92 (C8), 147.89 (C2), 140.43 (C8a), 128.18 
(C6), 123.52 (C4a), 113.35 (C5), 108.56 (C7), 100.88 (C3), 56.28 (C41), 56.17 
(C81), 53.23 (C91) HPLC-MS (Water-ACN 15→95%, g.t. 10 min), retention 
time 3.94 min, m/z =248.2 [M + H]+, calcd for [C13H13NO4 + H]+ 248.2 
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N-(2-(1-benzylpiperidin-4-yl)ethyl)-6-methoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.13 
Product 3.13 was obtained 
According to the general 
procedure 3.3, from 0.1 g 
(0,43 mmol) of 3.5 and 0.23 
g (1,07 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-amine as a white amorphous solid, 0.143g 
(80%), mp: 184 - 186 °C. 1H NMR (300 MHz, MeOD) δ 8.16 (d, J = 9.3 Hz, 
1H, H8), 7.75 – 7.41 (m, 8H, Ph, H3, 7, 5), 4.30 (s, 2H, H), 3.99 (s, 3H, H61), 
3.62 – 3.38 (m, 4H, H, 2’eq), 3.04 (t, J = 13.0 Hz, 2H, H2’ax), 2.07 (d, J = 
14.2 Hz, 2H, H3’eq), 1.93 – 1.61 (m, 3H, Hβ, 4’), 1.61 – 1.42 (m, 2H, H3’ax). 
13C NMR (75 MHz, MeOD) δ 171.74 (C4), 161.25 (C9), 160.95 (C6), 144.92 
(C2), 136.53 (C8a), 132.47 (C0), 131.19 (Cp), 130.42 (Ci), 130.30 (Cm), 
129.05 (C7), 124.45 (C4a), 123.40 (C8), 104.38 (C3), 102.42 (C5), 61.78 (C), 
56.69 (C61), 53.71 (C2’), 38.63 (C), 35.95 (Cβ), 32.35 (C4’), 30.35 (C3’). 
HRMS [ESI+] m/z =419.2203 [M]+, calcd for [C25H29N3O3]+ 419.2209. 
HPLC purity 100% 
 
N-(2-(1-benzylpiperidin-4-yl)ethyl)-6-hydroxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.14 
According to the general 
procedure 3.4, product 3.14 
was obtained from 0.03 g 
(0.07 mmol) of 3.13 and 0.5 
mmol of BBr3 (1M in DCM, 
0.5 mL). Purification was carried out by preparative TLC using 
EtOAc/MeOH 9:1 as eluent. White amorphous powder, 0,02 g (70%), 
mp:167 – 169 °C . 1H NMR (500 MHz, DMSO-d6) δ 11.71 (s, 1H, NH1), 
9.77 (s, 1H, OH), 8.93 (t, J = 5.7 Hz, 1H, NH10), 7.82 (d, J = 8.7 Hz, 1H, 
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H8), 7.56 – 7.42 (m, 5H, Ph), 7.36 (d, J = 2.9 Hz, 1H, H5), 7.18 (dd, J = 
8.7, 2.9 Hz, 1H, H7), 6.59 (s, 1H, H3), 4.28 (s, 2H, H), 3.33 (s, 4H, H, 2’eq), 
2.98 – 2.84 (m, 2H, H2’ax), 1.97 – 1.87 (m, 2H, H3’eq), 1.63 – 1.45 (m, 3H, 
Hβ, 4’), 1.44 – 1.34 (m, 2H, H3’ax).  13C NMR (126 MHz, DMSO-d6) δ 177.38 
(C4), 162.40 (C9), 154.51 (C6), 140.61 (C2), 133.75 (C8a), 131.82 (Co), 
129.99 (Ci), 129.37 (Cp), 129.26 (Cm), 127.56 (C4a), 123.12 (C7), 121.57 
(C8), 107.32 (C5), 105.44 (C3), 59.60 (C), 52.01 (C2’), 37.02 (C), 35.09 
(Cβ), 30.87 (C4’), 29.06 (C3’).  HRMS [ESI+] m/z =405.2059 [M]+, calcd for 
[C24H27N3O3]+ 405.2052. HPLC purity 100% 
 
N-(2-(1-benzylpiperidin-4-yl)ethyl)-6,7-dimethoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.15. 
3.15 was synthesized as 
described in the general 
procedure 3.3, from esther 3.6 
(0.12 g, 0.40 mmol)  and 0.22 g 
(0.9 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-
amine). White amorphous solid, 0.1 g (50%), mp:254 - 256 °C. 1H NMR 
(500 MHz, MeOD) δ 7.59 (s, 1H, H8), 7.54 – 7.50 (m, 2H, Ho), 7.47 – 7.43 
(m, 3H, Hm, p), 7.35 (s, 1H, H5), 6.81 (s, 1H, H5), 4.16 (s, 2H, H), 4.00 (s, 
3H, H71), 3.96 (s, 3H, H61), 3.50 (t, J = 6.7 Hz, 2H, H15), 3.39 – 3.33 (m, 
2H, H2’eq), 2.85 (t, J = 12.6 Hz, 2H, H2’ax), 2.01 (d, J = 13.2 Hz, 2H, H3’eq), 
1.70 – 1.63 (m, 3H, Hβ, 4’), 1.60 – 1.48 (m, 2H, H3’ax). 13C NMR (126 MHz, 
MeOD) δ 163.85 (C9), 156.23 (C7), 150.05 (C6), 142.81 (C2), 138.37 (C8a), 
132.11 (Co), 130.56 (Cp), 130.07 (Cm), 120.88 (C4a), 106.42 (C3), 104.27 
(C8), 101.21 (C6), 62.03 (C23), 56.78 (C71), 56.50 (C61), 53.64 (C2’), 38.38 
(C), 36.14 (Cβ), 32.74 (C4’), 30.60 (C3’). C4a, C2 Ci not observed. HRMS 
[ESI+] m/z =449.2315 [M]+, calcd for [C26H31N3O4]+ 449.2315. HPLC 
purity 100% 
Chapter 3 
159 
 
N-(2-(1-benzylpiperidin-4-yl)ethyl)-7-methoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.16 
According to the general 
procedure 3.3, compound 
3.16 was obtained from 0.1 
g (0,43 mmol) of 3.7 and 
0.23 g (1,07 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-amine as a white amorphous solid, 0.116 g 
(65%), mp:200 -203 °C. 1H NMR (300 MHz, MeOD) δ 8.27 (d, J = 9.4 Hz, 
1H, H5), 7.69 – 7.39 (m, 7H, Ph, H3, 8), 7.37 (dd, J = 9.4, 2.3 Hz, 1H, H6), 
4.30 (s, 2H, H), 4.02 (s, 3H, H71), 3.58 – 3.41 (m, 4H, H, 2’eq), 3.05 (t, J = 
12.5 Hz, 2H, H2’ax), 2.06 (d, J = 14.2 Hz, 2H, H3’eq), 1.80 – 1.44 (m, 5H, Hβ, 
4’, 3’ax). 13C NMR (75 MHz, MeOD) δ 172.32 (C4), 167.01 (C7), 160.96 (C9), 
146.61 (C2), 143.66 (C8a), 132.49 (Co), 131.14 (Cp), 130.45 (Ci), 130.26 
(Cm), 126.58 (C5), 122.17 (C6), 117.00 (C4a), 103.81 (C3), 100.32 (C8), 
61.73 (C), 57.04 (C71), 53.68 (C2’), 38.64 (C), 35.88 (Cβ), 32.29 (C4’), 
30.32 (C3’). HRMS [ESI+] m/z =419.2212 [M]+, calcd for [C25H29N3O3]+ 
419.2209. HPLC purity 100% 
 
N-(2-(1-benzylpiperidin-4-yl)ethyl)-8-methoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.17 
According to the general 
procedure 3.3, amide 3.17 was 
obtained from 0.1 g (0,43 mmol) 
of 3.8 and 0.23 g (1,07 mmol) of 
2-(1-benzylpiperidin-4-yl)ethan-
1-amine as a white amorphous solid,  0.108 g (60%), mp: 187 - 189 °C. 
1H NMR (500 MHz, MeOD) δ 7.80 (bs, 1H, CH), 7.56 – 7.49 (m, 6H, CH, 
Ph), 7.41 (bs, 1H, CH), 7.37 – 7.32 (m, 1H, CH), 6.89 (bs, 1H, NH), 4.30 
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(s, 2H, H), 4.11 (s, 3H, H81), 3.54 – 3.49 (m, 4H, H, 2’eq), 3.06 – 2.98 (m, 
2H, H2’ax), 2.09 (d, J = 13.7 Hz, 2H, H3’eq), 1.78 – 1.62 (m, 3H, H4’,β), 1.59 – 
1.45 (m, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 172.97 (C4), 163.29 (C9), 
150.74 (C8), 132.47 (Co), 132.05 (C), 131.26 (Cp), 130.50 (C), 130.37 (Ci), 
130.36 (Cm), 126.28 (CH), 116.99 (CH), 112.78 (CH), 61.95 (C), 57.10 
(C81), 53.88  (C2’), 38.38 (C), 36.16 (Cβ), 32.44 (C4’), 30.43 (C3’). HRMS 
[ESI+] m/z =419.2207 [M]+, calcd for [C25H29N3O3]+ 419.2209. HPLC 
purity 100% CH’s not assignable, CH-3 in 13C not detected 
 
N-(2-(1-benzylpiperidin-4-yl)ethyl)-8-hydroxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.18  
According to the general 
procedure 3.4; product 3.18 was 
obtained from 0.07 g (0.17 mmol) 
of 3.17 and 1.17 mmol of BBr3 
(1M in DCM, 1.2 mL). After 
column chromatography purification (DCM:MeOH 9:1), the product was 
obtained as a white amorphous powder 0,061 g (90%), mp: 184 - 187 °C. 
1H NMR (500 MHz, MeOD) δ 7.72 (dd, J = 8.4, 1.2 Hz, 1H, H5), 7.57 – 
7.46 (m, 6H, Ph, H3), 7.41 (dd, J = 8.4, 7.6 Hz, 1H, H6), 7.24 (bs, 1H, NH), 
7.19 (dd, J = 7.6, 1.2 Hz, 1H, H7), 4.30 (s, 2H, H), 3.54 (t, J = 6.8 Hz, 2H, 
H), 3.52 – 3.48 (m, 2H, H2’eq), 3.08 – 2.99 (m, 2H, H2’ax), 2.11 (d, J = 14.5 
Hz, 2H, H3’eq), 1.80 – 1.71 (m, 1H, H4’), 1.68 (q, J = 6.8 Hz, 2H, Hβ), 1.54 – 
1.43 (m, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 164.66 (C9), 132.38 (Co), 
131.29 (Cp), 130.37 ( Cm), 127.84 (C6), 114.76 (CH), 61.87 (C), 53.77 (C2’), 
38.08 (C), 36.29 (Cβ), 32.37 (C4’), 30.45 (C3’). HRMS [ESI+] m/z 
=405.2053 [M]+, calcd for [C24H27N3O3]+ 405.2052. HPLC purity 99% 
quaternary carbons not observed 
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N-(2-(1-benzylpiperidin-4-yl)ethyl)-4,6,7-trimethoxyquinoline-2-
carboxamide. 3.19. 
According to the general 
procedure 3.4, product 3.19 
was obtained from 0.05 g (0.18 
mmol) of 3.10 and 0.059 g 
(0.27 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-
amine as a white amorphous solid, 0.054 g (65%), mp:182 - 184 °C. 1H 
NMR (500 MHz, CDCl3) δ 8.45 (s, 1H, H8), 8.07 (s, 1H, H3), 7.67 – 7.56 
(m, 2H, Hm), 7.44 (s, 1H, H5), 7.40 – 7.33 (m, 3H, Ho, p), 4.35 (s, 3H, H41), 
4.11 (s, 5H, H71, ), 4.05 (s, 3H, H61), 3.66 – 3.52 (m, 2H, H), 3.51 – 3.38 
(m, 2H, H2’eq), 2.90 – 2.62 (m, 2H, H2’ax), 2.06 – 1.92 (m, 5H, H4’, 3’), 1.78 – 
1.60 (m, 2H, Hβ). 13C NMR (126 MHz, CDCl3) δ 167.05 (C4), 158.28 (C9), 
157.03 (C7), 152.21 (C6), 143.69 (C2), 137.12 (C8a), 131.62 (Cm), 130.03 
(Cp), 129.25 (Co), 128.48 (Ci), 116.90 (C4a), 101.10 (C3), 100.09 (C8), 77.41 
(C5), 61.15 (C), 58.62 (C41), 57.35 (C71), 56.72 (C61), 52.79 (C2’), 37.67 
(C), 34.32 (Cβ), 30.98 (C4’), 28.80 (C3’). HRMS [ESI+] m/z =463.24746 
[M]+, calcd for [C27H33N3O4]+ 463.24711. HPLC purity 100% 
 
N-(4-((benzyl(methyl)amino)methyl)phenyl)-5-methoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.20 
3.20 was synthesized as 
described in the general 
procedure 3.3, from 0.11 g (0.48 
mmol) of amine 1.8 and a 
mixture containing 80% of 3.7 
and 20% of its isomer bearing the methoxy group at position 5. This 
reaction yielded both 3.23 0,04 g (60%) and 3.20 0,01 g (61%). Light 
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brown amorphous solid. mp 263 - 265 °C. 1H NMR (500 MHz, CDCl3) δ 
10.20 (s, 1H NH10), 9.88 (s, 1H, NH1), 7.80 (d, J = 8.3 Hz, 2H, H2’), 7.75 
(s, 1H, H3), 7.73 (d, J = 0.9 Hz, 1H, H8), 7.63 (t, J = 7.8 Hz, 1H, H7), 7.46 
– 7.36 (m, 4H, H3’, o), 7.34 (t, J = 7.5 Hz, 2H, Hm), 7.29 – 7.26 (m, 1H, Hp), 
6.92 (dd, J = 7.8, 0.9 Hz, 1H, H6), 4.13 (s, 3H, H51), 3.57 (s, 4H, H, β), 
2.23 (s, 3H, H).  13C NMR (126 MHz, CDCl3) δ 164.19 (C4), 162.09 (C9), 
156.07 (C5), 152.06 (C2), 149.81 (C8a), 136.90 (C1’), 135.49 (C4’), 130.07 
(C7), , 129.88 (C3’), 129.23 (Co), 128.45 (Cm), 127.25 (Cp), 1213.37 (C8), 
119.77 (C2’), 112.61 (C4a), 105.39 (C6), 104.34 (C3), 61.84 (C), 61.49 (Cβ), 
56.76 (C51), 42.24 (C). Ci not detected. HRMS [ESI+] m/z =427.1900 [M]+, 
calcd for [C26H25N3O3]+ 427.1896. HPLC purity 99%  
 
N-(4-((benzyl(methyl)amino)methyl)phenyl)-6-methoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.21 
3.21 was synthesized as 
described in the general 
procedure 3.3, from 0.22 g of 
1.8 and 3.5 (0.1 g, 0.43 mmol). 
White amorphous solid, 0.049 g 
(60%), mp:261 - 264 °C. 1H 
NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H, NH), 7.96 (d, J = 9.1 Hz, 1H8), 
7.82 (d, J = 8.0 Hz, 2H, H2’), 7.49 (d, J = 2.9 Hz, 1H, H5), 7.40 (dd, J = 
9.1, 2.9 Hz, 1H, H7), 7.38 – 7.30 (m, 7H, H3, 3’, o, m), 7.28 – 7.23 (m, 1H, 
Hp), 3.89 (s, 3H, H61), 3.50 (s, 2H, Hβ), 3.48 (s, 2H, H), 2.08 (s, 3H, H). 
13C NMR (126 MHz, DMSO-d6) δ 157.07 (C6), 139.09 (Ci), 136.99 (C4’), 
134.98 (C1’), 128.98 (C3’), 128.60 (Cm), 128.20 (Co), 126.88 (Cp), 122.98 
(C7), 120.18 (C2’), 60.97 (Cβ), 60.57 (C), 55.43 (C61), 41.63 (C). C3 and 
quaternary carbons of chromone ring not detected. HRMS [ESI+] m/z 
=427.1905 [M]+, calcd for [C26H25N3O3]+ 427.1896. HPLC purity 99% 
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N-(4-((benzyl(methyl)amino)methyl)phenyl)-6-hydroxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.22  
According to the general 
procedure 3.4, product 3.22 
was obtained from 0.022 g 
(0.051 mmol) of 3.21 and 0.4 
mmol of BBr3 (0.4 mL, 1M in 
DCM). Purification MeOH in EtOAc (0→80%), white amorphous powder 
(90%). mp: 248 -251 °C. 1H NMR (300 MHz, DMSO-d6) δ 10.56 (s, 1H, 
NH), 7.90 (s, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.53 – 7.15 (m, 9H), 3.50 (s, 
2H, CH2), 3.48 (s, 2H, CH2), 2.08 (s, 3H, CH3). 13C NMR (75 MHz, DMSO-
d6) δ 139.08 (C), 137.00 (C), 128.96 (C3’), 128.58 (Co), 128.18 (Cm), 126.86 
(Cp), 122.80 (CH), 120.14 (C2’), 60.95 (CH2), 60.56(CH2), 41.61(CH3). Some 
quaternary carbons detected but not assignable just one CH detected. 
HRMS [ESI+] m/z =413.1751 [M]+, calcd for [C25H23N3O3]+ 413.1739. 
HPLC purity 99%  
 
N-(4-((benzyl(methyl)amino)methyl)phenyl)-7-methoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.23 
Compound 3.23 was 
synthesized as described in the 
general procedure 3.3, from 
0.105 g (0.48 mmol) of amine 
1.8 and 3.7 (0.045 g, 0.19 
mmol). Light brown amorphous solid, 0.051 g (62%). mp: 240 - 243 °C. 
1H NMR (300 MHz, DMSO-d6) δ 11.73 (s, 1H, NH1), 10.63 (s, 1H, NH10), 
8.01 (d, J = 9.0 Hz, 1H, H5), 7.79 (d, J = 8.1 Hz, 2H, H2’), 7.50 – 7.42 (m, 
1H, H8), 7.40 – 7.29 (m, 6H, H3’, o, m), 7.28 – 7.19 (m, 1H, Hp), 6.99 (bs, 
1H, H6), 6.86 (bs, 1H, H3), 3.87 (s, 3H, H71), 3.50 (s, 2H, Hβ), 3.49 (s, 2H, 
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H), 2.08 (s, 3H, H). 13C NMR (75 MHz, DMSO-d6) δ 177.03 (C4), 162.28 
(C7), 160.65 (C9), 139.04 (Ci), 136.88 (C1’), 135.22 (C4’), 128.98 (C3’), 
128.59 (Cm), 128.18 (Co), 126.87 (Cp), 126.44 (C5), 120.43 (C2’), 113.96 
(C6), 107.56 (C3), 100.31 (C8), 60.96 (Cβ), 60.53 (C), 55.45 (C71), 41.59 
(C). HRMS [ESI+] m/z =427.1898 [M]+, calcd for [C26H25N3O3]+ 427.1896. 
HPLC purity 99% 
N-(4-((benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.24 
Product 3.24 was 
synthesized as described in 
the general procedure 3.3, 
starting from 0.045 g (0.19 
mmol) of 3.6 and 0.11 g, 
(0.48 mmol) of amine 1.7. White amorphous solid, 0,028 g (35%), mp:245 
- 248 °C. 1H NMR (500 MHz, MeOD) δ 7.79 (d, J = 8.2 Hz, 2H, H2’), 7.59 
(s, 1H, H(5 or 8)), 7.42 (d, J = 8.2 Hz, 2H, H3’), 7.48 – 7.25 (m, 7H, H(8 or 5), 3, 
o, m, p), 7.05 (bs, 1H, NH), 4.00 (s, 3H, O-CH3), 3.96 (s, 3H, O-CH3), 3.70 
(bs, 4H, H, β), 2.30 (s, 3H, H). 13C NMR (126 MHz, MeOD) δ 156.16 (C-
OCH3), 150.33 (C-OCH3), 138.73 (C14), 137.98 (Ci), 134.68 (C11), 131.33 
(C13), 130.76 (Co), 129.57 (Cm), 128.89 (Cp), 122.06 (C12), 103.89 (CH), 
62.32 (C17), 61.85 (C15), 56.70 (C71), 56.48 (C61), 41.82 (C16). CH’s and 
quaternary carbons not detected. HRMS [ESI+] m/z =457.2009 [M]+, 
calcd for [C27H27N3O4]+ 457.2002. HPLC purity 100%  
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N-(4-((benzyl(methyl)amino)methyl)phenyl)-6,7-dihydroxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.25 
According to the general 
procedure 3.4, product 3.25 
was obtained from 0.018 g 
(0.04 mmol) of 3.24 and 0.4 
mmol of BBr3 (0.4 mL, 1M in 
DCM). Purification (MeOH in EtOAc 0→60%), white amorphous powder, 
0,015 (90%), mp: 248 -251 °C.  1H NMR (500 MHz, MeOD) δ 7.99 (d, J = 
8.1 Hz, 2H, H2’), 7.64 (d, J = 8.1 Hz, 2H, H3’), 7.62 (s, 1H, H3), 7.60 – 7.55 
(m, 2H, Hm), 7.54 – 7.50 (m, 5H, H5, 8, o, p), 4.58 – 4.51 (m, 2H, H), 4.39 – 
4.30 (m, 2H, Hβ), 2.77 (s, 3H, H). 13C NMR (126 MHz, MeOD) δ 194.03 
(C4), 170.55 (C9), 160.79 (C), 156.94 (C7), 150.15 (C6), 143.73 (C), 140.71 
(C4’), 133.97 (C), 133.26 (C3’), 132.39 (Co), 131.31 (Cp), 130.77 (Ci), 130.45 
(Cm), 127.38 (C1’), 122.65 (C2’), 118.34 (C8), 111.41 (C), 105.80 (C3), 
103.76 (C5), 60.76 (C), 60.30 (Cβ), 39.55 (C).  HRMS [ESI+] m/z 
=429.1700 [M]+, calcd for [C25H23N3O4]+ 429.1689. HPLC purity 99% 
 
N-(3-((benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-4-oxo-1,4-
dihydroquinoline-2-carboxamide. 3.26 
Product 3.26 was synthesized 
as described in the general 
procedure 3.3, from 0.05 g 
(0.19 mmol) of 3.6 and 0.085 g 
of 1.7 (0.38 mmol). Light brown 
amorphous solid, 0.078 g (90%). mp:  131 - 133 °C.1H NMR (500 MHz, 
MeOd) δ 7.92 (s, 1H, H2’), 7.76 (dd, J = 7.6, 1.3 Hz, 1H, H6’), 7.55 (s, 1H, 
CH), 7.50 – 7.38 (m, 7H, Ph, CH, H5’), 7.31 (s, 1H, CH), 7.27 (dt, J = 7.7, 
1.3 Hz, 1H, H4’), 4.04 – 4.00 (bs, 4H, H, β), 3.99 – 3.98 (m, 3H, OCH3), 
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3.94 (s, 3H, OCH3), 2.51 (s, 3H, H). 13C NMR (126 MHz, MeOD) δ 156.08 
(C6), 150.35 (C7), 139.66 (C1’), 131.43 (Co), 130.54 (Cp), 129.98 (Cm), 
129.98 (C5’), 127.84 (C4’), 123.80 (C2’), 122.42 (C6’), 103.75 (CH), 61.75 
(Cβ), 61.58 (C), 56.68 (O-CH3), 56.45 (O-CH3), 41.00 (C). Quaternary 
carbons not observed and just one CH detected HRMS [ESI+] m/z 
=457.2002 [M]+, calcd for [C27H27N3O3]+ 457.2001. HPLC purity 100%  
NMDA receptor agonist radioligand displacement. Affinity of 
compounds for the NMDA receptor was carried out in the rat cerebral 
cortex by CEREP Co.258 Membrane homogenates of cerebral cortex (1 mg 
protein) are incubated for 60 min at 4°C with 5 nM [3H]CGP 39653 in the 
absence or presence of the test compound in a buffer containing 5 mM  
Tris-HCl (pH 7.7) and 10 mM EDTA-Tris. Nonspecific binding is 
determined in the presence of 100 µM 
L-glutamate. Following incubation, the samples are filtered rapidly under 
vacuum through glass fiber filters (GF/B, Whatman) and rinsed several 
times with ice-cold incubation buffer using a 48-sample cell harvester 
(Brandel). The filters are dried then counted for radioactivity in a 
scintillation counter (LS series, Beckman) using a scintillation cocktail 
(Formula 989, Packard). The results are expressed as a percent inhibition 
of the control radioligand specific binding. The standard reference 
compound is CGS 19755, which is tested in each experiment at several 
concentrations to obtain a competition curve from which its IC50 is 
calculated.
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Cinnamic-Based Antioxidants as 
Multitarget Compounds for the Treatment 
of Alzheimer’s disease 
Introduction 
Although nowadays it is widely accepted that neuronal loss in 
neurodegenerative diseases is the outcome of a wide variety of factors, 
one of the most accepted factors explaining the origin of diseases like AD 
or PD is the oxidative stress.259 The oxidative stress hypothesis states 
that neuronal death results from the toxicity exerted by free radical 
species. These reactive entities are able to interact with lipidic molecules 
in cellular membranes, altering their composition, function and 
permeability. Not only unsaturated fatty acids in membranes are affected 
by free radicals; arachidonic acid and docosahexaenoic acid, two 
important molecules which concentration reaches the highest levels in 
brain, are susceptible to be oxidized under oxidative conditions. 
Byproducts from peroxidation of unsaturated acids include highly 
reactive and toxic species such as 4-hydroxynonenal (HNE), 
malondialdehyde (MDA) and acrolein, which seems to be especially 
increased in AD.260-262  
In spite of the effective system of the human body to counteract the 
harmful effects of oxidative metabolism (superoxide dismutase (SOD), 
aldehyde dehydrogenase and glutathione peroxidase), the brain is 
particularly sensitive to oxidative damage due to its great requirement of 
oxygen, its high levels of unsaturated acids and relatively low levels of 
antioxidant enzymes.263 
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Several investigations have demonstrated a correlation between the 
severity and advance of AD and free radicals. Moreover, Aβ has been 
proven to induce the production of H2O2 by reduction of metals such as 
iron and copper.264 Simultaneously, Aβ is able to stimulate glial cells, 
enhancing the production of an oxidative environment and pro-
inflammatory molecules.10,265,266   
According to the oxidative stress hypothesis, antioxidants and metal 
chelators could play an important role in prevention and therapy of AD. 
Among the most investigated natural antioxidants, are some derivatives 
of cinnamic acid (e.g., ferulic, caffeic, coumaric and umbellic acid) and 
natural molecules containing its structure, such as curcumin or some 
bioactive chalcones.267-272 (Figure 4.1) 
 
Figure 4.1 Natural antioxidants containing the cinnamic acid structure 
Antioxidant molecules per se might not be sufficient to treat or prevent 
AD, as shown by the ambiguous results obtained from several clinical 
trials with this kind of compounds.273 In light of this, here we propose the 
synthesis of hybrid molecules resulting from the combination of the 
privileged structures NBP and DBMA with several natural antioxidant 
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molecules derived from the cinnamic acid, in order to obtain multitarget 
directed molecules with enhanced antioxidant capacity and able to 
inhibit simultaneously cholinesterases, MAO or BACE1. 
Results and discussion 
Synthesis of Cinnamic acid-based Hybrids 
Commercially available cinnamic-derived acids were used to be coupled 
to amines carrying the NBP and DBMA fragments used along this work. 
Coupling reaction was carried out by activation of the corresponding 
acids with CDI in THF at 120 °C during 10 min and subsequent reaction 
with the proper amine during 10-40 min depending on its character, 
aliphatic or aromatic (scheme 4.1).   
 
Scheme 4.1 Synthesis of Cinnamic acid-based hybrids (a) CDI, THF, mw, 5 min, 
120 °C; (b) 2-(1-benzylpiperidin-3-yl)ethan-1-amine, mw, 10 min, 120 °C; (c) 
Amine (1.7, 1.8), mw, 40 min, 120 °C; (d) BBr3, THF, rt, overnight 
Deprotection of the methoxy groups was accomplished by treatment with 
BBr3, as described in previous chapters. Scheme 4.1  
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Biological Evaluation 
As explained above, we aimed to obtain better antioxidants than the 
chromone-based compounds synthesized in chapter two, improving, or at 
least preserving affinity for MAO and cholinesterases. Although we found 
that NBP containing hybrids (4.4) are included in an patent of year 
1989,274 we decided to synthesize a short series of these compounds, 
besides DBMA hybrids, in order to evaluate them as MAO inhibitors, 
since the privileged structure of cinnamic acid is contained in several 
chalcones with MAO inhibitory activity as explained above.271,272  
Table 4.1 Inhibition of human cholinesterases (hAChE and hBuChE) and 
monoaminoxidases (MAO-A and MAO-B) (IC50, µM); ORAC, trolox equivalents. 
 
  IC50 (μM) ORAC 
Comp. R hAChE hBuChE Trolox Eq. 
4.1 6,7-OMe 0.26±0.04 0.69±0.10 0.4±0.04 
4.2 6-OMe 0.75±0.10 0.98±0.12 NA 
4.3 7-OMe 0.49±0.06 0.76±0.20 NA 
4.4 5,7-OMe 0.63±0.08 4.39±0.86 NA 
4.5 6-OMe,7-OH  0.39±0.05 0.076±0.01 1.8±0.2 
4.6 6-OH 1.12±0.10 1.02±0.21 2.2±0.1 
4.7 7-OH 1.01±0.08 0.93±0.16 1.7±0.1 
4.8 5,7-OH 0.99±0.10 0.26±0.08 1.3±0.6 
4.9 6,7-OH 1.75±0.12 0.69±0.12 1.0±0.1 
Results are expressed as mean ± SD (an =3, bn =5), **Inactive at 200 µM, *** 
inactive at 1 mM, NA: not antioxidant 
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Although we preferred the hydroxy substituted compounds because their 
potential antioxidant capacity, all derivatives were assessed as inhibitors 
of MAO, AChE and BuChE. 
Hydroxy derivatives exhibited good antioxidant capacity in both series 
(NBP and DBMA). m-Coumaric derived hybrids 4.6 and 4.16 (6-OH 
substituted), exhibited the best results in ORAC assay, with trolox 
equivalents up to 2.2 and 3.2 in the NBP and DBMA series respectively. 
Simultaneously, they inhibit both cholinesterases in the low micromolar 
range but were unable to inhibit any isoform of MAO (Table 4.1). 
In the NBP series, the best multitarget profile was achieved by ferulic-
based compound 4.5, with antioxidant capacity of 1.8 trolox equivalents, 
potent inhibitory activity towards BuChE and moderate none-selective 
inhibitory activity towards MAO-A and MAO-B (IC50 = 76 nM, 11 μM and 
13 μM respectively). Di-hydroxy substituted compounds 4.9 and 4.8 
exhibited a similar profile with IC50’s in the low micromolar range for the 
cholinesterases and both isoforms of MAO (Tables 4.2 and 4.3). Although 
less potent, 4.7 was the one of this series able to inhibit selectively MAO-
A with an IC50 of 57 μM. 
The cinnamic-DBMA series provided moderated inhibitors of AChE with 
low micromolar IC50’s (table 4.3). 4.17 was inactive towards the 
cholinesterases but a moderated inhibitor of MAO-A and MAO-B (IC50 = 
29.7 and 29.0 μM respectively). Interestingly, in this series only 
compound 4.12 (ferulic derivative with a DBMA fragment at position 3’) 
exhibited a multitarget profile, with low micromolar IC50’s in all tested 
targets (h-AChE: 6.0 μM; h-BuChE: 5.9 μM; MAO-A: 4.5 μM; MAO-B: 7.7 
μM) and antioxidant capacity of 1.5 trolox equivalents. The rest of 
compounds were inactive as MAO inhibitors.  
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Table 4.2 Inhibition of h-AChE, h-BuChE (IC50, µM); ORAC 
 
  IC50 (μM) ORAC 
Comp. R MAO-Ab MAO-Bb Trolox Eq. 
4.1 6,7-OMe ** ** 0.4±0.04 
4.2 6-OMe ** ** NA 
4.3 7-OMe ** ** NA 
4.4 5,7-OMe ** ** NA 
4.5 6-OMe,7-OH  11.37±0.76 13.13±0.88 1.8±0.2 
4.6 6-OH *** ** 2.2±0.1 
4.7 7-OH 57.45 ± 3.8 ** 1.7±0.6 
4.8 5,7-OH 5.48±0.37 8.31 ± 0.55 1.3±0.6 
4.9 6,7-OH 3.50±0.23 5.98 ± 0.4 1.04±0.1 
Results are expressed as mean ± SD (an =3, bn =5), **Inactive at 200 µM, *** 
inactive at 1 mM, NA: not antioxidant 
 
Both series resulted inactive as BACE1 inhibitors. Only compounds 
4.14, 4.15, 4.13 and 4.12 were capable to inhibit poorly this enzyme 
with percentages around 23-33% at 10 μM (table 4.3). 
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Table 4.3 Inhibition of h-AChE, h-BuChE, MAO-A/B (IC50, µM) 
 
  IC50 (μM) ORAC hBACE1 
Comp. R h-AChEa h-BuChEb 
Trolox 
Eq 
%inh*  
4.10 5,7-OMe 8.73±0.92 >10 0.5±0.10 14% 
4.11 6,7-OMe 3.98±0.29 >10 0.4±0.08 18% 
4.12 6-OMe,7-OH 5.99±0.49 5,89±0,48 1.4±0.11 23% 
4.13 6-OMe,7-OH 33%* 45%* 1.5±0.18 33% 
4.14 6-OMe 4.67±0.31 35%*  0.6±0.06 32% 
4.15 7-OMe 5.76±0.40 25%*  NA 25% 
4.16 6-OH 3.49±0.31 46%*  3.2±0.2 8% 
4.17 7-OH 46%* 30%*  1.8±0.14 5% 
* % at a concentration of 10 μM; results are expressed as mean ± SD where n =3, 
NA: not antioxidant. 
 
4.16 the best antioxidant, 4.5, the most potent BuChE inhibitor and 
4.13, were evaluated as neuro-protectants in the MTT assay described 
previously. These compounds protected around 30-35% of cells at a 
concentration of 0.3 μM; however, a dose dependent relationship was not 
observed in these experiments, higher doses were not able to protect the 
cells. Nevertheless, in any case they did not potentiate the toxicity 
exerted by rotenone/oligomycin, which could be assumed as a lack of 
toxicity of our newly obtained hybrids.   
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Figure 4.2 Cell viability was measured as MTT reduction and data were 
normalized as % of control. Data are expressed as the means ± SEM. of triplicate 
of at least three different cultures. All compounds were assayed at increasing 
concentrations (0.1-3 µM)  
 
4.5, 4.6, 4.16 and 4.13 were evaluated as anti-aggregating agents in 
bacterial cells overexpressing tau protein and Aβ42 peptide. All 
compounds resulted inactive at 20 μM except 4.16; it was able to inhibit 
23% and 21% of the self-catalyzed aggregation of tau and Aβ42 
respectively.  
A selection of compounds including methoxy, hydroxy and di-hydroxy-
substituted derivatives from both series was evaluated in PAMPA assay. 
Table 4.4 summarizes the values of permeability for these products and 
those predicted for 10 known standard drugs. All DBMA derivatives were 
predicted to cross the BBB, while in NBP series, only methoxy 
substituted derivatives could reach the CNS; the rest of compounds gave 
permeability values included in the range of uncertainty, Pe (10-6 cm s-1) = 
9.8 – 12.3, r2= 0.95. 
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Table 4.4 Permeability (Pe 10-6 cm s-1) of 10 Commercial drugs used in the 
experiment validation, aTaken from Ref.147. bMean ± SD of three independent 
experiments 
Compd. Bibl.a Exp.b Compd Pe (10-6cm s-1)b Predict. 
Testosterone 17.0 26.5 ± 1.1 4.5   9.4 ± 0.8 CNS ± 
Verapamil 16.0 29.5 ± 1.0 4.1 12.4 ± 0.5 CNS + 
Imipramine 13.0 20.6 ± 3.0 4.9   9.7 ± 0.2 CNS ± 
Desipramine 12.0 22.9 ± 1.7 4.8   9.8 ± 0.8 CNS ± 
Promazine 8.8 20.8 ± 0.9 4.6 11.9 ± 0.2 CNS ± 
Corticosterone 5.1 11.0 ± 0.2 4.14 14.8 ± 0.5 CNS + 
Piroxicam 2.5 10.0 ± 0.1 4.15 14.9 ± 0.8 CNS + 
Hydrocortisone 1.9 10.2 ± 0.1 4.16 13.2 ± 1.2 CNS + 
Caffeine 1.3  7.9 ± 0.3 4.13 14.2 ± 0.5 CNS + 
Ofloxacin 0.8 6.11 ± 0.9 4.12 14.1 ± 1.2 CNS + 
 
Finally, caffeic – NBP hybrid 9, with a balanced multifunctional profile in 
hChEs, hMAOs and ORAC (h-AChE: 1.75 μM; h-BuChE: 0.69 μM; h-
MAO-A: 3.5 μM; h-MAO-B: 6.0 μM; ORAC: 1.0 trolox equivalents), was 
chosen to evaluate the ability of new cinnamic-based hybrids in 
promoting the differentiation of neural stem-cells towards a neuronal 
phenotype. To that purpose, neural stem cells (NSC) isolated from one of 
the main neurogenic niches in the adult, the subgranular zone (SGZ) of 
the dentate gyrus, were used as described chapter one. NSC were grown 
as neurospheres in the presence of hybrid 9 (10 µM) during 7 days and 
later on allowed for 3 days to differentiate when adhered on a substrate 
in the presence of serum and compound. At this point, 
immunocytochemical analysis was performed to evaluate the ability of 
tested compound to promote neuronal differentiation. Our results 
summarized in figure 4.3 showed that the new caffeic-based hybrid 9 
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clearly induced the differentiation of adult SGZ-derived NSC into a 
neuronal phenotype. After treatment with compound 9 a significant 
increase in the number of β-III-tubulin (early neurogenesis marker) and 
MAP-2 (microtubule-associated protein expressed in mature neurons) 
expressing cells in the neurospheres in shown. These results suggest 
that the new caffeic – NBP hybrid 9 has the ability to induce the 
differentiation of adult neural stem cells into neurons, promoting its 
maturation in vitro and showing a great neurogenic effect.  
 
Figure 4.3. Caffeic-based hybrid 9 promotes neuronal differentiation in vitro. 
Adult murine neural stem cells isolated from the neurogenic niche of the SGZ of 
the hippocampus were grown as NS during 7 days in the presence of compound 
9 (10 µM). Then, NS were allowed to differentiate on a substrate for another 3 
days in the presence of tested compound. Immunocytochemical analysis shows 
the expression of two well-known neuronal markers: β-III-tubulin (TuJ clone; 
green) and MAP-2 (red) inside the NS (inner part) and in the distal area (outer 
part). DAPI was used for nuclear staining. Scale bar, 200µm. 
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At this point, we decided to explore additional structural modifications in 
order to improve the antioxidant capacity of the hybrids obtained in this 
chapter. Based on compound 4.5, the new derivative 4.18 was 
synthesized as described in scheme 4.2.  
 
Scheme 4.2 Synthesis of ferulic acid-based compound 4.18  
 
The effect of this modification over AChE inhibition and antioxidant 
capacity was minimal, AChE (IC50)= 0.76 ± 0.2 μM, ORAC (trolox 
equivalents) = 1.70 ± 0.05. However, it was detrimental to affinity for 
BuChE; IC50 shifted from 76 nM in 4.5 to 27% of inhibition at 10 μM in 
4.18. Regarding to BACE1, a very interesting change was observed, while 
4.5 was utterly inactive, 4.18 was able to inhibit a 34 % of this enzyme 
at a concentration of 10 μM. Even though, it represents a modest 
percentage of inhibition; it is a remarkable change that should be studied 
in the future. In regard of BBB permeability, 4.18 was not predicted to 
reach the CNS, however, a simple change of methoxy group by a larger 
chain could be sufficient to solve this problem.  
Given that it is well known that BACE1 has a large active site, another 
modification we decided to explore was the length of the entire molecule. 
Taking advantage of the remaining hydroxy group in molecules such as 
4.12, we resolved to add an extra ferulic acid fragment to obtain 
compound 4.19. (Figure 4.3).  
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Figure 4.3 Structure of 4.19, BACE1 inhibitor, IC50 1.5 μM 
 
A remarkable change of activity from 23% at 10 μM in the case of 4.12 to 
an IC50 value of 1.5 μM for 4.19 was observed. At this point, this new 
derivative has been tested only as BACE1 inhibitor and remains to be 
evaluated in the rest of targets explored in this work. 
Taken together, these modifications open a new range of possibilities to 
improve the biological activity and the multitarget character of this kind 
of hybrids; however, these new compounds are out of the scope of this 
thesis and remain to be developed.  
Conclusions 
The combination of cinnamic structure with NBP and DBMA fragments 
gave hybrids with enhanced antioxidant capacity, compared to the 
chromone-based compounds obtained previously. As we have aimed 
along this work, we obtained several hybrids with multitarget profile; 
here, we highlight compounds 4.5, 4.9, 4.8 and 4.7 in the cinnamic-NBP 
and 4.12 in the cinnamic-DBMA series, as dual AChE-MAO inhibitors. 
The feature shared for all compounds with affinity for MAO is the 
hydroxy group at position 7; it seems to be crucial for their inhibitory 
activity.   
Regarding to the antioxidant capacity, hydroxy group at position 6 was 
the best improving the ORAC values, although it was detrimental for the 
affinity towards MAO; notwithstanding, the compounds exhibiting 
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concurrent affinity for cholinesterases and MAO, still display values up to 
1.8 equivalents of trolox. 
 Although it has been formerly proposed that cinnamic-NBP hybrids 
could be good inhibitors of AChE, it has not been evaluated if this 
combination could inhibit MAO and simultaneously protect the cells 
against oxidative stress. This could be the mechanism involved in 
protection against rotenone/oligomycin toxicity observed in the MTT 
assay; however, complementary studies must be developed in this regard. 
Newly synthesized compound 4.19 represents a new hit in the search of 
BACE1 inhibitors; if this hybrid preserves the activity of the smaller 
analogue 4.12 in cholinesterases and MAO, it could represent a new 
opportunity in the search of disease modifying drugs for AD treatment. 
Experimental Part 
General Procedure 4.1 Synthesis of Cinnamic-based Hybrids. The 
corresponding acid (1 mmol) and CDI (1.15 mmol) were mixed into a 
microwave tube under nitrogen atmosphere. The tube was sealed up and 
3 mL of anhydrous THF were added using a syringe to dissolve the 
mixture (CO2↑). This solution of activated acid was heated into a 
microwave reactor at 120 ⁰C during 7 min to complete the activation. 
Afterward, a solution of 1.2 mmol of the corresponding amine in 2 mL of 
THF was added with a syringe into the tube; this solution was heated at 
120 ⁰C during 10 min for NBP derivatives and 40 min for DBMA hybrids. 
After evaporation of the THF under reduced pressure the crude obtained 
was re-dissolved in 25 mL of EtOAc and washed 3x5 mL with water and 
3x5 mL with brine; dried over MgSO4 and concentrated under reduced 
pressure. The crude was purified by column chromatography using 
EtOAc:MeOH (9:1) or hexane/EtOAc (0→70%) as eluent. 
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(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(3,4-
dimethoxyphenyl)acrylamide. 4.1 
4.1 was obtained from 0.1 g 
of 4,5-dimethoxy cinnamic 
acid (0.48 mmol) and 0.126 
g (0.58 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-
1-amine. Ligth yellow solid, 0.170 g (90%) mp: 108.1-110.5⁰C. 1H NMR 
(500 MHz, MeOD) δ 7.46 (d, J = 15.7 Hz, 1H, H3), 7.32 (s, 2H, Hm), 7.31 
(s, 2H, Ho), 7.29 – 7.24 (m, 1H, Hp), 7.14 (d, J = 2.0 Hz, 1H, H5), 7.12 
(ddd, J = 8.2, 2.0, 0.5 Hz, 1H, H9), 6.96 (d, J = 8.2 Hz, 1H, H8), 6.47 (d, J 
= 15.7 Hz, 1H, H2), 3.86 (s, 3H, H71), 3.85 (s, 3H, H61), 3.51 (s, 2H, H), 
3.35 – 3.32 (m, 2H, H), 2.90 (dt, J = 12.1, 3.5 Hz, 2H, H2’eq), 2.05 – 1.99 
(m, 2H, H2’ax), 1.76 – 1.71 (m, 2H, H3’eq), 1.50 (dt, J = 7.9, 6.6 Hz, 2H, Hβ), 
1.37 (dddd, J = 16.4, 9.7, 6.4, 3.5 Hz, 1H, H4’), 1.28 (qd, J = 12.1, 3.5 Hz, 
2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 168.86 (C1), 152.20 (C6), 150.70 
(C7), 141.56 (C3), 138.19 (Ci), 130.92 (Co), 129.36 (C4), 129.26 (Cm), 
128.43 (Cp), 123.16 (C9), 119.67 (C2), 112.71 (C8), 111.31 (C5), 64.34 (C), 
56.42 (C61), 56.40 (C71), 54.64 (C2’), 38.10 (C), 37.10 (Cβ), 34.44 (C4’), 
32.72 (C3’). HRMS [ESI+] m/z =408.2407 [M] +, Calcd for [C25H32N2O3] + 
408.2413. HPLC purity 99% 
 
(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(3-
methoxyphenyl)acrylamide. 4.2 
4.2 was obtained from 0.25 
g of 5-methoxy cinnamic 
acid (1.4 mmol) and 0.36 g 
(1.61 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-
1-amine. White amorphous solid, 0.430 g (80%) mp: 68-70 ⁰C. 1H NMR 
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(300 MHz, MeOD) δ 7.48 (d, J = 15.8 Hz, 1H, H3), 7.39 – 7.21 (m, 6H, Ph, 
H7), 7.18 – 7.06 (m, 2H, H5,9), 6.94 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H, H8), 
6.58 (d, J = 15.8 Hz, 1H, H2), 3.82 (s, 3H, H61), 3.51 (s, 2H, H), 3.38 – 
3.32 (m, 2H, H), 2.90 (d, J = 11.4 Hz, 2H2’eq), 2.02 (t, J = 11.3 Hz, 2H, 
H2’ax), 1.74 (d, J = 12.2 Hz, 2H, H3’eq), 1.51 (q, J = 6.8 Hz, 2H, Hβ), 1.42 – 
1.19 (m, 3H, H3’ax, 4’). 13C NMR (75 MHz, MeOD) δ 168.47 (C1), 161.53 (C6), 
141.51 (C3), 138.28 (Ci), 137.68 (C4), 130.92 (C7), 130.90 (Co), 129.25 
(Cm), 128.40 (Cp), 122.16 (C2), 121.32 (C9), 116.48 (C8), 113.83 (C5), 64.37 
(C), 55.73 (C61), 54.66 (C2’), 38.13 (C), 37.06 (Cβ), 34.46 (C4’), 32.75 (C3’). 
HRMS [ESI+] m/z =378.2304 [M] +, Calcd for [C24H30N2O2] + 378.2307. 
HPLC purity 100% 
 
(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(4-
methoxyphenyl)acrylamide. 4.3 
4.3 was obtained from 0.25 g 
of 4-methoxy cinnamic acid 
(1.4 mmol) and 0.36 g (1.7 
mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-
amine. White amorphous solid, 0.424 g (80%) mp: 103-105 ⁰C. 1H NMR 
(500 MHz, MeOD) δ 7.49 (d, J = 8.5 Hz, 2H, H5), 7.45 (d, J = 15.7 Hz, 1H, 
H3), 7.34 – 7.28 (m, 4H, Ho, m), 7.28 – 7.23 (m, 1H, Hp), 6.93 (d, J = 8.5 
Hz, 2H, H6), 6.44 (d, J = 15.7 Hz, 1H, H2), 3.81 (s, 3H, H71), 3.50 (s, 2H, 
H), 3.32 – 3.30 (m, 2H, H, H), 2.89 (dt, J = 12.2, 3.5 Hz, 2H, H2’eq), 2.01 
(td, J = 11.8, 2.4 Hz, 2H, H2’ax), 1.73 (d, J = 12.3 Hz, 2H, H3’eq), 1.50 (q, J 
= 6.9 Hz, 2H, Hβ), 1.37 (dtq, J = 13.9, 6.9, 3.5 Hz, 1H, H4’), 1.27 (qd, J = 
12.2, 3.5 Hz, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 168.95 (C1), 162.56 
(C7), 141.34 (C5), 138.25 (Ci), 130.92 (Co), 130.37 (C5), 129.25 (Cm), 
128.87 (C4), 128.41 (Cp), 119.30 (C2), 115.33 (C6), 64.37 (C), 55.82 (C71), 
54.65 (C2’), 38.10 (C), 37.10 (Cβ), 34.45 (C4’), 32.74 (C3’). HRMS [ESI+] 
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m/z =378.2304 [M] +, Calcd for [C24H30N2O2] + 378.2307. HPLC purity 
100% 
 
(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(2,4-
dimethoxyphenyl)acrylamide. 4.4 
4.4 was obtained from 0.30 g 
of 4,6-dimethoxy cinnamic 
acid (1.44 mmol) and 0.37 g 
(1.73 mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-
amine. Beige solid, 0.517 g (91%) mp: 90-93 ⁰C. 1H NMR (300 MHz, 
MeOD) δ 7.74 (d, J = 15.8 Hz, 1H, H3), 7.44 (d, J = 8.2 Hz, 1H, H9), 7.36 – 
7.28 (m, 4H, Ho, m), 7.29 – 7.18 (m, 1H, Hp), 6.62 – 6.48 (m, 3H, H2, H6, 
H8), 3.87 (s, 3H, H51), 3.82 (s, 3H, H71) 3.49 (s, 2H, H), 3.37 – 3.26 (m, 
2H, H), 2.97 – 2.78 (m, 2H, H2’eq), 2.00 (t, J = 11.2 Hz, 2H, H2’ax), 1.80 – 
1.62 (m, 2.5 Hz, 2H, H3’eq), 1.49 (q, J = 6.9 Hz, 2H, Hβ), 1.39 - 1.19 (m, 
3H, H4’, H3’ax). 13C NMR (75 MHz, MeOD) δ 169.64 (C1), 163.96 (C7), 
161.03 (C5), 138.27(Ci), 136.98 (C3), 130.91 (Co), 130.83 (C9), 129.24 (Cm), 
128.39 (Cp), 119.53 (C2), 117.83 (C4), 106.69 (C6), 99.23 (C8), 64.37 (C), 
56.01 (C51), 55.91(C71), 54.66 (C2’), 38.08 (C), 37.13 (Cβ), 34.44 (C4’), 
32.74 (C3’). HRMS [ESI+] m/z =408.2416 [M] +, Calcd for [C25H32N2O3] + 
408.2413. HPLC purity 99% 
 
 (E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(4-hydroxy-3-
methoxyphenyl)acrylamide. 4.5 
4.5  was obtained from 0.1 
g of ferulic acid (0.5 mmol) 
and 0.135 g (0.6 mmol) of 
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2-(1-benzylpiperidin-4-yl)ethan-1-amine, according to the  general 
procedure 4.1. Bright yellow solid, 0.193 g (95%), mp: 83.1-84.5 ⁰C. 1H 
NMR (500 MHz, MeOD) δ 7.43 (d, J = 15.7 Hz, 1H, H3), 7.35 – 7.31 (m, 
4H, Ho, m), 7.30 – 7.24 (m, 1H, Hp), 7.12 (d, J = 2.0 Hz, 1H, H5), 7.03 (dd, J 
= 8.2, 2.0 Hz, 1H, H9), 6.80 (d, J = 8.2 Hz, 1H, H8), 6.42 (d, J = 15.7 Hz, 
1H, H2), 3.89 (s, 3H, H61), 3.54 (s, 2H, H), 3.35 – 3.33 (m, 2H, H), 2.92 
(dt, J = 11.9, 3.5 Hz, 2H, H2’eq), 2.05 (td, J = 11.9, 2.5 Hz, 2H, H2’ax), 1.75 
(dt, J = 13.0, 2.5 Hz, 2H, H3’eq), 1.51 (q, J = 7.0 Hz, 2H, Hβ), 1.39 (dtt, J = 
13.5, 6.6, 3.5 Hz, 1H, H4’), 1.30 (td, J = 12.5, 3.5 Hz, 2H, H3’ax). 13C NMR 
(126 MHz, MeOD) δ 169.11 (C1), 149.90 (C7), 149.30 (C6), 141.97 (C3), 
138.01 (Ci), 130.97 (Co), 129.29 (Cm), 128.51 (Cp), 128.23 (C4), 123.16 
(C9), 118.70 (C2), 116.49 (C8), 111.52 (C5), 64.29 (C), 56.36 (C61), 54.63 
(C2’), 38.06 (C), 37.10 (Cβ), 34.39 (C4’), 32.67 (C3’). HRMS [ESI+] m/z 
=394.2260 [M] +, Calcd for [C24H30N2O3] + 394.2256. HPLC purity 99% 
 
(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(3-hydroxyphenyl)acrylamide. 
4.6 
4.6  was obtained from 0.1 g 
(0.26 mmol) of 4.2 and 7 
mmol of BBr3 as described in 
general procedure 2.4. Light 
brown amorphous solid 93 mg 
(97%) mp: 190-193⁰C. 1H NMR (500 MHz, MeOD) δ 7.53 – 7.50 (m, 2H, 
Ho), 7.48 – 7.46 (m, 3H, Hm, p), 7.42 (d, J = 15.7 Hz, 1H, H3), 7.18 (t, J = 
7.8 Hz, 1H, H8), 6.99 (dt, J = 7.8, 1.2 Hz, 1H, H9), 6.95 (t, J = 2.0 Hz, 1H, 
H5), 6.78 (ddd, J = 7.9, 2.5, 1.0 Hz, 1H), 6.55 (d, J = 15.7 Hz, 1H, H2), 
4.29 (s, 2H, H), 3.49 – 3.45 (m, 2H, H2’eq), 3.37 – 3.33 (m, 2H, H), 3.01 
(td, J = 13.0, 3.0 Hz, 2H, H2’ax), 2.05 – 1.99 (m, 2H, H3’eq), 1.74 – 1.61 (m, 
1H, H4), 1.53 (q, J = 6.9 Hz, 2H, Hβ), 1.50 – 1.40 (m, 2H, H3’ax). 13C NMR 
(126 MHz, MeOD) δ 168.74 (C1), 159.01 (C6), 141.96 (C3), 137.49 (C4), 
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132.43 (Co), 131.22 (Cp), 130.95 (C6), 130.38 (Ci), 130.32 (Cm), 121.56 
(C2), 120.37 (C9), 118.00 (C7), 115.06 (C5), 61.78 (C), 53.73 (C2’), 37.55 
(C), 36.36 (Cβ), 32.33 (C4’), 30.36 (C3’). HRMS [ESI+] m/z =364.2150 [M] 
+, Calcd for [C23H28N2O2] + 364.2151. HPLC purity 98% 
 
(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide. 
4.7. 
4.7  was obtained from 0.1 g 
(0.26 mmol) of 4.3 and 7 
mmol of BBr3 as described in 
general procedure 2.4. white 
amorphous solid 83 mg (87%) 
mp: 164-166⁰C. 1H NMR (500 MHz, MeOD) δ 7.50 – 7.46 (m, 5H, Ph), 
7.44 (d, J = 15.7 Hz, 1H, H3), 7.40 (d, J = 8.7 Hz, 2H, H6), 6.79 (d, J = 8.6 
Hz, 2H, H5), 6.40 (d, J = 15.7 Hz, 1H, H2), 4.21 (s, 2H, H), 3.42 – 3.37 (m, 
2H, H2’eq), 3.34 (t, J = 7.0 Hz, 2H, H), 2.91 (m, 2H, H2’ax), 2.00 (d, J = 
14.0 Hz, 2H, H3’eq), 1.65 (bs, 1H, H4’), 1.55 (q, J = 7.0 Hz, 2H, Hβ), 1.48 – 
1.44 (m, 2H, H3’ax). 13C NMR (126 MHz, MeOD) δ 167.84 (C1), 159.20 (C7), 
140.48 (C3), 130.77 (Co), 130.74 (Ci), 129.49 (Cp), 129.13 (C5), 128.80 
(Cm), 126.14 (C4), 116.79 (C2), 115.30 (C6), 60.46 (C), 52.23 (C2’), 36.13 
(C), 35.01 (Cβ), 31.04 (C4’), 29.08 (C3’). HRMS [ESI+] m/z =364.2158 [M] +, 
Calcd for [C23H28N2O2] + 364.2151. HPLC purity 98% 
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(E)-N-(2-(1-benzylpiperidin-4-yl)ethyl)-3-(3,4-
dihydroxyphenyl)acrylamide. 4.9 
4.9  was obtained from 0.1 g 
(0.25 mmol) of 4.5 and 7 
mmol of BBr3 as described in 
general procedure 2.4; white 
amorphous solid 0.06 g (60%) 
mp: 164-166⁰C.1H NMR (500 MHz, MeOD) δ 7.48 – 7.40 (m, 5H, Ph), 7.37 
(d, J = 15.7 Hz, 1H, H3), 7.01 (d, J = 2.1 Hz, 1H, H5), 6.90 (dd, J = 8.2, 2.1 
Hz, 1H, H9), 6.77 (d, J = 8.2 Hz, 1H, H8), 6.39 (d, J = 15.7 Hz, 1H, H2), 
4.00 (s, 2H, H), 3.34 (t, J = 6.9 Hz, 2H, H), 3.24 (d, J = 12.3 Hz, 2H, 
H2’eq), 2.64 (t, J = 11.6 Hz, 2H, H2’ax), 1.95 – 1.82 (m, 2H, H3’eq), 1.56 (m, 
1H, H4’), 1.53 (q, J = 6.7 Hz, 2H, Hβ), 1.47 – 1.33 (m, 2H, H3’ax). 13C NMR 
(126 MHz, MeOD) δ 169.23 (C1), 148.77 (C7), 146.72 (C6), 142.15 (C3), 
133.40 (Ci), 131.86 (Co), 130.13 (Cp), 129.90 (Cm), 128.21 (C4), 122.15 
(C9), 118.33 (C2), 116.44 (C8), 114.93 (C5), 62.49 (C), 53.83 (C2’), 37.70 
(C), 36.52 (Cβ), 32.99 (C4’), 31.01 (C3’). HRMS [ESI+] m/z =380.2104 [M] 
+, Calcd for [C23H28N2O3] + 380.2100. HPLC purity 99% 
 
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(2,4-
dimethoxyphenyl)acrylamide. 4.10 
4.10 was synthesized as 
described in the general 
procedure 4.1, starting from 
0.150 g  (0.72 mmol) of 2,4-
dimethoxy cinnamic acid and 
0.195 g (0.86 mmol) of 1.8 White amorphous solid, 0.18 g (60%) mp: 
105-107 ⁰C. 1H NMR (300 MHz, MeOD) δ 7.90 (d, J = 15.8 Hz, 1H, H3), 
7.65 (d, J = 8.2 Hz, 2H, H2’), 7.51 (d, J = 8.7 Hz, 1H, H9), 7.35 – 7.23 (m, 
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7H, Ph, H3’), 6.77 (d, J = 15.7 Hz, 1H, H2), 6.62 – 6.49 (m, 2H, H8,6), 3.91 
(s, 3H, H51), 3.85 (s, 3H, H71), 3.52 (s, 2H, Hβ), 3.50 (s, 2H, H), 2.18 (s, 
3H, H). 13C NMR (75 MHz, MeOD) δ 167.83 (C1), 164.21 (C7), 161.26 (C5), 
139.69 (Ci), 139.33 (C1’), 138.31 (C3), 135.31 (C4’), 131.19 (C9), 130.84 
(C3’), 130.40 (Co), 129.30 (Cm), 128.25 (Cp), 121.05 (C2’), 119.82 (C2), 
117.83 (C4), 106.81 (C6), 99.27 (C8), 62.61 (Cβ), 62.21 (C), 56.05 (C51), 
55.93 (C71), 42.31 (C). HRMS [ESI+] m/z =416.2099 [M] +, Calcd for 
[C26H28N2O3] + 416.2100. HPLC purity 100% 
 
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(3,4-
dimethoxyphenyl)acrylamide. 4.11 
0.050 g  (0.24 mmol) of  4,5-
dimethoxy cinnamic acid, 
0.044 g and 0.065 g (0.28 
mmol) of 1.8, were reacted as 
described in general procedure 
4.1 to obtain 4.11 as a white 
amorphous solid, 60 mg (60%) mp: 107-110 ⁰C. 1H NMR (300 MHz, 
MeOD) δ 7.68 – 7.57 (m, 3H, H3,2’), 7.38 – 7.24 (m, 7H, Ph, H3’), 7.22 – 
7.13 (m, 2H, H5, 9), 6.98 (d, J = 8.0 Hz, 1H, H8), 6.67 (d, J = 15.5 Hz, 1H, 
H2), 3.89 (s, 3H, H61), 3.87 (s, 3H, H71), 3.52 (s, 2H, H), 3.50 (s, 2H, Hβ), 
2.17 (s, 3H, H). 13C NMR (75 MHz, MeOD) δ 166.97 (C1), 152.44 (C7), 
150.73 (C6), 142.78 (C3), 139.66 (Ci), 139.18 (C1’), 135.47 (C4’), 130.88 
(C3’), 130.40 (Co), 129.36 (C4), 129.31 (Cm), 128.26 (Cp), 123.43 (C9), 
121.03 (C2’), 119.98 (C2), 112.74 (C8), 111.43 (C5), 62.62 (C), 62.20 (Cβ), 
56.44 (C61), 56.42 (C71), 42.31 (C). HRMS [ESI+] m/z =416.2112 [M] +, 
Calcd for [C26H28N2O3] + 416.2100. HPLC purity 100% 
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(E)-N-(3-((benzyl(methyl)amino)methyl)phenyl)-3-(4-hydroxy-3-
methoxyphenyl)acrylamide. 4.12  
4.13  was obtained from 0.1 g 
of ferulic acid (0.5 mmol) and 
0.18 g (0.8 mmol) of amine 
1.7, according to the  general 
procedure 4.1. Bright yellow 
solid, 0.18 g (65%), mp: 72-74 ⁰C. 1H NMR (400 MHz, MeOD) δ 7.64 (s, 
1H, H2’), 7.56 (s, 1H, H6’), 7.56 (d, J = 15.7 Hz, 1H, H3), 7.36 – 7.21 (m, 
6H, Ph, H5’), 7.15 (d, J = 2.0 Hz, 1H, H5), 7.10 – 7.05 (m, 2H, H2, H4’), 
6.80 (d, J = 8.1 Hz, 1H, H8), 6.60 (d, J = 15.6 Hz, 1H, H2), 3.88 (s, 3H, 
H61), 3.51 (s, 2H, Hβ), 3.49 (s, 2H, H), 2.16 (s, 3H, H). 13C NMR (101 
MHz, MeOD) δ 167.27 (C1), 150.16 (C7), 149.33 (C6), 143.25 (C3), 140.66 
(C3’), 140.18 (Ci), 139.70 (C1’), 130.40 (Co), 129.78 (Cp), 129.32 (Cm), 
128.27 (C5’), 128.18 (C4), 126.08 (C4’), 123.42 (C9), 121.97 (C2’), 120.06 
(C6’), 119.04 (C2), 116.54 (C8), 111.65 (C5), 62.74 (Cβ), 62.62 (C), 56.36 
(C61), 42.41 (C). HRMS [ESI+] m/z =402.1934 [M] +, Calcd for 
[C25H26N2O3] + 402.1943. HPLC purity 99% 
 
 (E)-N-(4-((benzyl(methyl)amino)methyl)phenyl)-3-(4-hydroxy-3-
methoxyphenyl)acrylamide 4.13 
4.13  was obtained from 
0.1 g of ferulic acid (0.5 
mmol) and 0.18 g (0.8 
mmol) of amine 1.8, 
according to the  general 
procedure 4.1. Bright yellow solid, 0.16 g (64%), mp: 80-83 ⁰C.1H NMR 
(500 MHz, MeOD) δ 7.63 (d, J = 8.5 Hz, 2H, H2’), 7.57 (d, J = 15.6 Hz, 1H, 
H3’), 7.36 – 7.31 (m, 6H, Ph, H3’), 7.29 – 7.23 (m, 1H, Hp), 7.17 (d, J = 2.1 
Hz, 1H, H5), 7.08 (dd, J = 8.2, 2.2 Hz, 1H, H9), 6.82 (d, J = 8.2 Hz, 1H, 
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H8), 6.61 (d, J = 15.6 Hz, 1H, H2), 3.90 (s, 3H, H61), 3.56 (s, 2H, Hβ), 3.55 
(s, 2H, H), 2.20 (s, 3H, H). 13C NMR (126 MHz, MeOD) δ 167.23 (C1), 
150.16 (C6), 149.33 (C7), 143.26 (C3), 139.44 (Ci), 136.29 (C1’), 134.77 
(C4’), 131.03 (C3’), 130.54 (Co), 129.40 (Cm), 128.48 (C4), 128.19 (Cp), 
123.43 (C9), 121.05 (C2’), 119.00 (C2), 116.55 (C8), 111.67 (C5), 62.50 (C), 
62.09 (Cβ), 56.38 (C61), 42.12 (C). HRMS [ESI+] m/z =402.1902 [M] +, 
Calcd for [C25H26N2O3] + 402.1943. HPLC purity 97% 
 
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(3-
methoxyphenyl)acrylamide. 4.14 
3-Methoxy cinamic acid, 0.150 
g  and 0.22 g (1.0 mmol) of 1.8, 
were reacted as described in 
the general procedure 4.1 to 
obtain 4.14 as a white 
amorphous solid, 0.255 g (79%) mp: 90-93 ⁰C. 1H NMR (300 MHz, MeOD) 
δ 7.68 – 7.60 (m, 3H, H3, 2’), 7.38 – 7.25 (m, 8H, Ph, H8, 3’), 7.21 – 7.12 (m, 
2H, H5, 9), 6.97 (dd, J = 8.1, 2.6 Hz, 1H, H7), 6.79 (d, J = 15.7 Hz, 1H, H2), 
3.84 (s, 3H, H61), 3.52 (s, 2H, Hβ), 3.50 (s, 2H, H), 2.17 (s, 3H, H). 13C 
NMR (75 MHz, MeOD) δ 166.55 (C1), 161.56 (C6), 142.70 (C3), 139.70 (Ci), 
139.07 (C1’), 137.60 (C4), 135.67 (C4’), 130.99 (C8), 130.87 (C3’), 130.39 
(Co), 129.30 (Cm), 128.25 (Cp), 122.55 (C2), 121.48 (C9), 121.08 (C2’), 
116.72 (C7), 113.98 (C5), 62.64 (Cβ), 62.20 (C), 55.75 (C61), 42.32 (C). 
HRMS [ESI+] m/z =386.1998 [M] +, Calcd for [C25H26N2O2] + 386.1994. 
HPLC purity 99% 
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(E)-N-(4-((benzyl(methyl)amino)methyl)phenyl)-3-(4-
methoxyphenyl)acrylamide. 4.15 
4-Methoxy cinnamic acid, 
0.150 g  (0.84 mmol) and 
0.22 g (1.0 mmol) of 1.8, 
were reacted as described in 
the general procedure 4.1 to 
obtain 4.15 as a white amorphous solid, 0.23 g (70%) mp: 131-134 ⁰C. 
1H NMR (300 MHz, , MeOD) δ 7.70 – 7.60 (m, 3H, H3,2’), 7.57 (d, J = 8.6 
Hz, 2H, H5), 7.39 – 7.27 (m, 7H, Ph, H3’), 6.99 (d, J = 8.6 Hz, 2H, H6), 
6.67 (d, J = 15.6 Hz, 1H, H2), 3.86 (s, 3H, H71), 3.54 (s, 2H, Hβ), 3.52 (s, 
2H, H), 2.19 (s, 3H, H). 13C NMR (75 MHz, MeOD) δ 167.09 (C1), 
162.80(C7), 142.58(C3), 139.70(Ci), 139.20(C1’), 135.51(C4’), 130.87(C3’), 
130.59(Co), 130.39(C5), 129.31(Cm), 128.85(C4), 128.26(Cp), 121.08(C2’), 
119.65(C2), 115.42(C6), 62.64(Cβ), 62.21(C), 55.85(C71), 42.32(C). HRMS 
[ESI+] m/z =386.2000 [M] +, Calcd for [C25H26N2O2] + 386.1994. HPLC 
purity 99% 
 
(E)-N-(4-((benzyl(methyl)amino)methyl)phenyl)-3-(3-
hydroxyphenyl)acrylamide 4.16 
4.16  was obtained from 0.1 g 
(0.26 mmol) of 4.14 and 7 
mmol of BBr3 as described in 
general procedure 2.4. Light 
brown amorphous solid 69 mg 
(72%) mp: 156-158⁰C. 1H NMR (300 MHz, MeOD) δ 7.84 (d, J = 8.6 Hz, 
2H, H2’), 7.62 (d, J = 15.7 Hz, 1H, H3), 7.56 – 7.44 (m, 7H, Ph, H3’), 7.25 
(t, J = 7.7 Hz, 1H, H8), 7.09 (d, J = 7.7 Hz, 1H, H9), 7.04 (t, J = 2.1 Hz, 
1H, H5), 6.85 (dd, J = 7.8, 2.2 Hz, 1H, H7), 6.85 (d, J = 15.6 Hz, 1H, H2), 
4.50 (dd, J = 13.1, 10.3 Hz, 2H, H, β), 4.28 (d, J = 13.2 Hz, 2H, H, β),  
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2.73 (s, 3H, H). 13C NMR (75 MHz, MeOD) δ 166.91 (C1), 159.10 (C6), 
143.60 (C3), 142.00 (C1’), 137.38 (C4), 133.08 (Cm), 132.29 (Co), 131.33 
(Cp), 131.02 (C8), 130.77 (Ci), 130.48 (C3’), 125.82 (C4’), 121.76 (C2), 
121.53 (C2’), 120.58 (C9), 118.33 (C7), 115.28 (C5), 60.72 (CH2), 60.52 
(CH2), 39.49 (C). HRMS [ESI+] m/z =372.1844 [M] +, Calcd for 
[C24H24N2O2] + 372.1838. HPLC purity 99% 
 
(E)-N-(4-((benzyl(methyl)amino)methyl)phenyl)-3-(4-
hydroxyphenyl)acrylamide 4.17 
4.17  was obtained from 0.1 g 
(0.26 mmol) of 4.15 and 7 
mmol of BBr3 as described in 
general procedure 2.4. White 
amorphous solid 58 mg (60%) 
mp: 160-163⁰C. 1H NMR (300 MHz, MeOD) δ 7.82 (d, J = 8.7 Hz, 2H, H2’), 
7.63 (d, J = 15.6 Hz, 1H, H3), 7.55 – 7.45 (m, 5H, H5, 3’, p ), 7.20 (d, J = 8.5 
Hz, 2H, Ho), 6.84 (d, J = 8.5 Hz, 2H, H6), 6.76 (d, J = 8.4 Hz, 1H, Hm), 
6.63 (d, J = 15.6 Hz, 1H, H2), 4.35 (bs, 4H, H, β), 2.69 (s, 3H, H). 13C 
NMR (75 MHz, MeOD) δ 167.51 (C1), 161.00 (C7), 143.65 (C3), 142.13 
(C1’), 133.20 (Co), 132.21 (C3’), 131.28 (Ci), 131.20 (C4’), 130.89 (C5’), 
130.46 (Cp), 127.51 (C4), 121.46 (C2’), 118.33 (C2), 116.84 (C6), 116.07 
(Cm), 60.96 (CH2), 60.36 (CH2), 39.39 (C). HRMS [ESI+] m/z =372.1846 
[M] +, Calcd for [C24H24N2O2] + 372.1838. HPLC purity 96% 
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4-((1E,3E)-3-((2-(1-benzylpiperidin-4-yl)ethyl)imino)prop-1-en-1-yl)-2-
methoxyphenol. 4.18 
A mixture of 0.13 g (0.61 
mmol) of 2-(1-
benzylpiperidin-4-yl)ethan-1-
amine  and 0.1 g (0.56 
mmol) of 4-hydroxy-3-
methoxy cinnamaldehyde  was refluxed during 2 hours in 20 mL of 
ethanol, when reactants were consumed, the solvent was evaporated and 
the crude was purified by column chromathography using a mixture of 
EtOAc:MeOH 9:1. Brown amorphous solid, 0.18 g (85%). 1H NMR (300 
MHz, MeOD) δ 8.02 (dq, J = 9.0, 1.4 Hz, 1H, H1), 7.38 – 7.21 (m, 5H, Ph), 
7.13 (d, J = 1.9 Hz, 1H, H5), 7.07 – 7.01 (m, 1H, H8), 7.01 – 6.99 (m, 1H, 
H9), 6.79 (d, J = 8.2 Hz, 1H, H3), 6.70 (dd, J = 15.8, 9.1 Hz, 1H, H2), 3.88 
(d, J = 2.1 Hz, 3H, H6), 3.51 (d, J = 2.1 Hz, 4H, H, ), 2.90 (dd, J = 11.7, 
3.0 Hz, 2H, H2’eq), 2.01 (t, J = 11.7 Hz, 2H, H2’ax), 1.72 (d, J = 11.6 Hz, 2H, 
H3’eq), 1.57 (q, J = 6.8 Hz, 2H, Hβ), 1.45 – 1.20 (m, 3H, H3’ax, 4’). 13C NMR 
(75 MHz, MeOD) δ 166.25 (C1), 150.26 (C7), 149.46 (C6), 145.56 (C8), 
138.21 (Ci), 130.93 (Cm), 129.26 (Co), 128.77 (C4), 128.44 (Cp), 124.35 
(C2), 123.22 (C9), 116.59 (C3), 111.08 (C5), 64.35 (C), 58.60 (C), 56.38 
(C61), 54.66 (C2’), 38.64 (Cβ), 34.49 (C4’), 32.78 (C3’). 
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4-((E)-3-((3-((benzyl(methyl)amino)methyl)phenyl)amino)-3-oxoprop-1-
en-1-yl)-2-methoxyphenyl (E)-3-(4-hydroxy-3-
methoxyphenyl)acrylate. 4.19 
A mixture of ferulic acid 0.055 
g (0.29 mmol)  and 0.048 g 
(0.30 mmol) of CDI dissolved 
in 5 mL of DMF was heated at 
120 °C into a microwave 
reactor during 10 min ; to  
this mixture was added 4.12, 
0.1 g (0.25 mmol) dissolved in 
5 mL of DMF to heat at 120 
°C for 40 additional minutes. The DMF was evaporated under reduced 
pressure and the crude was purified by column chromatography in a 
mixture of EtOAc in hexane (0→65%). Yellow solid, 0.13 g  (90%). m.p: 
86-89  ⁰C 1H NMR (500 MHz, MeOD) δ 7.81 (d, J = 15.9 Hz, 1H, H3), 7.74 
– 7.72 (m, 1H, H4’), 7.68 (d, J = 15.7 Hz, 1H, H12), 7.62 (ddd, J = 8.2, 2.3, 
1.1 Hz, 1H, H5’), 7.41 – 7.32 (m, 6H, Ph, H7), 7.31 – 7.28 (m, 2H, H5, H6’), 
7.26 (dd, J = 8.2, 1.9 Hz, 1H, H18), 7.19 – 7.13 (m, 3H, H2’, 9, 17), 6.86 (dd, 
J = 8.3, 0.8 Hz, 1H, H8), 6.80 (d, J = 15.7 Hz, 1H, H11), 6.59 (d, J = 15.9 
Hz, 1H, H2), 3.93 (s, 3H, H61), 3.89 (s, 3H, H151), 3.63 (s, 2Hβ), 3.62 (s, 2H, 
H), 2.25 (s, 3H, H). 13C NMR (126 MHz, MeOD) δ 167.01 (C1), 166.56 
(C10), 153.19 (C15), 151.12 (C7), 149.47 (C6), 148.82 (C3), 142.79 (C16), 
142.19 (C12), 140.13 (C1’), 139.90 (C3’), 138.90 (Ci), 135.22 (C13), 130.57 
(Co), 129.93 (Cp), 129.44 (Cm), 128.56 (C6’), 127.53 (C4), 126.40 (C9), 
124.61 (C17), 124.44 (C11), 122.54 (C4’), 122.19 (C18), 121.74 (C5’), 120.37 
(C8), 116.55 (C8), 114.11 (C2), 112.67 (C14), 111.90 (C5), 62.58 (Cβ), 62.46 
(C), 56.49 (C61), 49.51 (C151), 42.17 (C). HRMS [ESI+] m/z =578.2425 [M] 
+, Calcd for [C35H34N2O6] + 578.2417. HPLC purity 99% 
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The biological evaluation was developed according to the experimental 
protocols described in previous chapters. 
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Concluding Remarks 
As described in the general objective of this work, we aimed to obtain new 
molecules able to interact simultaneously with some of the most 
important enzymes related to  AD. With this idea in mind, we to take 
advantage of the N-benzyl piperidine and the N, N-dibenzyl amine 
fragments which are present in several bioactive molecules as found in 
the initial bibliographic review and described in the general approach 
section. 
In order to achieve this objective, we resolved to apply the multitarget 
strategy and the privileged structure concept. Synthetic ease and 
accessibility to the biological experiments was always kept in mind to 
develop in the most rapid and efficient way this research. New hybrids 
were obtained combining the NBP and DBMA fragments with different 
scaffolds endowed with antioxidant properties and which could play a 
complementary role to give to the resulting hybrids a multitarget profile. 
Along this work we have demonstrated that NBP and DBMA fragments 
are able to give to the new hybrids affinity the cholinesterases, as we 
expected from the very beginning according to the initial bibliographic 
review. Depending on the complementary scaffold, newly obtained 
hybrids exhibit affinity for the several enzymes related to AD.  
We have found that the combination of these two fragments with LA give 
molecules with affinity for the 1R, and consequently, with the potential 
to preserve the health of the neurons affected in AD. As explained in the 
in the introduction and conclusions sections of the first chapter, we 
believe that agonizing the 1R could be beneficial to maintain the
communication between ER and mitochondria, the proper functioning of 
calcium channels and to avoid excitotoxicity. 
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In this first approximation we effectively obtained molecules with a 
multitarget profile. Even though, more experiments are needed to 
corroborate the agonist character the 1R ligands obtained here, they are 
starting point to continue the investigation in order to improve the 
activity towards AChE and BACE1. On the other hand, we believe that 
further experiments should be addressed in order to determine the 
possible antidepressant effects of these molecules, since there is enough 
evidence demonstrating that 1R could be involved in the mechanism of 
some antidepressants such as fluvoxamine. 275 
In the second and fourth chapter we successfully combined the 
fragments of interest with the chromone scaffold and the cinnamic 
structure respectively. Once more, naturally occurring scaffolds were the 
inspiration to obtain the desired multitarget products. These new hybrids 
exhibited the desired MAO inhibitory activity and the radical scavenger 
capacity; apart from the ability to inhibit simultaneously AChE and 
BACE1. 
Yet again, complementary experiments must be carried out in order to 
take this new hybrids one step further. Taking into account their ability 
to inhibit MAO-A and MAO-B, the antidepressant activity must be 
explored; as well as their antiparkinsonian effects. MAO-B inhibitors are 
valuable tools in the pharmacotherapy of PD. However, drugs with 
additional properties are urgently needed and this kind of compounds 
could be a starting point.  
The neurogenic properties exhibited by compounds of chapter one and 
four were a nice discovery. Although these are qualitative results, it is 
clear that a neurogenic effect was observed. Even though, the role of 
neurogenesis in adults is not yet fully understood and the usefulness of 
the neurogenic agents is still a topic of discussion; it is worth to continue 
the study of this kind of compounds. Maybe their ability to influence this 
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process could be a valuable tool that may help us to increase our 
understanding in this field.  
In regard of the lack of affinity of hybrids obtained in the third chapter, it 
is true that more substituents could have been used to obtain a wider 
series. However we must admit that the current model of research, 
sometimes force the researchers to sweep aside some projects in order to 
focus their efforts in the most promising ones in order to use resources in 
the most efficient manner. Although it was a disappointment, a 
conclusion can be drawn from this chapter: not always you hit the target 
you aimed to. Maybe this is the case; maybe this combination of 
privileged scaffolds in the way it was developed has not affinity for NMDA 
receptors. The results are the results. 
Summarizing, the N-benzyl piperidine and the N, N-dibenzyl-N-methyl 
amine fragments have proved to behave as privileged structures 
providing four series of new compounds with affinity for the targets 
aimed in this work. The new molecules presented in this work intend to 
be a small contribution in the quest for the urgently needed disease 
modifying drug to treat Alzheimer’s disease. 
.
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Resumen 
Introducción 
La enfermedad de Alzheimer (EA) es una patología que se caracteriza por 
una pérdida progresiva de neuronas en áreas específicas tales como la 
corteza frontal, el neocórtex, y las proyecciones subcorticales del nucleus 
basalis de Meynert. Dicha pérdida de neuronas colinérgicas produce 
niveles bajos de acetilcolina, ocasionando una interrupción de la 
transmisión entre las células implicadas en los procesos de memoria y 
aprendizaje. Esta interrupción es el origen de los síntomas cognitivos de 
la EA, tales como pérdida de memoria, incapacidad para pensar, para 
razonar y hacer juicios, así como dificultades de comunicación. 
El conocimiento de la disfunción en el sistema colinérgico condujo a 
proponer a la acetilcolinesterasa como la primera diana farmacológica en 
la búsqueda de agentes terapéuticos para el tratamiento del alzheimer. 
Los inhibidores de la acetilcolinesterasa fueron la primera clase de 
fármacos usados con éxito en el tratamiento sintomático de esta 
enfermedad. Sin embargo, a pesar de mejorar los indicadores cognitivos y 
comportamentales en pacientes tratados con inhibidores de 
acetilcolinesterasa, esta clase de fármacos ha sido incapaz de detener la 
degeneración neuronal. 
Es por esto que una explicación del origen de los síntomas cognitivos no 
basta para saber lo que causa realmente la pérdida de neuronas en la 
EA. Actualmente, el péptido beta amiloide (Aβ) es considerado la 
sustancia que  inicia el proceso que lleva a la muerte neuronal. Las 
fibrillas insolubles de este péptido son el componente principal de las 
placas seniles, consideradas como el elemento tóxico que desencadena la 
cascada de respuestas celulares que finalmente producirán la
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 neurodegeneración.  Algunos de estos eventos moleculares y celulares 
son la inflamación neural, la producción de especies reactivas de oxígeno  
y la hiperfosforilación de la proteína tau. Una estrategia importante en la 
búsqueda de nuevos fármacos capaces de prevenir la formación del 
péptido Aβ y la consecuente formación de placas seniles ha sido la 
síntesis de inhibidores de la beta secretasa, una de las tres enzimas 
responsable del procesamiento de la proteína precursora de amiloide. 
Por otra parte, además de la disminución de los niveles de acetilcolina, se 
ha demostrado una disminución en los niveles cerebrales de otros 
neurotransmisores tales como: dopamina, serotonina y noradrenalina, en 
comparación con los niveles observados en el envejecimiento saludable. 
Simultáneamente, se sabe que los niveles de MAO-B se incrementan con 
la edad, tanto en personas saludables como en personas con EA. Este 
incremento se correlaciona con una producción exagerada de especies 
reactivas de oxígeno, responsables del ambiente tóxico que caracteriza 
las enfermedades neurodegenerativas. La inhibición de MAO se ha 
evaluado también como una alternativa en la búsqueda de nuevos 
fármacos para tratar la EA, tanto para reducir los niveles de estrés 
oxidativo, inhibiendo MAO-B, como para tratar la depresión asociada 
esta enferemedad, inhibiendo MAO-A. 
Esta breve descripción pone de manifiesto que la EA es una compleja red 
influenciada por una extensa variedad de factores. En el resto de esta 
memoria se explicará de una manera más profunda el papel de cada una 
de las enzimas que se ha seleccionado como diana farmacológica, así 
como la estrategia utilizada y los resultados obtenidos. Dicha 
complejidad de factores nos ha llevado a proponer el desarrollo del 
siguiente objetivo general. 
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Objetivo 
En este trabajo se ha propuesto evaluar la utilidad de los fragmentos de 
N-bencilpiperidina (NBP) y de N, N-dibencil-N-metilamina (DBMA) para el 
diseño, síntesis y evaluación farmacológica de nuevos compuestos 
multidiana con afinidad por enzimas relevantes en la aparición y 
desarrollo de la EA. Para lograr este objetivo, algunas estructuras 
químicas de origen natural (cromona, 4-quinolinona, ácido lipóico y ácido 
cinámico) han sido combinadas con los fragmentos de NBP y DBMA en 
moléculas sencillas buscando un perfil multidiana. La sencillez en las 
rutas de síntesis y la accesibilidad a los ensayos biológicos fue tenida en 
cuenta para desarrollar de la manera más eficiente y rápida este 
proyecto. Los nuevos compuestos obtenidos en este trabajo fueron 
evaluados en varios ensayos biológicos, in vivo e in vitro, así como en 
experimentos in sílico con el fin de encontrar una relación entre la 
estructura química y la actividad biológica.  
Resultados 
Los fragmentos de NBP y DBMA fueron útiles en la síntesis de nuevos 
híbridos con afinidad por acetilcolinesterasa, tal como se esperaba desde 
la revisión bibliográfica inicial. Dependiendo de la estructura 
complementaria con la que estos fragmentos fueron combinados, los 
nuevos compuestos presentan actividad sobre varias enzimas 
relacionadas con la EA.  
La combinación de los fragmentos de NBP o DBMA con el ácido lipóico 
permitió la obtención de nuevas moléculas con afinidad por el receptor 
sigma 1. Gracias a esta propiedad, estos compuestos pueden ayudar a  
preservar la salud de las neuronas afectadas en la EA, ayudando a evitar, 
o al menos retrasar, los procesos neurodegenerativos. Simultáneamente, 
estos compuestos son capaces de inhibir a la beta-secretasa y estimular 
procesos neurogénicos.  
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En el segundo y cuarto capítulos de esta tesis, se combinaron con éxito 
los fragmentos de interés con la estructura de la cromona y el ácido 
cinámico. Nuevamente, los compuestos obtenidos estuvieron inspirados 
en estructuras de origen natural. Estos nuevos híbridos demostraron 
tener actividad en AChE y MAO, así como capacidad antioxidante, tal 
como se esperaba de su diseño. Los compuestos basados en el ácido 
cinámico demostraron ser antioxidantes más efectivos que aquellos 
basados en la cromona, así como poseer también propiedades 
neurogénicas. 
Los compuestos del tercer capítulo, combinando la estructura del ácido 
kinurénico con los fragmentos de NBP y de DBMA, fueron completamente 
inactivos en el receptor de NMDA para el cual fueron diseñados. Sin 
embargo son inhibidores de AChE y MAO. 
Los efectos neurogénicos observados en los compuestos del capítulo 
primero y tercero, fueron un agradable descubrimiento. Aunque estos 
son resultados cualitativos, un efecto neurogénico fue claramente 
observado. A pesar de que el papel de la neurogénesis en adultos no está 
entendido completamente y de que la utilidad de agentes neurogénicos 
sigue siendo tema de debate, vale la pena continuar con su estudio. Es 
posible que su habilidad de intervenir en este proceso los convierta en 
una herramienta que nos ayude a incrementar nuestro conocimiento en 
esta área. 
Conclusiones 
Los fragmentos de NBP y DBMA han demostrado ser estructuras 
privilegiadas en la búsqueda de nuevas moléculas con posible aplicación 
en la EA. Con base en estas estructuras se han generado ocho familias 
de nuevos compuestos bioactivos. 
La estrategia de hibridación utilizada a lo largo de este trabajo, fue 
efectiva en la obtención de nuevos compuestos con perfil multidiana. 
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Todos los compuestos fueron diseñados bajo esta estrategia, acoplando 
en una molécula pequeña dos estructuras privilegiadas. Los compuestos 
resultantes de esta combinación presentaron en la mayoría de los casos 
la actividad biológica esperada.  
Las moléculas presentadas en esta tesis doctoral, pretenden ser una 
pequeña contribución en la gesta por encontrar el tan necesitado 
fármaco capaz de modificar el avance de la enfermedad de Alzheimer. 
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